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ABSTRACT
BACKGROUND 
Most of the chemotherapeutic agents are characterized by a low therapeutic index and 
significant variability in therapeutic and toxic effects. Thus, despite the increasing 
amount of knowledge produced in the last years on the molecular bases of anticancer 
therapy, a large part of the anticancer treatments still result to be ineffective. For this 
reason, many efforts have been made to optimize the dosage and the administration of 
antiblastic drugs in order to obtain a maximal anti-tumour effect with acceptable levels 
of toxicity. This has led to the personalized therapy concept, which aims at tailoring the 
medical treatment to the individual characteristics and needs of the single patient.  
In particular, important advances in the pharmacogenetics (PGx) field deserve the 
inclusion of patient genetic profiling in the optimization of antineoplastic 
chemotherapy and in clinical drug development. In this context, our group has 
developed new strategies for phase I studies driven by patient's genetic makeup, that is 
genotype-guided phase I clinical trials. This approach aimed at redefining the dose of 
cytotoxic drugs, already used in clinical setting, taking into account the 
pharmacogenetic determinants associated to tumour response and toxicities. 
The phase I studies here proposed are related to: (1) irinotecan (CPT-11) administered in 
combination with 5-fluorouracil/leucovorin (FOLFIRI) and bevacizumab in metastatic 
colorectal cancer (mCRC) patients; (2) CPT-11 administered in FOLFIRI regimen and 
cetuximab as first-line therapy in mCRC patients; (3) weekly paclitaxel (PTX) in ovarian 
cancer patients. 
These clinical studies were also supported by the analysis of the drugs 
pharmacokinetics (PK). In addition, in this thesis a different strategy to personalize the 
treatment has been explored for a tyrosine kinase inhibitor, sunitinib. Since no PGx 
biomarkers are known up–to-date for dosage optimization of this drug, a therapeutic 
drug monitoring approach should be consider in order to maintain the plasma drug 
concentration within the therapeutic window. 
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AIMS 
The primary aim of these clinical studies was to redefine the maximum tolerated dose 
(MTD) and the dose limiting toxicity (DLT) of CPT-11, administered in FOLFIRI regimen 
plus bevacizumab or cetuximab, and of weekly PTX according to UGT1A1*28 and 
ABCB1-2677G>T/A patient’s genotype, respectively. Additional aims were to evaluate 
the correlation between the PK of CPT-11 and PTX and patients’ different genotypes, as 
well as the effect of the PK on toxicity and response rate. In the case of CPT-11, the 
possible effect of bevacizumab and cetuximab on the drug PK has also been 
investigated. In order to obtain these data, an important part of this PhD project has 
been employed for the development and validation of LC-MS/MS methods for the 
quantification of these drugs and their metabolites in human plasma.  
Regarding sunitinib, the project aimed to develop and validate an analytical method, 
suitable for the clinical practice, for the quantification of sunitinib and its main 
metabolite, N-desethyl sunitinib. 
METHODS 
Phase I trials (1) and (2): eligible patients were stratified in two groups, based on the 
UGT1A1 *1/*1 or *1/*28 genotype. For ethical reasons, high risk toxicity patients 
(*28/*28) were excluded. CPT-11 was administered as a 2-h continuous i.v. infusion 
once every 2 weeks over 28-day cycles. The starting dose was fixed at 260 mg/m2, and 
the following dose at 310 and 370 mg/m2. The study has been designed to evaluate the 
PK of CPT-11 and its main metabolites in absence and presence of 
bevacizumab/cetuximab during the first chemotherapy cycle, in order to define the 
potential effect of the biological agents.  
Phase I trial (3): eligible patients were stratified in two groups based on the ABCB1-
2677G>T/A polymorphism: group 1 (ABCB1-2677GG genotype) and group 2 (ABCB1-
2677GT; GA, AA, TT, AT genotypes). PTX was administered as 1-h i.v. infusion every 
week over 28-day cycles. The starting dose was 80 mg/m2 and was escalated by steps of 
10 mg/m2. The pharmacokinetic profile of the drug was evaluated twice during the first 
chemotherapy cycle, during the first and the fourth administration, in order to 
investigate the phenomenon of metabolic autoinduction of this taxane, which has been 
reported. 
Abstract 
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The “3+3” dose escalation method has been applied in all these phase I studies. The 
MTD was defined as the dose at which <4/10 patients had a DLT (grade 3-4 non 
hematologic or grade 4 hematologic toxicity during the first one or 2 cycles of therapy 
in study (1)-(2) and (3), respectively).  
Bioanalytical methods: the LC-MS/MS methods have been developed using a HPLC 
system consisted of a SIL-20AC XR auto-sampler and LC-20AD UFLC XR pumps 
coupled with an API 4000 triple quadrupole mass spectrometer AB SCIEX. To quantify 
the chromatographic peaks, data were processed with Analyst 1.5.2 software package 
(AB SCIEX). Pharmacokinetic parameters were calculated using the non-
compartmental model with Phoenix® WinNonlin™ 6.4, Pharsight, Certara Company.  
RESULTS 
Development and validation of bioanalytical methods: Two LC-MS/MS methods 
have been developed for the quantification of: 1) CPT-11 and its main metabolites, SN-
38, SN-38G, and APC; 2) PTX and its 6α-hydroxy metabolite (6α-OH-PTX). Moreover, 
beyond the phase I projects, a third method has been developed for the quantification 
of sunitinib and its active metabolite, N-desethyl sunitinib. These methods require a 
small plasma volume and a simple and fast protein precipitation as sample proccessing. 
The concentration ranges, defined for all the analytes, generously covered the clinical 
expected drug quantities, and resulted appropriate both for pharmacokinetic studies 
and for dose escalation trials (high doses). They have also been fully validated according 
to FDA-EMA guidelines on bioanalytical method validation. In fact, the recovery, 
linearity, intra- and inter-day precision and accuracy, reproducibility, limit of detection 
and quantification, selectivity, matrix effect, and stability have been successfully 
assessed. Noteworthy, the method for the quantification of sunitinib, molecule that 
undergoes Z-E isomerization, does not require the light protection during the sample 
handling, thus resulting more suitable for the clinical laboratory routine. 
Phase I study (1): 48 patients were enrolled (47 were evaluable for DLTs: 24 *1/*1 
patients and 23 *1/*28 patients). For *1/*1 patients, 2 DLTs were observed among 10 
patients at 310 mg/m2, while 370 mg/m2 was not tolerated (2 DLTs in 4 patients). For 
*1/*28 patients, 2 DLTs were observed among 10 patients at 260 mg/m2, while 310 
mg/m2 was not tolerated (4 DLTs in 10 patients). Therefore, the MTD resulted 260 
Abstract  
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mg/m2 in the *1/*28 cohort and 310 mg/m2 in the *1/*1 cohort. No significant 
differences in the pharmacokinetic parameters of CPT-11 and its main metabolites have 
been observed among the two genotype groups. Moreover, changes in the AUCs of 
CPT-11 and SN-38 associated with bevacizumab treatment were marginal.  
Phase I study (2): at the moment, 2 patients were enrolled in this study. The PK of 
these patients was followed, as per protocol, during the days 1-3 and the days 15-17 of 
the first chemotherapy cycle.  
Phase I study (3): until now, 37 patients were enrolled (35 patients were evaluable: 10 in 
the group 1 and 25 in the group 2). For group 2 no DLTs were observed among 10 
patients at 120 mg/m2, while 130 mg/m2 was not tolerated (2 DLTs in 3 patients). Hence, 
the MTD resulted 120 mg/m2 for this group. For group 1, 1 DLT was observed among the 
first 3 patients at 110 mg/m2, thus the cohort needs to be enlarged up to 6 patients 
before to proceed with the dose escalation. Preliminary analyses have showed no 
significant difference in the pharmacokinetic parameters of both PTX and 6α-OH-PTX 
among the two genotype groups. Moreover, on the basis of the results related to the 
comparison between the I and the IV administration it is possible to exclude the PTX 
metabolism autoinduction. Furthermore, a switching from linear to non-linear PK has 
been observed when doses higher than 110 mg/m2 were administered. 
CONCLUSIONS 
Our genotype-guided phase I studies have demonstrated that doses of both CPT-11 and 
PTX higher than the standard level (180 and 80 mg/m2, respectively) can be safely 
administered. In particular, different MTDs have been assessed according to the 
patient’s genotype, thus demonstrating the effective role of genetic stratification to 
deliver safe doses of anticancer drugs to patients. Moreover, the different LC-MS/MS 
methods, developed and validated according to FDA-EMA guidelines, have been 
successfully applied to plasma samples collected from the patients enrolled in our phase 
I studies and pharmacokinetic data have been obtained to more deeply investigate the 
PK/PD relationship.  
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1.1 Chemotherapy: from cytotoxic agents to targeted 
therapies 
The use of chemotherapy to treat cancer began at the start of the 20th century. The 
term “chemotherapy” was coined by the famous German chemist Paul Ehrlich, in the 
early 1900s, and was defined as the use of chemicals to treat diseases (DeVita and Chu, 
2008). Nitrogen mustards were the first anticancer agents to be used clinically. The 
effects of an accidental spill of sulphur mustards on troops from a bombed ship in Bari 
Harbour, Italy, during the World War II led to the observation that both bone marrow 
and lymph nodes were markedly depleted in those men exposed to the mustard gas 
(DeVita and Chu, 2008) (Thurston, 2006). In 1942, Alfred Gilman and Louis Goodman 
began clinical studies of intravenous nitrogen mustards in patients with lymphoma, 
launching the modern era of cancer chemotherapy (Gilman and Philips, 1946).  
Since then, important improvements have been made in the development of new 
anticancer drugs. Advances in understanding the molecular basis of malignant 
transformation have led to dramatic changes in the strategy for the discovery of 
anticancer drugs. In prior years, most of the anticancer agents were synthetic chemicals 
and natural products, and their mechanism of action was based on the interaction with 
DNA or its precursor, inhibiting the synthesis of new genetic material and causing 
broad-based damage to DNA in both malignant and normal cells.  
More recently, the expanding knowledge of the molecular changes underlying cancer 
has led to the development of new anticancer agents for targeted therapy (Sawyers, 
2004). The term “targeted therapy” refers to a new generation of anticancer drugs 
designed to interfere with a specific molecular target (typically a protein) that is 
believed to have a critical role in tumour growth or progression (e.g. growth factor 
receptors, intracellular signalling pathways, tumour vascularity). This approach 
contrasts with the conventional, more empirical approach used to develop cytotoxic 
chemotherapeutics — the mainstay of cancer drug development in past decades. 
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1.1.1 Cytotoxic agents 
The cytotoxic compounds actually used in chemotherapy are different in structure and 
mechanism of action. They include: 1) alkylating agents and platinum coordination 
complexes, 2) antimetabolite analogs of folic acid, pyrimidine, and purine, and 3) 
natural products (Brunton et al., 2011) (Nussbaumer et al., 2011). 
1) Alkylating agents. At present, six major types of alkylating agents are used: nitrogen 
mustards, ethyleneimines, alkyl sulfonates, nitrosoureas, the triazenes, and DNA-
methylating drugs, including procarbazine, temozolomide, and dacarbazine. These 
agents have in common the property of forming highly reactive carbonium ion 
intermediates, which covalently link to sites of high electron density, such as 
phosphates, amines, sulfhydryl, and hydroxyl groups. Their chemotherapeutic and 
cytotoxic effects are directly related to the alkylation of reactive amines, oxygens, 
or phosphates on DNA, which leads to the creation of DNA strand breaks by repair 
enzymes, and an apoptotic response. In addition, because of similarities in their 
mechanisms of action and resistance, platinum complexes are listed in this 
category. They do not form carbonium ion intermediates like other alkylating 
agents or formally alkylate DNA but instead covalently bind to nucleophilic sites on 
it and share many pharmacological attributes with alkylators. 
2) Antimetabolites. This class of drugs occupies a special place in the history of cancer 
treatment since they produced the first striking, although temporary, remission in 
leukaemia (Farber and Diamond, 1948) and the first cure of the choriocarcinoma 
(Berlin et al., 1963). The mechanism of action is based on the interaction with 
essential biosynthesis pathways. These drugs are structural analogues of pyrimidine 
or purine and, therefore, they are incorporated into cell components to disrupt the 
synthesis of nucleic acids. 5-fluorouracil and mercaptopurine are typical pyrimidine 
and purine analogues, respectively. Other antimetabolites, such as methotrexate, 
interfere with essential enzymatic processes of metabolism. 
3) Natural products. Many anticancer drugs are either natural compounds or have been 
developed from naturally occurring parent compounds. Among them, several 
compounds act as antitubulin agents, interfering with microtubule dynamics (i.e. 
1 Introduction: Chemotherapy 
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spindle formation or disassembly), blocking division of the nucleus and thus leading 
to cell death. The main members of this family include taxanes and vinca alkaloids. 
A new class of agents, the epothilones, resembles the taxanes in their action but has 
limited cross-resistance with taxanes. Natural products as anticancer drugs include 
also topoisomerase inhibitors (e.g. irinotecan and etoposide), which inhibit the 
responsible enzyme for the cleavage, annealing, and topological state of DNA. 
Moreover, the family includes intercalating agents that act by binding between base 
pairs, such as anthracyclines (e.g., doxorubicin, epirubicin), mitoxantrone and 
actinomycin-D. Lastly, DNA-cleaving agents, such as bleomycin, are included, and 
they interact with DNA and cause strand scission at the binding site. 
An understanding of the life cycle of tumours is essential for the rational use of 
antineoplastic agents. Since many cytotoxic agents act by damaging DNA, their toxicity 
is greatest during the S, or DNA synthetic, phase of the cell cycle. Others block the 
formation of a functional mitotic spindle in the M phase. Therefore, these agents are 
most effective on cells entering mitosis, the most vulnerable phase of the cell cycle. 
Accordingly, human malignant neoplasms most susceptible to chemotherapy are those 
having a high percentage of proliferating cells (e.g. leukaemias and lymphomas). 
Likewise, normal tissues that proliferate rapidly (bone marrow, hair follicles, and 
intestinal epithelium) are thus highly vulnerable to damage from cytotoxic drugs 
(Brunton et al., 2011). For this reason, unpleasant side effects such as bone marrow 
suppression, gastrointestinal tract lesions, alopecia, nausea, as well as the rapid 
development of clinical resistance represent the main disadvantages of many cytotoxic 
agents (Thurston, 2006) (Brunton et al., 2011). 
Moreover, in some cases, cytotoxicity may also depend on the presence, in the 
pharmaceutical preparations, of organic solvents/detergents necessary to improve the 
poor solubility in water of many of these cytotoxic agents. Thus, the toxicity can be 
decreased significantly combining the cytotoxic compounds with a variety of drug 
carrier vehicles, which alter also the drug pharmacokinetics (PK) (Figure 1). 
Recent advances in drug delivery include the use of biocompatible polymers with 
functional monomers attached in such a way as to permit linkage of drug molecules to 
the polymer (Posocco et al., 2015). A drug-polymer conjugate can be designed to be a 
stable, long-circulating prodrug by varying the molecular weight of the polymer and the 
1 Introduction: chemotherapy 
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cleavable linkage between the drug and the polymer. The linkage is designed to keep 
the drug inactive until it is released from the backbone polymer by a disease- specific 
trigger, typically pH condition or enzyme activity in the targeted tissue that delivers the 
active drug at or near the site of pathology. Thus, an increasing interest in the 
development of targeted drug delivery systems has been showed, giving rise to new 
intriguing scenarios in chemotherapy.  
 
Figure 1 Schematic representation of the main benefits derived from the use of drug delivery systems. 
EPR effect: Enhanced Permeability and Retention Effect. Adapted from (Posocco et al., 2015) 
1.1.2 Targeted therapies 
The targeted therapies include two main classes of drugs with very different 
pharmacological properties: monoclonal antibodies that attack cell surface receptors 
and antigens, and synthetic small molecules that enter cells and inhibit multiple 
enzymatic sites. It is convenient to distinguish the different drugs belonging to the 
targeted therapies on the basis of their specific target: 1) protein tyrosine kinase 
inhibitors, 2) epidermal growth factor receptor (EGFR) inhibitors, 3) inhibitors of 
angiogenesis (Brunton et al., 2011) (Sawyers, 2004). 
1) Protein tyrosine kinase inhibitors. Protein kinases are critical components of signal 
transduction pathways that regulate cell growth and adaption to the extracellular 
environment. These signalling pathways influence gene transcription and/or DNA 
synthesis, as well as cytoplasmic events. Growth factors and other ligands bind to 
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and activate the receptor tyrosine kinases under physiological conditions. In a 
growing number of human malignancies, mutations that constitutively activate 
protein tyrosine kinases are implicated in malignant transformation; thus, protein 
tyrosine kinases are targets for cancer therapy. For instance, imatinib targets the 
BCR-ABL tyrosine kinase, which underlies chronic myelogenous leukemia (CML). A 
single molecular event, in this case the 9:22 translocation, leads to expression of the 
Abelson proto-oncogene kinase ABL fused to BCR (breakpoint cluster region), 
yielding a constitutively activated protein kinase. Imatinib binds to a segment of the 
kinase domain that fixes the enzyme in a closed or non-functional state, in which 
the protein is unable to bind its substrate/phosphate donor, ATP (Weisberg et al., 
2005). As a result, these cells stop growing, and even die by apoptosis (Goldman and 
Melo, 2003). Other protein tyrosine kinase inhibitors are dasatinib and nilotinib. 
2) Epidermal growth factor receptor inhibitors. The EGFR belongs to the ErbB family of 
transmembrane receptor tyrosine kinases. EGFR, also known as ErbB1 or HER1, is 
essential for the growth and differentiation of epithelial cells. Ligand binding to the 
extracellular domain of EGFR family members causes receptor dimerization and 
stimulates the protein tyrosine kinase activity of the intracellular domain, resulting 
in autophosphorylation of several Tyr residues in the C-terminal domain. 
Recognition of the phosphotyrosines by other proteins initiates protein-protein 
interactions that result in stimulation of a variety of signalling pathways that 
regulate cell proliferation, metabolism, and survival (Schlessinger, 2000). Drugs 
targeting EGFR pathway have become important agents in the therapy of solid 
tumours and can be divided in two main classes: the EGFR tyrosine kinase inhibitors, 
such erlotinib and gefitinib, which bind to the kinase domain and block the 
enzymatic function of EGFR, and the monoclonal antibodies. Cetuximab and 
panitumumab, belonging to this latter class, bind specifically the extracellular 
domain of EGFR. They inhibit EGFR-dependent signalling through the inhibition of 
ligand-dependent activation and receptor dimerization, the downregulation of 
EGFR expression, and the induction of antibody-dependent cell mediated 
cytotoxicity (Ciardiello and Tortora, 2008). 
3) Inhibitors of angiogenesis. Angiogenesis is the formation of new capillaries from pre-
existing vessels and circulating endothelial precursors. It is a tightly controlled 
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dynamic process that can occur physiologically in those tissues that undergo active 
remodelling in response to stress and hypoxia (El-Kenawi and El-Remessy, 2013). 
However, it can be aberrantly activated during many pathological conditions such as 
cancer. In fact, tumour cells secrete angiogenic factors that induce the formation of 
new blood vessels that guarantee the flow of nutrients to the tumour cells. An 
additional benefit of anti-angiogenic agents derived from the observation that leaky 
capillaries within tumours have increased permeability and cause an enhancement 
in tumour interstitial pressure. This increased pressure inhibits blood flow, 
decreases oxygenation, and prevents drug delivery within the tumour (Jain, 2009). 
Antibodies directed at the primary angiogenic factor, vascular endothelial growth 
factor (VEGF), “normalize” interstitial pressure and improve blood flow, thus 
enhancing the ability of chemotherapeutic agents to reach the tumour. An example 
of antibody targeting VEGF is bevacizumab, which was the first FDA-approved 
molecule that specifically targeted angiogenesis. Moreover, three small molecules 
(pazopanib, sorafenib, and sunitinib), which inhibit the kinase function of VEGF-2, 
have been approved for clinical use.  
Although molecularly targeted drugs have had outstanding successes in selected type 
of cancer, traditional cytotoxics are not likely to be replaced by these new therapies in 
the near future. Rather, targeted drugs and cytotoxics will continue to be used in 
combination (Brunton et al., 2011) (Nussbaumer et al., 2011). Moreover, cytotoxic 
agents are also used as a support to either surgery or radiotherapy (Brunton et al., 
2011).  
In the present thesis, about all the different chemotherapy treatments reported above 
has been taken in consideration: from a single cytotoxic agent-based therapy related to 
paclitaxel (PTX) in ovarian cancer patients to two combination therapies of irinotecan 
(CPT-11) with 5-fluorouracil/leucovorin in association with targeted agents 
(bevacizumab and cetuximab) in metastatic colorectal cancer (mCRC) patients. Finally, 
also a tyrosine kinase inhibitor (sunitinib)-based therapy for metastatic renal-cell cancer 
patients has been considered. 
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1.2 Determining the optimal dose: phase I study and 
pharmacokinetics 
The theoretical aim of an anticancer therapy is to treat the patient with the highest 
possible dose in order to achieve the maximum possible effect on tumour cells. 
Nevertheless, many of anticancer treatments, be they cytotoxic chemotherapy drugs, 
biologic agents, or radiation, are associated with acute toxicities that can affect a wide 
range of organ systems and are frequently life threatening (Shanholtz, 2001). 
Therefore, the challenge has been and still remains to find a balance between efficacy 
and toxicity. This requires the definition of dose-limiting toxicity (DLT) and the so-called 
maximum tolerated dose (MTD). The main principle is indeed that the observed dose-
limiting toxicities define the maximal tolerable dose (Mathijssen et al., 2014). Thus, this 
recommendation was determined according to safety aspects and the assumption that 
toxicity is a surrogate of activity: the highest safe dose is assumed to be the one most 
likely to be efficacious (Eisenhauer et al., 2000). As a consequence, the therapeutic 
window of cytotoxic agents is commonly narrow (Figure 2), meaning that relatively 
small changes in drug concentration may lead to a lower drug activity or extreme 
toxicities. 
 
Figure 2 Schematic representation of the therapeutic window. Below a certain threshold- concentration 
the drug is inactive, while above a certain concentration side effects appear. 
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1.2.1 Development of anticancer drugs: clinical phase I-II-III-IV 
The conventional approach for the identification of the optimal dose is based on 
identifying the MTD in phase I trials and incorporating it within subsequent trials. In 
Figure 3 the different phases involved in the translation of new cancer therapies from 
bench to bedside are represented.  
 
Figure 3 Main steps of anticancer-drug development. 
They are designed to answer a specific research question (Arrondeau et al., 2010): 
 Phase I: a new drug or drug combination is tested in a small group of patients for 
the first time to evaluate its safety, determine a safe dosage range, and identify 
side effects. The phase I for anticancer drug/therapy development differs from 
non-oncology phase I in that it is usually performed in patients with a terminal 
diagnosis, who typically have exhausted standard treatment options, rather 
than in healthy volunteers (Miller and Joffe, 2008) (Ivy et al., 2010). This choice 
has a dual purpose: to prevent healthy volunteers from being exposed to very 
toxic drugs and to give to some patients suffering from cancer the possibility to 
benefit from the investigational drug. The primary goal of phase I cancer trials is 
to collect data on toxicity, pharmacologic and pharmacodynamic properties of a 
specific drug or therapy regimen, allowing determination of the recommended 
phase II dose. Moreover, pharmacokinetic analyses are performed to determine 
the relationship of increasing dose to drug absorption, distribution, and 
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metabolism. In addition, drug interactions are also investigated in combination 
regimen phase I trials. 
 Phase II: they are screening studies aiming to identify signals of anti-tumour 
activity in a homogenous population of patients with a particular tumour type 
(Dhani et al., 2009). The gold standard for evaluation of any new cancer therapy 
is the improvement in overall survival (OS), that is the length of time from either 
the date of diagnosis or the start of treatment for the disease that patients 
diagnosed with the disease are still alive (www.cacer.gov). However, OS has 
limited utility in phase II trials due to the limited length of observation and the 
confounding effects of subsequent therapies and, thus, other endpoints such as 
progression-free survival (PFS- the length of time during and after the treatment 
of the disease that a patient lives with the disease but it does not get worse 
(www.cacer.gov)) and biomarkers may be preferable (Dhani et al., 2009) 
(Seymour et al., 2010).  
 Phase III: this kind of trial is a critical step before licensing and it consists of the 
evaluation of the new treatment efficacy against the best current standard 
therapy. In order to conduct a scientifically valid comparison between the two 
treatment cohorts, the groups need to be alike as much as possible, with the 
only exception being the specific treatments under investigation (Thall, 2008). 
Phase III trials can be classified by their goals. On the one side, difference 
(superiority) trials, the most frequent studies, aim to determine if sufficient 
evidence exists that one treatment arm is different from another. On the other 
side, equivalence trials aim to determine whether two treatment arms are 
equivalent (or nearly so). Equivalence trials are performed to demonstrate that a 
less expensive or less toxic new treatment provides similar clinical benefit to the 
standard therapy. 
 Phase IV: after licensing, phase IV post-marketing trials may be undertaken to 
explore the long-term safety/morbidity of the treatment. However, these phase 
IV trials are infrequently done (Arrondeau et al., 2010). 
More in details regarding the phase I trials, objects of this thesis, the guiding principle 
for dose escalation in these studies is to avoid unnecessary exposure of patients to very 
low doses of an agent while preserving safety and maintaining rapid accrual. Phase I 
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clinical studies are conducted by selecting a safe starting dose deduced from animal 
toxicology testing (i.e. one tenth of the lethal dose in mouse (Eisenhauer et al., 2000)). 
In a stepwise manner the dose is subsequently increased in defined cohorts of patients 
until DLT is reached in a given number of patients. Dose escalation methods are divided 
in two main categories: the rule-based designs, which include the traditional “3+3” 
design; and the model-based designs (Le Tourneau et al., 2009).  
The former design proceeds with cohorts of three patients; the first cohort is treated at 
a starting dose that is considered to be safe based on extrapolation from animal 
toxicological data, and the subsequent cohorts are treated at increasing dose levels that 
have been fixed in advance (Figure 4). 
 
Figure 4 Schematic description of the 3+3 cohort expansion design. 
Historically, dose escalation has followed a modified Fibonacci sequence in which the 
dose increments become smaller as the dose increases (e.g. the dose first increases by 
100% of the preceding dose, and thereafter by 67%, 50%, 40%, and 30% – 35% of the 
preceding doses). In most of the cases, the pre-specified dose levels do not fit the exact 
Fibonacci sequence (Le Tourneau et al., 2009). If none of the three patients in a cohort 
experienced a dose-limiting toxicity, another three patients will be treated at the next 
higher dose level. Otherwise, if one of the first three patients experienced a dose-
limiting toxicity, three more patients will be treated at the same dose level. The dose 
escalation continues until at least two patients among a cohort of three to six patients 
experience dose-limiting toxicities (i.e. ≥ 33% of patients with a DLT at that dose level). 
The MTD recommended for phase II studies is conventionally defined as the dose level 
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immediately below the one at which 33% of patients have experienced DLT. Therefore 
at the MTD, 1/3 out of at least 10 patients experienced DLT. 
Despite the traditional “3+3” design is safe and easy to implement, it presents a 
limitation due to the fact that the early dose levels involve treating patients at very low 
doses which are almost certainly biologically inactive, while few patients actually 
receive doses at or near the recommended phase II dose (Arrondeau et al., 2010). An 
alternative rule-based strategy, known as the accelerated titration design attempts to 
minimize this problem. In this case, a single patient is treated per cohort, with the dose 
doubling between each cohort in the absence of any grade 2 toxicities. As soon as a 
grade 2 toxicity occurs, dose escalation is switched to the slower and more traditional 
“3+3” design. In some of these designs, intrapatient dose escalation is also allowed 
(Arrondeau et al., 2010). 
The second dose escalation method for phase I clinical trials, the model-based design 
mentioned above, is based on the use of statistical models that actively seek a dose 
level that produces a prespecified probability of DLTs by using toxicity data from all 
enrolled patients and compute a more precise dose – toxicity curve. It also attempts to 
reduce the number of patients treated at very low doses (Le Tourneau et al., 2009). 
However, the use of this design is challenging, as it needs biostatistical expertise and 
available software on site to perform model fitting in real time, as well as expedited 
collection of data from each cohort of patients to fit the model (Arrondeau et al., 2010). 
For these reasons, the traditional “3+3” design remains the prevailing method for 
conducting phase I cancer clinical trials (Arrondeau et al., 2010) (Le Tourneau et al., 
2009). Hence, the phase I trials objects of this PhD project have been designed adopting 
this traditional dose-escalation model. 
According to the Italian legislation (DPR n°439/2001,art.3), it is necessary to design a 
Phase I study with: 
 New pharmaceutical products never tested in human subjects; 
 Pharmaceutical products resulted from a new association of already registered 
agents; 
 Pharmaceutical products already registered in other countries but declared new 
by the Italian Ministry of Health; 
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 Pharmaceutical agents already registered but for which new pharmaceutical 
forms, excipients, recommendations, dosages, administration routes are 
proposed. 
The last category identifies the so-called phase Ib studies, specifically object of this 
thesis. 
1.2.2 Pharmacokinetic principles 
As reported in the previous section, the determination of the pharmacokinetic 
properties of the study drug represents an important aim of phase I clinical trials. 
PK describes the temporal patterns of response to drug administration following acute 
or chronic dosing. In order to understand and control the therapeutic action of drugs in 
the human body, it is necessary to know how much drug will reach the site(s) of drug 
action and when this will occur. In fact, understanding and employing pharmacokinetic 
principles can increase the probability of therapeutic success and reduce the occurrence 
of adverse drug effects in the body (Brunton et al., 2011). Pharmacokinetic studies are 
essential to determine how the body handles drug, that is, how drug is absorbed, 
distributed, metabolized and eliminated (Figure 5).  
 
Figure 5 The interrelationship of the absorption, distribution, binding, metabolism, and excretion of a 
drug and its concentration at its sites of action (possible distribution and binding of metabolites in 
relation to their potential actions at receptors are not depicted). 
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All these processes, collectively called ADME, are influenced by patient’s characteristics 
(i.e. genetics, body size, age, and co-morbidity) and by dosage, drug formulation, route 
of administration and by the possible co-administration of other drugs. 
Bioavailability is a term used to indicate the fractional extent to which a dose of drug 
reaches its site of action or a biological fluid from which the drug has access to its site of 
action. By definition, when a drug is administered intravenously, its bioavailability is 
100% and, on the contrary, when a drug is administered via other routes, its 
bioavailability decreases because of several losses during the absorption phase. For 
example, a drug given orally must be absorbed first from the gastrointestinal tract, but 
net absorption may be limited by the characteristics of the dosage form, the drug’s 
physicochemical properties, the intestinal metabolism, and the transporter export back 
into the intestinal lumen. 
Following absorption or systemic administration into the bloodstream, a drug 
distributes into interstitial and intracellular fluids. This process reflects a number of 
physiological factors and the particular physicochemical properties of the individual 
drug. Drug circulating in the bloodstream is responsible of pharmacological activity and 
several processes regulate its level: 1) the organs uptake; 2) the drug binding with 
plasma proteins (albumin is a major carrier for acidic drugs; α1-acid glycoprotein binds 
basic drugs. The binding is usually reversible), red cells or platelets; 3) the permeability 
of tissue membranes, and 4) the drug metabolism and elimination. 
Drugs are eliminated from the body either unchanged by the process of excretion or 
converted to metabolites. In fact, drug elimination occurs by two processes, excretion 
and metabolism; excretion is the irreversible loss of chemically unchanged drug in urine 
and in faeces (renal excretion of unchanged drug is a major route of elimination for 25–
30% of drugs), while metabolism is the conversion of one chemical species to another. 
Excretory organs, the lung excluded, eliminate polar compounds more efficiently than 
substances with high lipid solubility. Lipid-soluble drugs thus are not readily eliminated 
until they are metabolized to more polar compounds. Drug metabolism is obtained by 
two types of enzymatic reactions: phase I (biotransformation) characterized by 
reactions of oxidation, hydroxylation, reduction and hydrolysis and phase II 
(conjugation) characterized by reactions of addition of a new functional group such as 
glucuronide, sulphate, methyl and acetyl groups, glutathione and amino acids. 
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Although drug metabolism is the physiological way of detoxification, some metabolites 
can retain (or increase) the pharmacological activity. Understanding drug metabolism 
has spawned the new disciplinary focus of pharmacogenetics, which offers the promise 
that understanding the expression and activities of specific metabolizing enzyme 
isoforms in a given individual will permit the clinician to tailor treatments, particularly in 
chemotherapy (Dawood and Leyland-Jones, 2009), to maximize therapeutic outcomes 
and minimize risks of toxicity or drug-drug interactions. Anyway, this aspect will 
discussed more in details in the following chapter. 
The most important parameters governing drug disposition are reported in Table 1. 
Table 1 Main pharmacokinetic parameters and their clinical significance. 
Parameter Name Significance Key features 
Cmax 
Maximum plasma 
concentration 
The highest drug 
concentration observed in 
plasma following 
administration 
Cmax and Tmax are correlated 
and both depend on how 
quickly the drug enters into 
and is eliminated from the 
body Tmax 
Time until Cmax is 
reached 
The time at which the 
highest drug concentration 
occurs 
AUC 
Area under the 
concentration-
time curve 
The measure of the total 
systemic exposure to the 
drug 
It represents the amount of 
unchanged drug that has 
reached the general 
circulation and it is useful to 
define the bioavailability of a 
drug 
Vd 
Volume of 
distribution 
The apparent volume into 
which the drug is dissolved 
It depends on binding to 
plasma proteins and tissues 
and it is useful to correlate 
the drug concentration in 
plasma with its amount in the 
body 
t1/2 
Half-life in the 
terminal phase 
The time taken for the 
plasma concentration to 
fall by one half once 
distribution equilibrium has 
been achieved 
It is independent of the 
amount of drug in the body 
and it is useful for the 
determination of the 
frequency of drug 
administration 
Cl Clearance 
The rate of drug 
elimination by all routes 
normalized to the 
concentration of the drug 
It is the sum of all organs 
clearance, especially hepatic 
and renal clearance 
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1.2.2.1 Mass spectrometry for pharmacokinetic analysis  
Measuring drug plasma concentration in samples collected at specific time points, it is 
possible to obtain the plasma concentration-time profile and the shape and the 
mathematical elaboration of this profile provide the main pharmacokinetic parameters 
reported in the previous Table 1.  
In order to obtain the plasma concentration-time profile, the method and the analytical 
technique used are fundamental. A higher method sensitivity correlates with a the 
better description of the drug kinetics, in terms of a much longer monitoring of drug 
concentration, which also means a better measurement of the area under the 
concentration-time curve (AUC) and a description of the half-life in the terminal phase 
(t1/2). In the last 35 years, there have been significant improvements in analytical 
technologies applied in cancer pharmacology to measure drug concentration and to 
study drug metabolism. At the beginning, the concentration data from plasma or other 
biological matrix were usually obtained by LC-UV/VIS methods. The next step was to 
prefer, when possible, the use of a fluorescence detector (FLD), but the real change in 
bio-analysis began with the development of bench-top mass spectrometry instruments, 
combined with liquid chromatography (LC-MS). Within a few years, LC-MS has become 
the method of choice for quantitative drug analysis to support PK and drug metabolism 
studies (Hopfgartner and Bourgogne, 2003) (Crotti et al., 2015). Coupling the mass 
spectrometer with LC provided significant improvements in assay sensitivity, specificity 
and capability to analyze samples with very different concentration ranges. The 
increase in sensitivity and specificity caused three important effects: 
 the possibility to detect drugs and metabolites at very low concentration; 
 the possibility to use very small amount of sample (that is particularly important in 
preclinical studies conducted in small animals or in paediatric studies); 
 a selective analytes detection in presence of complex matrices such as tissues or 
whole blood. 
Mass spectrometry owes its success to its performances in drug quantitative (PK) and 
qualitative (metabolites identification) analysis. Accurate and sensible quantitation is 
obtained by operating in tandem mass (MS/MS) mode (Saint-Marcoux et al., 2007). 
MS/MS is necessary because of possible interfering compounds present in the biological 
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sample exhibiting the same integer mass, while the fragmentation pattern is compound 
specific. Tandem mass experiments, performed by means of triple quadrupole 
instrumentation, are obtained through collision-induced dissociation (CID). Detection is 
based on selective reaction monitoring (SRM), also called multiple reaction monitoring 
(MRM), based on monitoring of fragmentation reaction(s) from the analyte molecular 
ion to analyte specific fragment ion(s) (de Hoffmann, 1996). The combination of parent 
mass and its fragment ions is used to monitor selectively the compound that has to be 
quantified. 
Despite the need for chromatographic separation is often low with MRM detection 
mode thanks to its specificity, co-eluting matrix components may cause problems in the 
ionization process by so called matrix effects. Moreover, other factors such as the drug-
proteins binding ant the analyte instability during the untreated sample storage could 
affect the quantitative drug analysis. Sample preparation is one of the most time-
consuming steps in the bioanalysis aiming to isolate, clean-up and pre-concentrate 
analytes of interest from biological matrices (Nováková, 2013). Sample preparation 
procedures mainly employed in PK studies are schematized in Figure 6.  
 
Figure 6 Schematic representation of the conventional sample preparation techniques used in 
pharmacokinetic analysis. 
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Solid phase extraction (SPE), liquid-liquid extraction (LLE) and protein precipitation 
(PP) are considered the conventional sample preparation techniques still highly 
employed in contrast to modern approaches such as on-line techniques or 
microextractions (Nováková, 2013). Basically, LLE and SPE provide selective analytes 
recovery (depending on the solvent and/or stationary phase choice) and result in cleaner 
extracts with respect to PP. SPE has advantages in terms of less sample amount 
required, a minor solvent consumption, and the possibility to be used in on-line 
systems. 
In LC-MS analysis the analytes are introduced into the ion source of mass spectrometer 
after their separation in a LC column. There are different types of MS ion sources, but 
the most commonly employed in pharmacokinetic studies is Electrospray Ionization 
(ESI), an atmospheric pressure ionization. ESI is a soft ionization technique - as very 
little internal energy is retained by the analyte after ionization - and does not cause 
decomposition of labile compounds. It is characterized by an efficient ion production, 
mainly by protonation or cationization reactions, and it can operate in either positive or 
negative ion mode. In a typical ESI source, schematized in Figure 7, the solution is 
injected in a stainless steel capillary.  
 
Figure 7 Ions formation in positive electrospray ionization. Under these conditions the capillary is placed 
at a positive voltage, while the counter electrode is placed to a negative voltage. Adapted from (Crotti et 
al., 2011). 
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Between this capillary and their counter electrode, a voltage in the order of 3-5 kV is 
applied. Under these conditions, the formation of a solution cone just outside the 
capillary occurs. The cone formation is due to the presence of charged species inside 
the solution, which experiment the electrostatic field existing between the capillary and 
the counter electrode (Taylor, 1964). After the cone production, the droplets formation 
from the cone apex is observed, charged droplets further migrate through the 
atmosphere to the counter electrode (Taylor, 1964). Droplets formation is strongly 
influenced by solvent chemical-physical characteristics, ionic analytes concentration, 
inorganic salts concentration, and the applied voltage. The so generated charged 
droplets, decrease their radius after solvent evaporation still conserving their total 
charge amount. The energy required for the solvent evaporation is due to the 
environment thermal energy, further enhanced through by the use of a heated capillary 
or by collisions with heated gas flow. As the droplet radius decrease, the surface charge 
density increases; when the radius reaches the Rayleigh stability limit, the electrostatic 
repulsion equals the surface tension. For lower radii, the charged droplets are unstable 
and decompose through a process defined “Columbic Fission” (Rayleigh, 1882). This 
produces smaller droplets that ultimately liberate unsolvated charged analyte 
molecules. Alternatively, the “ion evaporation” mechanism has been proposed, based 
on the direct emission of ions from the charged droplets occurring when the surface 
charge density shows a large increase. Far to be fully understood, the mechanism(s) of 
gas phase ions production from the small/highly charged droplets has been investigated 
by several authors, as discussed in some recent reviews (Crotti et al., 2011) (Kebarle and 
Verkerk, 2009). Typically, in ESI the production of smaller droplets is enhanced by lower 
mobile phase flow rate and by the use of volatile mobile phases; the pH and volatility of 
the LC eluent has a very high role in ionization efficiency and thus detection sensitivity.  
Another, commonly used, ionization type is atmospheric pressure chemical ionization 
(APCI), which is based on the interaction of solution vapours with a corona discharge, 
leading to gas phase ionization reactions. APCI has been used typically for less polar 
(neutral) analyte compounds, such as steroid-like compounds. 
Physicochemical properties (i.e. hydrophilicity and ionization behaviour) of the analyte 
have a major role in affecting the method performance in both chromatographic 
separation step and mass spectrometric detection. The detection response of 
1 Introduction: Determining the optimal dose 
27 
compounds varies due to the ionization efficacy and co-presence of interfering 
molecules, thus quantitative analysis by LC-MS should require that pure standards are 
available for each analyte. The use of isotope labelled compounds as internal standards 
is recommend to reduce those problems caused by matrix effects. 
1.2.2.2 Validation of a bioanalytical method 
Selective, sensitive, and validated analytical methods for the quantitative evaluation of 
drugs and their metabolites are critical for the successful conduction of nonclinical and 
clinical pharmacology studies. Indeed, the quantitative measurements of drugs, 
metabolites, and biomarkers provide essential information in the assessment of safety 
and efficacy of drugs. Moreover, drug or biomarker concentrations frequently serve as 
the primary or secondary endpoints of many clinical studies in drug development. 
Consequently, the reliability or quality of that data underpins the study outcome (Booth 
et al., 2015; FDA, 2013a). For this reason, validating bioanalytical methods includes 
performing all of the procedures that demonstrate that a particular method used for 
quantitative measurement of analytes in a given biological matrix (e.g. blood, plasma, 
serum, or urine) is reliable and reproducible for the intended use (FDA, 2013a). 
The measurements should be based on established principles and scientists should 
utilize a common, vetted paradigm of practices, independent of the analytical platform 
to demonstrate that the assays provide reliable data. The necessity to establish the 
main guiding principles for the validation of an analytical method and to disseminate 
them to the pharmaceutical community was received, in 1990, by the first American 
Association of Pharmaceutical Scientist (AAPS)/ FDA Bioanalytical Workshop (Shah et 
al., 1991). Scientists in the bioanalytical field worked with the regulatory community to 
establish a common language and expectations in generating pharmacokinetic data for 
drugs and metabolites. These validation principles were introduced into regulations by 
Health Canada in 1992 (Canadian Minister of Health, 1991) and then by the FDA which 
published the first edition of its Guidance on Bioanalytical Method Validation in 2001 
(FDA, 2001). 
This guidance explains the course of action for the validation of analytical procedures 
such as gas chromatography; high-pressure liquid chromatography; GC-MS; LC-MS; 
ligand binding assays, immunological assays and microbiological procedures. In doing 
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so, the specific features of these methods in the quantitative determination of drugs 
and metabolites in biological matrices are taken into account. Validation involves 
documenting, through the use of specific laboratory investigations, that the 
performance characteristics of the method are suitable and reliable for the intended 
analytical applications. The acceptability of analytical data corresponds directly to the 
criteria used to validate the method. Fundamental parameters for this validation 
include the following: accuracy, precision, selectivity, sensitivity, reproducibility, 
stability. The FDA guidance described in detail all these parameters and the correct way 
to validate them. 
Since the publishing of this guidance in 2001, the dialogue has broadened significantly 
through scientific conferences not only within the USA, but globally. In 2011 the 
Guidance on Bioanalytical Method Validation was introduced in EU (EMA, 2011). 
Successively, in September 2013 the FDA released a draft revision of the Guidance for 
Industry Bioanalytical Method Validation that included a number of changes to the 
expectations for bioanalysis (FDA, 2013a). 
In particular, taking into account the AAPS/FDA Workshop on Incurred Sample 
Reanalysis (Fast et al., 2009), this revised version has introduced an additional measure 
of assay reproducibility: the Incurred Sample Reanalysis (ISR). This analysis is now well 
established as an important element of bioanalysis and it is intended to verify the 
reliability of the reported subject sample analyte concentrations. ISR is conducted by 
repeating the analysis of a subset of subjects’ samples from a given study in a separate 
run to critically support the performance of assays. 
Accordingly to what reported above, the development and validation processes of the 
LC-MS/MS methods, represent an essential task of the PhD project herein reported in 
order to correctly define the drug PK as a support to the phase I studies conducted by 
our group. 
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1.3 New challenge in cancer chemotherapy: the 
personalization of the therapy 
Personalized medicine represents one of the most important challenges in cancer 
therapy. The increasing amount of knowledge produced in the last years on the 
molecular bases of anticancer therapy has led to the development of new therapeutic 
targeted molecules and to a better understanding of the molecular bases of 
chemotherapy with traditional drugs. Nevertheless, cancer still remains an enormous 
global health burden (the second most common cause of death in the US, exceeded 
only by heart disease, accounting for nearly 1 of every 4 deaths). Today, cancer 
accounts for about 1 in every 7 deaths worldwide – more than HIV/AIDS, tuberculosis, 
and malaria combined. In 2016 about 1685210 new cancer cases are expected to be 
diagnosed in US and about 595690 Americans are expected to die of cancer (Cancer 
Facts and Figures, 2016). More than 60% of cancer deaths occurs in low- and middle-
income countries, many of which lack the medical resources and health systems to 
support the disease burden (Cancer Facts and Figures, 2016). Anyway, a large part of 
patient’s treatment results to be ineffective: it is estimated that in only 25% of patients 
a response is achieved (Spear et al., 2001) (FDA, 2013b). This represents a big issue not 
only in oncology, but also in medicine in general: everyday millions of people take drugs 
that will not help them, as depicted in the Figure 8. 
 
Figure 8 Imprecision medicine: average percentage of the patient population for which a particular drug 
in a class is ineffective (Spear et al., 2001). 
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Certainly, this problem becomes particularly serious considering drugs characterized by 
both severe side effects and a low therapeutic index such as those administered in 
cancer patients. 
1.3.1 Current practice for individualize anticancer drug dose: 
the Body Surface Area  
In the early days of cancer chemotherapy, cytotoxic drug doses were either fixed at the 
level defined by the phase I studies or recalculated on the basis of the body weight (BW) 
(Pinkel, 1998). Successively, the huge variability in cancer patients’ outcomes in terms 
of both toxicity and efficacy along with the narrow therapeutic index characterising 
anticancer drugs has led clinicians to propose a new strategy for a corrected 
chemotherapy dosing. 
In 1883, it was discovered that small animals utilise relatively more oxygen and produce 
relatively more heat than larger animals. These findings could be explained because 
smaller animals have relatively larger surface areas per unit mass, when compared with 
larger animals. These observations were confirmed and applied to humans, giving rise 
to the practice of expressing human basal metabolism in terms of body surface area 
(BSA) rather than BW (Pinkel, 1958).  
Initially, BSA was recommended in dosage calculations for intravenous fluids, 
electrolytes, drugs and blood replacement needs in children, as it gave better outcomes 
than dosing based on BW or age. Then, prompted by publications by Pinkel (Pinkel, 
1958) and Freireich et al. (Freireich et al., 1966), recommending the use of BSA to 
extrapolate chemotherapy doses from animals to human phase I studies and for the 
dosing of patients, many paediatricians started using BSA for anti-cancer drug dosing, 
and they were followed by medical oncologists (Pinkel, 1998). In fact, correlations 
between blood volume and BSA were observed, and in the 1940s-1950s relationships 
were found between BSA and the total amount of circulating plasma proteins. The 
relationship between BSA and renal function was also considered, as the total number 
of glomeruli and kidney weight were found to be proportional to BSA for various 
mammals, and the ratio of kidney weight to BSA were similar for rat, dog, and man. The 
Addis urea excretion rate (used as a measure of renal function) was in turn proportional 
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to kidney weight, and consequently it was considered that there was a relationship 
between renal function and BSA (Pinkel, 1958).  
Body surface area is a measurement that is extremely difficult to reproduce. Several 
different formulae for predicting surface area from measurements of height and weight 
have been derived. In 1916, Du Bois and Du Bois examined nine individuals of varying 
age, shape, and size and measured their BSA directly using moulds. From these 
measurements, they derived a formula to estimate BSA using height and weight alone 
(DuBois and DuBois, 1916): 
BSA (m2) = 0.007184 * (height (cm) 0.725* weight (kg)0.425) 
Although the Du Bois formula was determined on only nine individuals and certain 
assumptions were made in developing the formula (e.g. Du Bois and Du Bois only 
measured one leg and one arm, assuming the body to be symmetrical (Jones et al., 
1985)), it has prevailed from other proposed formula and it is the most popular one for 
BSA calculation in current use. Anyway, many limitations have been pointed out in the 
use of BSA dose individualization. Except for the inherent inaccuracies in methods for 
BSA calculation (Du Bois and Du Bois estimated the maximal error as ±5% (DuBois and 
DuBois, 1916)), there is a substantial risk of arithmetical errors. In fact, mistakes in the 
use of dosage equations have been found to account for more than 15% of medication 
prescribing errors (Lesar, 1998). On the one side, the patient’s BSA calculation is 
dependent on the accuracy of weight and height measurements. For many cancer 
patients, body size will probably vary during the course of the disease, due to conditions 
such as cachexia and anorexia. Despite this, BSA is not always re-calculated between 
treatment cycles, although there are recommendations that BSA should be re-
calculated when BW has changed by more than 5-10%. On the other side, in clinical 
practice, the calculated cytotoxic drug doses are also frequently manipulated by 
rounding to the nearest convenient dose (Kaestner and Sewell, 2007). Furthermore, 
given the complexity of drug clearance, drug-related toxicity and anti-tumour activity, it 
is unlikely that only one factor such as BSA can be used to adjust the dosage. Moreover, 
once a specific dose is determined for a specific patients’ population, this does not 
necessary mean that this dose will be the best dose for each individual patient even if 
calculated in respect of BSA. 
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Another important point to highlight regarding the anticancer dosage is that toxicity is 
commonly regarded as the most important effect to control, partly because it is easier 
to measure, but the risk of under-dosing and reduced efficacy must also be considered. 
In clinical practice it is more common to reduce doses, increase dose intervals, or skip 
courses in response to adverse effects than to increase the dose intensity in cases where 
treatment is well tolerated and there is no significant toxicity. This approach may 
reduce the severity of toxic effects, but it could also result in a suboptimal therapeutic 
effect (Kaestner and Sewell, 2007). For all these reasons, in order to overcome the BSA 
approach and to optimize the dose, the recent progresses in the cancer field introduced 
the concept of personalized therapy with the aim of tailoring medical treatment to the 
individual characteristics and needs of the single patient. 
1.3.2 Beyond the BSA-based dose: the genomic era 
Many parameters are responsible for the different responses observed in patients with 
the same diagnosis and treated with the same drugs, such as age, gender, 
comorbidities, dietary factors, lifestyle, and molecular background (Figure 9).  
 
Figure 9 Schematic summary of the main factors that can influence the systemic exposure to a drug. BMI: 
body-mass index; CAM: complementary and alternative medicine; PPI: proton-pump inhibitor; SNPs: 
single-nucleotide polymorphisms. Adapted from (Mathijssen et al., 2014). 
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The resulting marked interpatient variability caused by all these factors is not 
considered by the current used BSA-dosing approach that results insufficient for 
adequately dosing cytotoxic drugs (Mathijssen et al., 2014). 
This has led clinicians and researchers to change the way to conceive patients, 
highlighting the uniqueness of each clinical case, and paved the way to the so called era 
of personalized (or precision) medicine. The goal of personalized medicine is to 
streamline clinical decision-making by distinguishing in advance those patients most 
likely to benefit from a given treatment from those who will suffer side effects and incur 
costs without gaining benefit.  
As reported by FDA (FDA, 2013b), many definitions of personalized therapy have been 
proposed and coined. In particular, we can mention these ones:  
 “The use of new methods of molecular analysis to better manage a patient’s 
disease or predisposition to disease” (Personalized Medicine Coalition)  
 “Providing the right treatment to the right patient, at the right dose at the right 
time” (European Union)  
 “The tailoring of medical treatment to the individual characteristics of each 
patient” (President’s Council of Advisors on Science and Technology ) 
 “Health care that is informed by each person’s unique clinical, genetic, and 
environmental information” (American Medical Association)  
 “A form of medicine that uses information about a person’s genes, proteins, and 
environment to prevent, diagnose, and treat disease” (National Cancer Institute, 
NIH) 
From these definitions it is clear that heavy importance is given to the individual 
peculiarity in terms of clinical-, genetic-, and environmental information, factors that 
can impact disease prevention, diagnosis and treatment. 
The concept of personalized medicine dates back many hundreds of years, but only now 
the possibility to sequence the entire genome and the enormous evolution in 
computational biology and other medical areas, have created the possibility for 
scientists to transform the personalized medicine from an idea to a practice. Indeed, 
personalized oncology is actually mainly based on the effect of genetic (germline and 
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somatic) differences among individuals on the response of cancer patients to 
chemotherapy. 
These genetic variations led to the definition of  biomarkers, generally described as 
“any substance, structure, or process that can be measured in the body or its products 
and influence or predict the incidence of outcome or disease” (Strimbu and Tavel, 
2010). To date, the labelling (drug labelling is intended to provide a summary of the 
essential scientific information needed for the safe and effective use of the drug) of 
more than 100 approved drugs contains information on genomic biomarkers (including 
gene variants, functional deficiencies, expression changes, chromosomal abnormalities, 
and others) (www.fda.gov). Some, but not all, of the labelling include specific actions to 
be taken based on genetic information. Moreover, among the new drugs approved by 
the FDA since 2011, approximately one-third included in the submission some types of 
genetic or other biomarker data to characterize efficacy, safety, or PK. Data from the 
last few years indicate that more and more drugs are being designed for small 
populations, a trend that is consistent with the increasing use of stratification in drug 
development (FDA, 2013b). 
On the one side, genomic and proteomic technologies have made possible to 
subclassify different kinds of solid tumours according to differences in gene sequence 
and/or expression patterns, thus leading to the development of new personalized drugs 
(Figure 10). 
 
Figure 10 Using the genetic changes in a patient’s tumour to determine their treatment is known as 
personalized medicine (www.cancer.gov). 
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For instance, the development of imatinib against chronic myelocytic leukemia (CML) is 
the greatest success in the personalized cancer field so far (Gravitz, 2014). In CML, a 
single molecular event, the 9:22 translocation, leads to expression of the Abelson proto-
oncogene kinase ABL fused to BCR (breakpoint cluster region), yielding a constitutively 
activated protein kinase, BCR-ABL, and then the malignant phenotype. Imatinib attacks 
the unique and specific protein obtained with the BCR-ABL translocation, inducing 
clinical and molecular remissions in >90% of CML patients in the chronic phase of 
disease (Gharwan and Groninger, 2015). 
On the other side, genetic information can be used to explain interindividual differences 
in drug ADME (PK) and physiological drug response (pharmacodynamics-PD), 
identifying responders and non-responders to a drug, and predicting its efficacy and/or 
toxicity (FDA, 2013b) (Figure 11). This research field, called pharmacogenetics (PGx), 
arises from the convergence of advances in pharmacology (the science of drugs) and 
genetics (the study of genes and their functions).  
 
Figure 11 Genetic information can be used to explain interindividual differences in drug PK and 
physiological drug response, identifying responders and non-responders to a drug, and predicting its 
efficacy and/or toxicity. 
Despite the extraordinary advances that have been made till now, we have a long way 
to go in understanding why different individuals respond differently to treatments. The 
issue is of such importance that in January 2015, the American President Barack Obama 
launched a national Precision Medicine Initiative, founding it with 215 million dollars, 
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aiming at promoting the introduction of personalized medicine concepts into the 
clinical practice, with a special focus on oncology and genetics (Schork, 2015).  
1.3.3 Personalized chemotherapy: pharmacogenetics and 
phase I clinical trials 
PGx, the study of those DNA and RNA mutations related to drug response, is one of the 
most exciting areas of personalized medicine today. As reported above, patients 
typically have variability in response to many drugs that are currently available. PGx 
tries to understand how genetic mutations affect the body’s response to medications, in 
order to predict who will benefit from a medication, who will not respond at all, and 
who will experience adverse effects (FDA, 2013b). 
Physiological variations within the human genome have a frequency of about 1 every 
500±1000 bases. These cause the interindividual variability that is observed also in drug 
response and are the object of PGx. Although there are a huge number of different 
types of polymorphic markers, over the last years, the scientific community has focused 
on single-nucleotide polymorphisms (SNPs), and on the potentiality they offer in 
determining the individual drug response profile. Conventionally, a SNP is defined as a 
nucleotide variation having an allele frequency greater than 1%, whereas, when the 
frequency is lower, the genetic variation is indicated as mutation or as rare variant 
(Chakravarti, 2001). 
On the one hand, predictive PGx biomarkers are usually SNPs located in genes that are 
direct targets of drugs, such as molecules involved in DNA repair or in drug metabolism, 
and are specifically associated with the response to a therapy, that can be defined as 
the probability to have a response or as the risk to develop toxicities. Prognostic PGx 
biomarkers, on the other hand, predict the natural course of a specific disease and 
patients’ outcome (Sawyers, 2008). Examples of prognostic oncology markers are SNPs 
located in proteins involved in tumour cell proliferation, dedifferentiation, angiogenesis, 
invasion or metastasis. 
As discussed in the previous section, using SNPs as predictive and prognostic 
biomarkers, it may possible to tailor drug prescription and dosage, moving from “one 
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dose fits all” model to the introduction of the “personalized medicine” model (Figure 12) 
(Duffy et al., 2011) (Patel, 2014) (Shankaran et al., 2008).  
 
Figure 12 Representation of the “one-dose-fits-all” approach versus personalized medicine. The left 
panel shows a situation in which everyone gets the same dose of a drug. The right panel shows a 
personalized medicine approach in which the drug dose is selected on the basis of specific characteristics 
of the patients (FDA, 2013b). 
Furthermore, the introduction of predictive and prognostic biomarkers in the clinical 
practice enables to enhance patients’ quality of life and to decrease overall health care 
costs (Huang and Ratain, 2009).  
PGx allows, on the basis of genotype analysis, the “stratification” of patients with a 
particular disease into subgroups as who respond more frequently to a particular drug 
or, alternatively, who are at decreased risk of side effects in response to a certain 
treatment (Patel, 2014). 
This possibility could be used as a new strategy for phase I clinical trials, in order to 
select a study population in which the assessment of a drug dose is more efficient, in 
term of both efficacy and toxicity, than it would be in an unselected population (Carden 
et al., 2010) (Hollingsworth and Biankin, 2015). In fact, the feasibility of incorporating 
genotype into early phase clinical trials could really improve the optimization of the 
MTD, thereby enhancing clinical efficacy. Moreover, selecting patients by genetic 
biomarkers is becoming a common practice to reduce the size of trials and achieve end 
points faster and at a lower cost (Innocenti et al., 2014) (FDA, 2013b). 
In fact, many drugs under development never reach the stage of being submitted to 
FDA (Food and Drug Administration) in an application requesting approval for 
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marketing. High attrition rates indeed stem largely from failure of drugs to meet 
expected efficacy levels, to demonstrate improved outcomes over a comparator drug, 
or to demonstrate sufficient safety to justify their use (FDA, 2013b). This problem is 
particularly huge for the newer molecular-targeted treatments. Although it has been 
suggested that targeted agents might have more successful development rates than 
conventional cytotoxic chemotherapies, attrition rates are still unacceptably high 
(Walker and Newell, 2009). Only 1 in 20 cancer drugs entering clinical trials gains 
regulatory approval: of the agents tested at each stage, 70% fail at Phase II, 59% fail at 
Phase III and 30% fail at the registration stage (Carden et al., 2010). The major causes 
for failure are inadequate therapeutic activity (30%) and toxicity (30%) (Kola and Landis, 
2004). Moreover, the cost of developing an anticancer drug are typically US$ 700–1700 
million, amount that are strongly influenced by the high rate of failure of evaluated 
agents and the length of time the process typically takes (eight to ten years from 
discovery to registration) (DiMasi and Grabowski, 2007).  
In this context of an inefficient drug development process, there is a clear scientific, 
ethical and financial imperative to improve phase I trial design. 
For instance, it has been recently proposed to design phase I and phase II studies to 
redefine the dose or the treatment modalities with conventional cytotoxic drugs taking 
into account the newer pharmacogenetic knowledge: the so called genotype-guided 
phase Ib clinical trials (Toffoli et al., 2010) (Marcuello et al., 2011) (Innocenti et al., 2014) 
(Lu et al., 2015). These genotype-based phase I studies, indeed, require the patients 
stratification on the basis of patient’s genetic profile in order to find the MTD 
accordingly. Thus, these studies are intended to produce not one optimal dose for the 
unselected population, but different dose levels for different patient’s genetic profiles, 
as required by the personalized approach (Figure 12).  
The genotype-guided phase I trials are not widespread. At the best of our knowledge, 
only four published papers report this kind of approach, and all aimed at redefining the 
optimal dose of CPT-11 according to UGT1A1 genotype (more details about it will be 
provided in following sections) (Toffoli et al., 2010) (Marcuello et al., 2011) (Innocenti et 
al., 2014) (Lu et al., 2015). The fundamental principle in order to design a phase I trial 
genotype-guided is indeed a strong pharmacogenetic rationale. Surely, one barrier to 
genotype-guided phase I studies implementation is the lack of freely available, peer-
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reviewed, updatable, and detailed information about PGx biomarkers to be introduced 
in drug guidelines. Moreover, despite traditional chemotherapeutic agents still 
represent the core of cancer treatment, most of them have an “off-patent” status and 
pharmaceutical companies generally do not perform further profit research on these 
drugs. 
For all these reasons, our group has developed, starting from a strong PGx background, 
several genotype-guided phase I clinical trials of traditional, off-patent, and extensively 
used against several solid tumours, cytotoxic drugs: PTX and CPT-11.  
In order to obtain additional information about the drug’s PK and its relationship with 
PD, particularly with toxicities, two LC-MS/MS methods have been developed and 
validated, according to FDA and EMA guidelines, for the drug quantification in human 
plasma samples. 
1.3.3.1 Genotype-guided phase I study of irinotecan administered in 
combination with 5-fluorouracil/leucovorin (FOLFIRI) and bevacizumab 
in advanced colorectal cancer patients 
The genotype-guided approach was applied to a phase I study, developed in our group, 
related to the administration of CPT-11 in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and bevacizumab in mCRC patients. 
CRC is the third leading cause of cancer death in both men and women and the second 
leading cause of cancer death when men and women are combined. An estimated 
49190 deaths from this malignancy are expected to occur in 2016. The 5- and 10-year 
relative survival rates for CRC are 65% and 58%, respectively. Although 5-year survival 
for localized disease is 90%, only 39% of patients are diagnosed at this stage, in part 
due to the underuse of screening (Cancer Facts and Figures, 2016).  
5- FU and folinate calcium (leucovorin (LV)) have been the standard therapy against 
CRC until chemotherapy has improved with the introduction of several new cytotoxic 
and biologic agents in the therapeutic armamentarium. These agents include CPT-11 
and newer monoclonal antibodies (e.g. bevacizumab and cetuximab) (Hegde et al., 
2008).  
Randomized trials have shown improvements in clinical efficacy as related to overall 
response rates (ORR), time to tumour progression (TTP), and median OS when CPT-11 
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has been added to either infusional (FOLFIRI) (Douillard et al., 2000) or bolus (IFL) (Saltz 
et al., 2001) of 5-FU and LV in the initial treatment of patients with mCRC. These two 
studies demonstrated, in terms of overall response and survival, the superiority of CPT-
11 in combination with 5-FU/LV compared to 5-FU/LV or CPT-11 alone.  
In 2007 FDA approved the bevacizumab (Avastin®) in combination with 
fluoropyrimidine-based chemotherapy for first-line treatment of patients with mCRC 
(Krämer and Lipp, 2007). Bevacizumab is a recombinant humanized monoclonal 
antibody that binds and neutralizes effects induced by human vascular endothelial 
growth factor (VEGF) (Presta et al., 1997) in cell proliferation and new blood vessel 
formation (angiogenesis process). The addition of bevacizumab (5 mg/kg every 2 
weeks) as an intravenous infusion in combination with CPT-11 5-fluorouracil and 
leucovorin (FOLFIRI) has been found to increase the response rates from 34.8% to 
44.8% and extend median OS from 15.6 months to 20.3 months. Moreover, this 
treatment prolonged the duration of response from a median of 6.2 months to 10.6 
months as compared to FOLFIRI alone (Hurwitz et al., 2004). Although the 
improvements offered by the introduction of bevacizumab, a great inter-patient 
variability in both response and toxicity associated to CPT-11 treatment still remain the 
major concern. 
In this context, our group has developed a phase I clinical study of CPT-11, in FOLFIRI 
regimen in combination with bevacizumab, guided by the advanced CRC patient’s 
genotype. The principal aim of this study was indeed to apply the personalization 
approach to the clinical practice, addressing the role of PGx on the MTD of CPT-11, in 
combination therapy. Hence, this section will present the main aspects characterizing 
the pharmacology of CPT-11 and the rationale underlying our phase I study. 
Irinotecan 
CPT-11 is a camptothecin analogue. Camptothecins are potent, cytotoxic antineoplastic 
agents that target the nuclear enzyme topoisomerase I (TOP1). Camptothecin (CPT), 
the lead compound of this class, was first isolated from the bark of the Chinese tree, 
Camptotheca acuminata (Wall et al., 1966). Several aspects make the camptothecins 
pharmacologically unique. Indeed, TOP1 is their only target, as it has been shown using 
yeast cells, which become totally resistant to CPT when the TOP1 gene is removed 
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(Wall and Wani, 1995). Moreover, all camptothecins have a fused five-ring backbone 
that includes a labile lactone ring (at physiological pH): the hydroxyl group and S-
conformation of the chiral centre in the lactone ring are required for biological activity 
(Brunton et al., 2011). The camptothecins bind to and stabilize the normally transient 
DNA-TOP1 cleavable complex, leading to the accumulation of single-stranded breaks in 
DNA. The collision of a DNA replication fork with this cleaved strand of DNA causes an 
irreversible double-strand DNA break, ultimately leading to cell death (Tsao et al., 
1993). Since the cytotoxic activity of camptothecins depends on cellular cycle and is 
more pronounced during S phase, a sufficient exposure of tumour cells to drug 
concentrations above a minimum threshold is necessary for the implementation of the 
cytotoxic activity of these agents (Brunton et al., 2011) (Lorusso et al., 2010). 
Camptothecin carboxylate was tested clinically in the mid-1970s and showed anticancer 
activity, but was discontinued because of its severe and unpredictable toxicity, 
principally myelosuppression and haemorrhagic cystitis (Muggia et al., 1972) (Moertel et 
al., 1972) (Schaeppi et al., 1974). After the discovery that TOP1 was the cellular target of 
this drug, more soluble and less toxic analogs of CPT, topotecan and CPT-11, were 
successfully developed. CPT-11 received accelerated approval by FDA in 1996 and the 
full approval in 1998 (www.accessdata.fda.gov) for the treatment of CRC. Nowadays it 
is one of the most active drugs in the ﬁrst- and second-line treatment of this malignancy 
(Conti et al., 1996) (Saltz et al., 2001).  
CPT-11 differs from topotecan in that it is a prodrug. In fact, it is activated by the 
enzyme carboxylesterase to 7-ethyl-10-hydroxycamptothecin (SN-38), that, compared 
with the parent drug, is 100- to 1000-times more cytotoxic (Newton et al., 2012) (Figure 
13). 
 
Figure 13 Chemical structures of the prodrug CPT-11 and its active metabolite SN-38. 
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Approved single-agent dosage schedules of CPT-11 in the U.S. include 125 mg/m2 as a 
90-min infusion administered weekly (on days 1, 8, 15, and 22) for 4 out of 6 weeks, and 
350 mg/m2 given every 3 weeks. In patients with advanced CRC, CPT-11 is used as first-
line therapy in combination with fluoropyrimidines or as a single agent or in 
combination with cetuximab following failure of a 5-FU/oxaliplatin regimen (Brunton et 
al., 2011). The DLT with all dosing schedules is delayed diarrhoea, with or without 
neutropenia (Brunton et al., 2011). In the initial studies, indeed, up to 35% of patients 
experienced severe diarrhoea. The second most common CPT-11-associated toxicity is 
myelosuppression. Severe neutropenia occurs in 14-47% of the patients treated with 
the every-3-weeks schedule and is less frequently encountered among patients treated 
with the weekly schedule. Febrile neutropenia is observed in 3% of patients and may be 
fatal, particularly when associated with concomitant diarrhoea. 
Irinotecan pharmacokinetics 
Despite CPT-11 is present as two forms (lactone and carboxylate), monitoring of total 
(lactone and carboxylate forms) CPT-11, as well as total SN-38, has essentially the same 
clinical significance as the monitoring of lactone forms of the two agents, because the 
PK of total CPT-11 and total SN-38 are significantly correlated with those of lactone 
CPT-11 and lactone SN-38, respectively (www.accessdata.fda.gov). Most of the initial 
studies have been performed with the drug administered as a short i.v. infusion (0.5–1.5 
h). After such administration, peak plasma concentrations were reached at the end of 
the infusion, with a rapid decrease thereafter as a result of multiple distribution and 
elimination pathways (Sparreboom et al., 1998) (Rivory et al., 1994) (Chabot et al., 
1995) (Rivory et al., 1997). A rebound peak in the concentration-curve has been noticed 
in some studies (Abigerges et al., 1995) (Catimel et al., 1995) (Gupta et al., 1997) (Rivory 
et al., 1997) and it was initially ascribed to enterohepatic recirculation. More recently, it 
has been suggested that this phenomenon is related to substantial uptake of CPT-11 
lactone by erythrocytes and its subsequent release, followed by accumulation of the 
carboxylate form in the plasma compartment (Loos et al., 1999). The peak 
concentration of CPT-11 appears to be dose-proportional in a large dose range (100–750 
mg/m2), although substantial interpatient variability has been noted (Canal et al., 1996) 
(Abigerges et al., 1995) (Rowinsky et al., 1994) (Catimel et al., 1995) (Rothenberg et al., 
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1996). This variability seemed to increase at later time points (Mick et al., 1996). CPT-11 
AUC also increases in a dose-dependent way at doses ranging from 33 to 180 mg/m2 
(Rothenberg et al., 1993) (Catimel et al., 1995) (Rothenberg et al., 1996) , indicating 
linear PK. CPT-11 and SN-38 have differential binding affinity for several plasma 
proteins: from 30% to 68% of CPT-11 is bound to plasma protein (predominantly 
albumin) while SN-38 is highly bound (approximately 95% bound) (Combes et al., 2000). 
The volume of distribution of CPT-11 is large, suggesting extensive tissue distribution, 
and remained unchanged with an increase in dose (Slatter et al., 2000) (Abigerges et al., 
1995) (Rothenberg et al., 1993) (Gupta et al., 1997). Similarly, the total plasma clearance 
of CPT-11 was found to be dose-independent, with a value of 13.5 ± 3.5 L/h/m2 (Chabot 
et al., 1995). The clearance is unaltered during repeated cycles, despite a mean 
interpatient variability of ~30% and an intra-patient variability of ~13.5% (Canal et al., 
1996) (Chabot et al., 1995). 
Irinotecan metabolism 
As mentioned above, CPT-11 acts as a soluble prodrug of the biologically active form 
SN-38, generated in vivo from the parent drug through the cleavage of the ester-bond 
at C10 by liver carboxylesterase (Mathijssen et al., 2001). SN-38 AUC of is only 4% of the 
CPT-11 AUC, suggesting that only a relatively small fraction of the dose is ultimately 
converted to the active form of the drug ((www.accessdata.fda.gov). Moreover, SN-38 
concentrations have been shown to increase with the CPT-11 dose over the dose range 
studied (100–750 mg/m2) (Chabot et al., 1995). 
After formation, SN-38 is further metabolized in human liver by conjugation with 
glucuronic acid to form the inactive SN-38 glucuronide (SN-38G) through an enzymatic 
reaction mediated by the UDP-glucuronosyl transferase 1A1 isoform (UGT1A1). Mostly, 
the plasma concentrations of SN-38G are related to SN-38 plasma concentrations, with 
peak values at ~1.2 h after the end of infusion (Gupta et al., 1997) (Kehrer et al., 2000). 
Simultaneously, CPT-11 undergoes an oxidative degradation mediated by CYP3A4 to 
form the inactive 7-ethyl-10-(4-N-[5-aminopentanoic-acid]- 1-piperidino)-carbonyl-
oxycamptothecin (APC) and 7-ethyl- 10-(4-amino-1-piperidino) carbonyloxy-
camptothecine (NPC) metabolites. APC is the major metabolite detectable in plasma 
and it is formed by a CYP3A-mediated oxidation of the distal piperidine group at C10 of 
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CPT-11. NPC is also formed through this pathway, by cleavage of the distal piperidino 
group of CPT-11 (Lokiec et al., 1996) (Haaz et al., 1998) (Santos et al., 2000) (Figure 14). 
APC peaks at ~2 h after the end of infusion, and AUC values increase linearly with 
increasing CPT-11 dose, despite important interpatient variation (Rivory et al., 1997). 
Biliary excretion appears to be the primary elimination route of the oxidation 
compounds (APC and NPC), the parent drug, and the SN-38 metabolite (Mathijssen et 
al., 2001). 
 
Figure 14 Metabolic pathways of CPT-11 showing carboxylesterase (CE)-mediated formation of the 
active metabolite SN-38 and its subsequent conversion to SN-38G by UGT1A1. CPT-11 can also undergo 
CYP3A4-mediated oxidative metabolism to form APC and NPC, of which the latter can be hydrolyzed by 
CE to release SN-38. 
Rationale of the phase I study 
Despite the improvements offered by the introduction of bevacizumab, a great inter-
patient variability in both response and toxicity associated to CPT-11 treatment still 
remain the major concern. This could be related to differential plasma levels of the 
active metabolite SN-38 (Mathijssen et al., 2001) among patients. Several factors can 
affect SN-38 plasma levels, such as the activation of CPT-11 to SN-38 by 
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carboxylesterase enzymes or glucuronidation of SN-38 to the inactive SN-38G by 
UGT1A1. 
In particular, the PGx research mainly focused on the UGT1A family, responsible for 
conjugation of the active SN-38 to inactive SN-38G. Among the most studied SNPs 
within these genes, UGT1A1*28 (rs81753479) SNP is surely one of the most well-known. 
The UGT1A1*28 allele is characterized by seven thymine-adenine (TA) repeats within 
the promoter region, as opposed to six that characterizes the wild-type allele 
(UGT1A1*1). These extra repeats impair proper gene transcription, resulting in 
decreased gene expression by approximately 70% (Tukey et al., 2002) (Bosma et al., 
1995). This SNP is thought to be associated with a reduced glucuronidation of SN-38 
compared with wild-type genotype, leading to variability in PK of SN38 (Ando et al., 
2002) (Innocenti et al., 2004) (Iyer et al., 2002). Moreover, patients homozygous or 
heterozygous for the UGT1A1*28 commonly develop dose limiting severe neutropenia 
and late diarrhoea and the current US package insert includes homozygosity of 
UGT1A1*28 as a risk factor for severe neutropenia (www.fda.gov). Recently, a French 
joint working group comprising the National Pharmacogenetics Network (RNPGx) and 
the Group of Clinical Onco-pharmacology (GPCO-Unicancer) have published an 
itemized guideline for the use of UGT1A1*28 genotype when prescribing CPT-11 
(Etienne-Grimaldi et al., 2015) (Figure 15). 
 
Figure 15 Scheme of the guidelines for the use of UGT1A1*28 genotype when prescribing CPT-11. 
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Thus, on the background of the CPT-11 PGx dosing guidelines described above, this 
drug is a perfect candidate for genotype-driven phase Ib studies. 
Previously, our group performed a dose-finding study in mCRC patients treated with 
FOLFIRI regimen and with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes. By dose 
escalating CPT-11 only in patients without the high-risk UGT1A1*28/*28 genotype (10% 
on average in patients of European descent), they demonstrated that the 
recommended dose of 180 mg/m2 for CPT-11 in FOLFIRI is considerably lower than the 
dose that can be tolerated by the non–UGT1A1*28/*28 patients. Specifically, patients 
with UGT1A1*1/*1 genotype can safely be treated with dose of 370 mg/m2, while the 
MTD for UGT1A1*1/*28 was assessed at 310 mg/m2 (Toffoli et al., 2010). 
In early registration studies, where FOLFIRI was given with bevacizumab, the CPT-11 
plasma concentrations were found similar to those observed in patients receiving 
FOLFIRI alone. However the concentrations of the active metabolite SN38 were 33% 
higher in patients receiving FOLFIRI plus bevacizumab as compared with FOLFIRI alone 
that can in part explain the higher incidence of NCI-CTC Grade 3-4 diarrhoea and 
neutropenia observed in the group of patients receiving FOLFIRI plus bevacizumab 
(McCormack and Keam, 2008) (Avastin® product information). This observation 
imposes caution to CPT-11 dose increment when administrated in combination with 
bevacizumab. 
In this contest, our group proposed a phase I study to assess the recommended dose of 
CPT-11 according to UGT1A1 genotype for FOLFIRI plus bevacizumab regimen in 
patients with mCRC with the intent of increasing the overall efficiency of the treatment. 
1.3.3.2 Genotype-guided phase I study of irinotecan administered in 
combination with 5-fluorouracil/leucovorin (FOLFIRI) and cetuximab as 
first-line therapy in metastatic colorectal cancer patients 
This genotype-guided phase I study was designed on the basis of the initial results 
obtained from the previous trial (Section 1.3.3.1). In fact, in a preliminary analysis of 22 
patients, bevacizumab decreased the AUC of SN-38 (p = 0.026 by Wilcoxon matched 
pairs signed rank test), suggesting a role of this monoclonal antibody in the PK of CPT-
11 (Manish, 2014). Hence, a following phase I study of CPT-11 administered in FOLFIRI 
regimen in combination with cetuximab was designed and approved, in order 1) to 
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define the CPT-11 MTD in this combination therapy according to UGT1A1*28 genotype, 
and 2) to investigate the potential effect of this targeted agent on CPT-11 PK.  
At present, cetuximab combined with FOLFIRI represents one of the most active 
therapeutic options for mCRC patients with EGFR+/K-RAS wild-type tumours. This is 
based on the results of a phase III trial (CRYSTAL trial), conducted as first-line treatment 
for mCRC, comparing cetuximab plus FOLFIRI with FOLFIRI alone, showed improved 
progression-free survival, and, in patients with K-RAS wild-type tumours, a particularly 
significant increase in response rates (59.3%) and metastasis resection rates (7.0% vs 
3.7%) (Van Cutsem et al., 2009). 
The role of K-RAS mutational status in predicting tumour responsiveness to cetuximab 
has been previously shown in studies aimed to compare the administration of 
cetuximab alone or in combination with CPT-11 to patients with mCRC that had 
progressed after previous treatment (Lièvre et al., 2008) (De Roock et al., 2008) 
(Karapetis et al., 2008). Thus, as data from multiple clinical trials of cetuximab in mCRC 
have demonstrated that patients whose tumours contain activating mutations in the K-
RAS gene do not derive clinical benefit from antibody therapy, and have significantly 
shortened survival compared to patients whose tumour expresses wild-type K-RAS 
(Amado et al., 2008) (Lièvre et al., 2008), cetuximab use is limited to EGFR-positive K-
RAS wild-type tumours. 
The effect of cetuximab on the PK of high-dose of CPT-11 is also not known, although 
the non-overlapping pharmacology of both drugs is not suggestive of clinically-relevant 
drug-drug interactions at the level of drug disposition. Hence, we proposed to study the 
safety and PK of genotype-driven higher doses of CPT-11 in mCRC patients treated with 
FOLFIRI plus cetuximab. 
Thus, this second study, as the previous reported, will define the recommended dose of 
CPT-11 according to UGT1A1 genotype for FOLFIRI plus cetuximab regimen in patients 
with mCRC. The definition of MTD of CPT-11 (FOLFIRI) associated to cetuximab is 
essential to define the optimal CPT-11 dose for phase II-III studies in which CPT-11 
dosage will be based on UGT1A1 genotype. 
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1.3.3.3 Genotype-guided phase I study for weekly paclitaxel in 
ovarian cancer patients 
The American Cancer Society estimates about 22280 new diagnoses of ovarian cancer 
and 14240 deaths for this cancer in the United States for 2016. Ovarian cancer ranks 
fifth in cancer deaths among women, accounting for more deaths than any other cancer 
of the female reproductive system.  
Despite the fact that this cancer is highly treatable when caught early and confined to 
the ovary, less than one-fifth of cases are diagnosed while still in this early stage 
(American Cancer Society. Ovarian Cancer Detailed Guide). As a result, the 5- and 10-
year relative survival rates for ovarian cancer patients are 46% and 35%, respectively. 
However, survival varies substantially by age; women younger than 65 are twice as 
likely to survive 5 years as women 65 and older (58% versus 28%). Overall, only 15% of 
cases are diagnosed at a local stage, for which 5-year survival is 92% (Cancer Facts and 
Figures, 2016).  
To date, intensive surgical staging and cytoreduction, followed by first-line 
chemotherapy with the carboplatin-PTX regimen, are considered the gold standard for 
the management of this disease.  
The weekly administration of PTX, the treatment applied in our phase I study, has been 
investigated as treatment of platinum resistant ovarian cancer by several groups, with 
reports suggesting that approximately 10-20% of patients will achieve an objective 
response to the regimen (Fennelly et al., 1997) (Markman et al., 2002) (Kita et al., 2004). 
The results of a phase I study conducted by Takano et al., in 2002 (Takano et al., 2002) 
showed that weekly PTX has a different toxicity profile than higher-dosed schedules 
with less neutropenia, alopecia and neurotoxicity.  
In this context, our group has developed a third phase I clinical study of weekly PTX 
based on the ovarian cancer patient’s genetic profile. The genotype-guided phase I 
study design and aim are the same reported for the previously described trial. Hence, 
this section will present the main aspects characterizing the pharmacology of PTX and 
the rationale underlying our phase I study. 
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Paclitaxel  
PTX is a natural product isolated in 1971 from the bark of the Pacific Yew (Taxus 
brevifolia) (Wani et al., 1971). It belongs to taxanes, a very important class of anticancer 
agents available for clinical use since 1990s. It is approved for the treatment of several 
solid tumours, including ovarian (du Bois et al., 2003) (Parmar et al., 2003), breast 
(Sparano et al., 2008) (Sledge et al., 2003), non-small cell lung cancer (NSCLC) (Belani et 
al., 2005), and AIDS-related Kaposi Sarcoma (KS). It is administered in monotherapy or 
in association with other antineoplastic agents in several therapeutic schemes. 
PTX is a microtubule-interfering agent. Microtubules are part of cytoskeleton -within 
the cell's cytoplasm - and are involved in numerous cellular functions, including the 
maintenance of cell shape, intracellular transport, secretion and neurotransmission. 
Microtubules are made up of polymers of tubulin, which, in their turn, are made up of a 
heterodimer consisting of α- and β-tubulin subunits. Microtubules are highly dynamic 
and unstable structures that are constantly incorporating free dimers and releasing 
dimers into the soluble tubulin pool (Figure 16).  
 
Figure 16 Microtubules dynamic instability (polymerization and depolymerization Interconversion). They 
are dynamic polymers that are assembled from tubulin heterodimers, which are organized such that the 
microtubules have an intrinsic polarity. Although microtubules exhibit dynamic instability at both ends of 
the microtubule, the plus ends are more dynamic than the minus ends. Adapted from (Walczak et al., 
2010). 
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PTX binds to the β-tubulin subunit of the tubulin heterodimer, accelerate the 
polymerization of tubulin and stabilize the resultant microtubules inhibiting their 
depolymerization. This inhibition results in the arrest of the cell division cycle which 
triggers the cell signalling cascade, leading to apoptosis of cancer cells (Schiff and 
Horwitz, 1980) (Schiff and Horwitz, 1981). 
PTX is insoluble in aqueous solution and it is therefore formulated in 50% ethanol and 
50% cremophor-EL (a polyoxyethylated castor oil derivative that forms micelle) to 
improve its solubility (Gelderblom et al., 2001). This vehicle is responsible for increasing 
the risk of neuropathy and hypersensitive reactions in neoplastic patients (ten Tije et al., 
2003). PTX is a substrate of P-glycoprotein (P-gp). Being P-gp expressed in the luminal 
side of plasma membrane of gut epithelial cells (Cordon-Cardo et al., 1990) (Thiebaut et 
al., 1987), the absorption in the gut of PTX is prevented (Helgason et al., 2006), 
explaining its low bioavailability (5-8%) and the necessity to administer it only 
intravenously. It is administered as a 3-h i.v. infusion of 135-175 mg/m2 every 3 weeks or 
as a weekly 1-h i.v. infusion of 80-100 mg/m2. The most concerning side effects of PTX are 
neutropenia and neuropathy. Many patients experience myalgias for several days. Mucositis is 
prominent in 72- or 96-h i.v. infusions and in weekly schedule. Hypersensitivity reactions 
occurred in patients receiving PTX infusions of 1 to 6 hours but have largely been averted by 
premedication (Brunton et al., 2011) 
Paclitaxel pharmacokinetics 
A substantial number of clinical pharmacokinetic studies with PTX have been 
performed and have shown a nonlinear pharmacokinetic behaviour. The elimination of 
PTX has been described by a three-phase elimination curve and by a non linear profile, 
particularly with shorter infusions (Huizing et al., 1997). Moreover, a disproportional 
increase in Cmax and AUC at the increasing of the dose suggests the saturation of both 
elimination and distribution processes (where the saturable distribution has been 
described as saturable transport (Sonnichsen et al., 1994) or saturable binding (Karlsson 
et al., 1999)) at higher concentrations of PTX (Henningsson et al., 2001) (Mross et al., 
2000) (Gianni et al., 1995). Several studies with PTX given as a 6-h i.v. infusion 
documented nonlinear PK with doses higher than 250 mg/m2 (Brown et al., 1991) 
(Wiernik et al., 1987) (Grem et al., 1987), while others reported that a lower dose of 135 
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mg/m2 is the critical threshold for non-linear kinetics (Ohtsu et al., 1995) (Panday et al., 
1998). Similar findings were noted with 3-h i.v. infusion schedules in patients who 
received doses of 135 and 175 mg/m2, (Gianni et al., 1995) (Ohtsu et al., 1995) (Ye et al., 
2000).  
Cremophor-EL has been proposed to augmented the nonlinear pharmacokinetic 
behaviour of PTX in plasma by trapping the drug in micelles (because the highly 
hydrophobic PTX favours partitioning in cremophor-EL micelles) and thereby making it 
less available for distribution to tissues, metabolism, and biliary excretion (Sparreboom 
et al., 1996) (Van Tellingen et al., 1999) (van Zuylen et al., 2001). It has been reported 
indeed that the volume of distribution for cremophor-EL is small (ten Tije et al., 2003), 
thereby indicating that its distribution is more or less limited to plasma. Additionally 
cremophor-EL itself shows nonlinear kinetics. Although in minor extent, other 
mechanisms by which cremophor-EL affects PTX PK are hemodynamic changes 
(Bowers et al., 1991) and alteration in P-gp function (Schuurhuis et al., 1990). In the 
blood stream, the protein binding is 95-98 % (Longnecker et al., 1987) (Wiernik et al., 
1987). PTX binds α1-glycoprotein-acid and, in minor extent, albumin and lipoproteins 
(Kumar et al., 1993). Supporting extensive drug binding in vivo, total volumes of 
distribution have been reported as significantly variable, dependent from the 
dose/schedule and larger than that of total body water, ranging from 50 L/m2 to over 
650 L/m2 (Brown et al., 1991) (Tamura et al., 1994) (Wiernik et al., 1987). In addition, PTX 
shows high distribution in specific tissue of organs as kidney, lung, spleen, and in third 
space fluids, including ascitic and pleural fluid (Wiernik et al., 1987), while it does not 
penetrate in tumour sanctuary tissues, including testicles and brain, and it is not present 
in cerebral spinal fluid (Glantz et al., 1995) (Lesser et al., 1995). PTX clearance is 
nonlinear and decreases with increasing dose or dose rate. It disappears from plasma 
with a half-life of 10-14 hours and a clearance ranging from 15 to 18 L/hr/m2 (Brunton et 
al., 2011). The major route of elimination is biliary excretion (Monsarrat et al., 1993) 
(Walle et al., 1995), while renal excretion and other extrahepatic excretion mechanisms 
account for less than 10% of elimination (Longnecker et al., 1987) (Wiernik et al., 1987). 
The best model to predict the relationship between PTX plasma concentration and 
effects is the threshold model, in which the length of time that PTX concentration 
exceeds a threshold concentration is predictive of toxicity. In fact, it has been reported a 
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higher incidence of neutropenia and neuropathy in relation to how long the PTX plasma 
concentration exceeds 0.05 μmol/L (Gianni et al., 1995), 0.1 µmol/L (Huizing et al., 
1993), or 0.197 µmol/L (Henningsson et al., 2001). In a subsequent study, the estimated 
threshold concentration of 0.05 µmol/L was found correlated with the development of 
peripheral neuropathy (Mielke et al., 2005b). Moreover, patients with progressive 
disease showed significantly lower times of PTX concentrations above 0.05 µmol/L 
(Mielke et al., 2005a). Finally, an exposure-response relation was found in 
chemotherapy-naive patients with advanced NSCLC receiving PTX and carboplatin, 
whereas PTX concentrations above 0.1 µmol/L for >15 hours were related to improve 
OS (Huizing et al., 1997). 
Paclitaxel metabolism 
The major human metabolite identified is 6α-hydroxypaclitaxel (6α-OH-PTX) and 
corresponds to a stereospecific hydroxylation at the 6-position on the taxane ring as 
determined by nuclear magnetic resonance (Harris et al., 1994). Moreover, multiple 
hydroxylated products were found in plasma, such as 3’-p-hydroxypaclitaxel, 
corresponding to an hydroxylation at the para-position on the phenyl ring at the C3'-
position of the C13 side chain, and 6α,3’-p-dihydroxypaclitaxel (Figure 17) (Cresteil et al., 
1994) (Monsarrat et al., 1997).  
 
Figure 17 PTX and its main metabolites chemical structures. 
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Rahman et al. and more recently Henningsson et al. showed the role of cytochrome 
P450 2C8 (CYP2C8) in metabolism of PTX to 6α-OH-PTX (Henningsson, 2005) (Rahman 
et al., 1994). Cresteil et al. also showed that cytochrome P450 3A4 (CYP3A4) was 
responsible for the metabolism of PTX to 3’-p-hydroxypaclitaxel (Cresteil et al., 1994). 
6α-OH-PTX is approximately 30 times less cytotoxic than PTX when tested against 
ovarian and CRC cell lines and, thus, the formation of 6α-OH-PTX is likely an important 
detoxification pathway (Harris et al., 1994).  
Moreover, Kang et al. demonstrated that PTX cytotoxicity in HL60 and K562 human 
leukaemia cells had been increased in the presence of noncytotoxic concentrations of 
6α-OH-PTX (Kang et al., 2001). Activity of 3’-p-hydroxypaclitaxel was, in contrast, 
reduced but not absent in ovarian cancer cell lines. All the three metabolites cited 
before retained bone marrow toxicity when tested on human bone marrow cells 
(Sparreboom et al., 1995). 
Rationale of the phase I study 
Understanding the mechanism underneath the interindividual differences observed in 
the PTX PK and the related pharmacodynamic profile (toxicity and tumour response), 
could make treatment individualization feasible. 
As reported above, the systemic elimination of PTX involves CYP3A4 (that converts PTX 
to 3’-p-hydroxypaclitaxel) and CYP2C8 (that converts PTX to 6α-OH-PTX). Genes 
encoding these well-known metabolizing enzymes have been investigated in a large 
number of studies. The genetic variants CYP2C8*3 (Gréen et al., 2009) (Bosó et al., 
2014) (Hertz et al., 2012) (Leskelä et al., 2011) for PTX have shown predictive potential 
for haematological toxicity and neurotoxicity, although these positive associations 
could not be confirmed by other groups, as recently revised by Frederiks et al. 
(Frederiks et al., 2015).  
CYP3A4 expression is known to be regulated by the pregnane/steroid X receptor (PXR), 
coded by the NR1I2 gene. PXR is a well established regulator of many other genes 
including CYP3A5, CYP2C8 and ABCB1. Polymorphisms in the NR1I2 gene have been 
reported to modulate CYP3A4 expression (He et al., 2006), although their clinical effect 
remains to be elucidated. A novel genetic polymorphism in CYP3A4, CYP3A4*22, has 
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been identified as possible risk factor for neurotoxicity in patients receiving a PTX-
containing regimen (de Graan et al., 2013).  
PTX is a substrate of P-gp; a reduced P-gp mediated transport from blood to intestine 
indeed would increase systemic drug exposure, affecting PTX PK. Thus, cancer cells 
with an ineffective P-gp efflux should be more sensitive to the drug. P-gp is encoded by 
the ATP Binding Cassette gene (ABCB1). 
Among at least 50 common SNPs described in ABCB1 gene in Caucasians, 2677G>T/A 
(responsible for the substitution from alanine to serine or threonine) and 3435C>T 
(responsible for the wobble effect on the glutamic acid) SNPs have been shown to 
correlate with the P-gp expression and phenotype. In particular, the 2677G>T/A allele 
has demonstrated to impact PTX PK and PD in ovarian cancer patients (Hamidovic et 
al., 2010). Johnatty et al. (Johnatty et al., 2008) found a significant association between 
ABCB1-2677G>T/A and progression free survival in 309 patients from the Australian 
Ovarian Cancer Study treated with PTX/carboplatin. The SCOTROC1 trial failed to 
confirm this evidence in the entire group of 914 ovarian cancer patients treated with 
taxanes (Marsh et al., 2007), but in a selected subset of patients with optimal debulking, 
the significant association with progression free survival, was confirmed (Johnatty et al., 
2008). An association of the SNP with higher risk of severe haematological and non-
haematological toxicity was demonstrated in 118 ovarian cancer patients of Asian 
ethnicity treated with PTX and carboplatin (Kim et al., 2009).  
The mechanism underneath the association of ABCB1-2677G>T/A with toxicity and 
efficacy seems related to an effect on the PK: the presence of the 2677T/A genotype 
affects PTX clearance, that resulted lowered in patients carrying the variant allele 
(Green, 2008) (Wong et al., 2005). Moreover, a pilot study on 20 carboplatin/PTX 
treated ovarian cancer patients conducted by our group confirmed a lowered PTX 
clearance for patients carrying the variant 2677T/A allele (unpublished data).  
Based on this background, our group designed a genotype-guided phase I clinical trial 
of weekly PTX in order to define the MTD and DLTs according to the ABCB1-2677G>T/A 
SNP in epithelial ovarian cancer patients. 
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1.3.4 Personalized chemotherapy: therapeutic drug 
monitoring 
Therapeutic drug monitoring (TDM), introduced in the clinical care from the early 
1960s, involves the measurement and interpretation of drug concentrations in 
biological fluids in order to individualize the drug dosages or schedules thus maximizing 
the therapeutic outcomes and/or minimizing toxicities (Alnaim, 2007). 
In theory, a drug should fulfil several criteria in order to apply the TDM approach 
(Sanavio and Krol, 2015): 
 presence of considerable inter- or intra-individual variability in PK; 
 existence of a defined and ascertainable relationship between concentration and 
pharmacological effects; 
 narrow therapeutic window; 
 absence of a simple accessible parameter to evaluate clinical efficacy; 
 availability of a defined and accurate method for drug quantification in biological 
fluids. 
TDM is broadly applied to drugs from different therapeutic classes, such as 
cardiovascular agents, antiepileptics, antibiotics, respiratory smooth muscle relaxants, 
anti-inflammatory agents, immunosuppressants, and antidepressants (Bardin et al., 
2014). Anticancer drugs also fit many of the criteria commonly defined as prerequisites 
for utilizing TDM approaches. Firstly, the extent of inter-individual pharmacokinetic 
variability exhibited is large in the majority of cases, with coefficients of clearance 
variation of more than 50%. Variability in PK leads also to plasma concentration 
fluctuation that may vary over 10-fold range when fixed doses of chemotherapeutic 
agents are administered (Bardin et al., 2014). Secondly, relationships have been 
described between drug plasma concentrations and PD end-points such as percentage 
decrease in neutrophil counts between pretreatment and nadir values (Paci et al., 2014). 
Moreover, TDM in cancer chemotherapy has additional advantages like enhancement 
of compliance, dose adjustment in patients with hepatic and renal dysfunction, and 
detection of drug interactions (Reynolds and Aronson, 1993). Furthermore, adjusting 
the drug dose on the basis of its plasma concentration potentially allow to take in 
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consideration simultaneously all the individual factors that affect the systemic exposure 
(Figure 9) in order to minimize the pharmacokinetic variability among patients. 
Despite the potential benefits deriving from the application of TDM in cancer 
chemotherapy, the clinical value of TDM for antineoplastic agents still remains 
restricted by several factors (Alnaim, 2007). First of all, there is naturally a long lag time 
between the measurement of drug in plasma and evaluation of the definitive 
pharmacodynamic effect, which is, usually, cure. If improvement in cure rate is used as 
the outcome variable, this usually requires at least 5 years of follow-up to dependably 
evaluate the outcome. Consequently, studies require more time and more complex 
process than that of studies for drugs with quicker effects, such as antibiotics. 
Furthermore, the identification of the concentration–effect relationships results 
complicated since antineoplastic agents are almost always given in combination 
(Chatelut et al., 2000), condition that renders very difficult to accurately define the PK 
of each individual agent. In addition, combination therapy also complicates the PK of 
drug toxicity. 
Another limitation in implementing TDM in clinical practice is due to the heterogeneous 
feature of cancer, with inherent characteristics that affect the concentration–effect 
relationship for antineoplastic agents. They display heterogeneity in blood supply and 
cellular characteristics, leading to different levels of sensitivity and resistance to 
antineoplastic agents (Pignon et al., 1994).  
Lastly, sensitive, precise and reproducible assays available for the clinical use are 
required in order to implement TDM use in daily practice. Equally, the implementation 
of the analytical assays for a rapid and sensitive quantification of drugs in human 
plasma could enhance the effort in order to better and more extensively define the 
concentration–effect relationship with antineoplastic agents. 
1.3.4.1 Therapeutic drug monitoring: the case of sunitinib 
Despite targeted therapies are now revolutionizing cancer treatment by transforming 
some previously deadly malignancies into chronically manageable conditions, poor 
tolerability and therapeutic failure are not uncommon, and relapse is a nearly inevitable 
consequence of treatment interruption (Widmer et al., 2014). In addition, oral 
administration of these drugs is, on the one side, associated with a better quality of life 
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but, on the other side, also generates a complex step in the PK of these drugs. Thus, 
standard dosage regimens rarely result in comparable circulating concentrations of the 
active drug in all patients, possibly favouring the selection of resistant cellular clones (in 
case of sub-therapeutic drug exposure) or the development of undesirable toxicity (in 
case of overexposure) (Gao et al., 2012).  
Moreover, retrospective studies have shown that targeted drug exposure, reflected in 
the AUC, correlates with treatment response (efficacy/toxicity) in various cancers 
(Widmer et al., 2014). 
Surely, these characteristics render the targeted therapies suitable for TDM. In 
particular, this section will take in consideration the case of sunitinib. 
Sunitinib 
Sunitinib (SUTENT) is an oral multi-targeted tyrosine kinase inhibitor. It competitively 
inhibits the binding of ATP to the tyrosine kinase domain on the VEGF receptor-2, 
which mediates the majority of the downstream effects of VEGF-A, including vascular 
permeability, endothelial cell proliferation, invasion, migration, and survival (Dvorak, 
2002). This inhibitor is a low molecular-weight, ATP-mimetic agent that binds to the 
ATP-binding catalytic site of the tyrosine kinase domain of VEGFR, resulting in a 
blockade of intracellular signalling. It has both direct antiproliferative effects and 
antiangiogenic properties. Sunitinib also inhibits other protein tyrosine kinases (FLT3, 
PDGFR-α, PDGFR-β, RET, CSF-1R, and c-KIT) at concentrations of 5-100 nM (Fabian et 
al., 2005). It has activity in metastatic renal-cell cancer (mRCC), producing a higher 
response rate (31%) and a longer progression-free survival than any other approved 
anti-angiogenic drug (Motzer et al., 2007). Sunitinib is also approved for treatment of 
gastrointestinal stromal tumour (GIST) that has developed resistance to imatinib as a 
consequence of c-KIT mutations (Heinrich et al., 2008). Sunitinib is administered orally 
in doses of 50 mg once a day. The typical cycle of sunitinib is 4 weeks on treatment 
followed by 2 weeks off treatment. The dosage and schedule of sunitinib can be 
increased or decreased according to toxicity (hypertension, fatigue). Dosages <25 
mg/day typically are ineffective (Brunton et al., 2011). 
Sunitinib is primarily metabolized by CYP3A4 to an equipotent N-desethyl metabolite 
(N-desethyl sunitinib) (Sakamoto, 2004) (Figure 18). 
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Figure 18 Chemical structures of sunitinib and its metabolite, N-desethyl sunitinib. 
Protein binding of sunitinib and N-desethyl sunitinib is 95% and 90%, respectively. AUC 
and Cmax are increasing proportionally with increasing dose within a range of 25–100 mg 
and are not affected by food. Maximum plasma concentrations of sunitinib are reached 
between 6 and 12 h and the terminal half-lives of sunitinib and N-desethyl sunitinib are 
40–60 h and 80–110 h, respectively (Le Tourneau et al., 2007) (Goodman et al., 2007) 
(Mendel et al., 2003).  
Recent studies suggested sunitinib as a candidate for a TDM program. In fact, increased 
exposure to sunitinib in patients with advanced solid tumours is associated with 
improved clinical outcomes (longer time to tumour progression, longer overall survival, 
a higher probability of a response and greater tumour-size decreases), as well as some 
increased risks of adverse effects (incidence of fatigue, increase of diastolic blood 
pressure, decrease of absolute neutrophil count) (Houk et al., 2009). Additionally, a 
recent retrospective analysis of 521 patients with mRCC has shown that plasma 
concentration might be better correlated to PFS than to the administered dose of drug 
(Khosravan, 2012). Thus, based on preclinical data (Houk et al., 2010) and on a phase I 
study (Faivre, 2006), a target plasma concentration of sunitinib and active metabolite in 
the range of 50–100 ng/mL has been suggested. 
The analytical issue 
Despite this information, in order to introduce the TDM of sunitinib in the clinical 
practice it is necessary also to have a rapid, specific, sensitive and reproducible 
analitycal method. One of the most challenging peculiarities of sunitinib for the setup of 
an analytical method is represented by its isomerization in presence of light. In fact, 
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sunitinib and N-desethyl sunitinib are 5-fluoro-2-oxindoles attached to a dimethyl 
pyrrole carboxamide by an exocyclic double bond prone to showing light-induced Z/E-
isomerism (Figure 19). 
 
Figure 19 Z/E-isomerism of sunitinib. The symbol * indicates the double bond that undergoes 
isomerization. 
Similar photo induced isomerism of molecules with double bonds has been reported in 
literature and have shown to result in the formation of the less stable isomer 
(Whitesides et al., 1969) (Zhang et al., 2001). In this case, the predominance of Z-isomer 
results from an intramolecular hydrogen bond between the C-2 carbonyl oxygen atom 
of the indolin-2-one ring and the proton of the pyrrole NH-group (Rodamer et al., 2011).  
The group of Sistla studied the isomerization of a precursor of sunitinib, semaxanib, 
and, in order to determine the reversion kinetics, they exposed an analytical solution of 
this drug to light for 23 hours to attain equilibrium between the two Z and E isomers. 
This solution was then protected from light at different temperatures to study the E- to 
Z-isomer conversion. The E-isomer was observed to revert to the Z-isomer following 
storage in the dark with an increase in the reconversion rate at higher temperatures. 
This observation indicates that the reversion of E- to Z- isomer is a thermal reversion 
(Sistla and Shenoy, 2005). Their infusate studies indicated also that <2% E-isomer will 
be dosed to patients and would likely convert to the Z-isomer, following administration. 
This report implies no limitations towards ensuring pharmaceutical product quality. 
Anyway, special attention must be paid to both isomers during any patient’s plasma 
analysis steps, from the collection to the samples treatment and analysis. 
In this context, a LC-MS/MS method has been developed, particularly taking into 
account the isomerisation issue, and validated in order to set up a simple, rapid and 
sensitive analytical assay for the application of TDM in the sunitinib-based therapy. 
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2 AIMS 
The great inter-patient variability in the PK and PD of the anticancer drugs and their low 
therapeutic index dramatically complicate the dosing of these drugs, leading to a 
significant variability in both therapeutic and toxic effects. Moreover, the traditional 
method based on the measurement of the BSA does not account for the complex 
processes of anticancer drug metabolism and elimination and, over the years, the need 
for a new dosing approach has become increasingly evident. 
The recent progresses in the research field against cancer introduced the concept of 
personalized therapy with the aim of tailoring medical treatment to the individual 
characteristics and needs of the single patient. In particular, the giant steps made in the 
PGx field paved the way for a tailoring therapy leading to personalize the anticancer 
drugs dose on the basis of the patient genotype. However, for drugs such as targeted 
anti-cancer agents, which are only recently introduced in the clinical practice, no PGx 
biomarkers are known up-to-date for dosage optimization. Thus, in these cases there is 
the necessity to apply other methods to personalize the therapy, such as the TDM.  
On the one hand, the object of this PhD project has been the redefinition of the MTD of 
two conventional and widely used anticancer drugs, CPT-11 and PTX, on the basis of 
patient’s genotype, in order to move from “one dose fits all” model to the “personalized 
medicine” approach. For this reason, innovative genotype-guided phase I clinical studies 
have been designed using PGx biomarkers for patients stratification.  
On the other hand, additional purpose of this thesis has been the development of 
different LC-MS/MS methods for the quantification of both the two cytotoxic drugs 
cited before and sunitinib, one of the most important targeted anti-cancer agent. These 
methods were developed to quantify these drugs, along with their main metabolites, in 
human plasma samples in order to obtain the pharmacokinetic data related to the 
phase I studies for CPT-11 and PTX, and TDM for sunitinib. These methods have also 
been validated according to FDA-EMA guidelines, in order to assess the robustness of 
the methods and the reliability of the obtained data. 
The specific aims of each clinical study are reported below: 
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Genotype-guided phase I study of irinotecan administered in combination with 5-
fluorouracil/leucovorin (FOLFIRI) and bevacizumab in advanced colorectal cancer patients 
The primary aim of this study was: 
 to define the MTD and the DLTs of CPT-11 administered in the FOLFIRI regimen 
plus bevacizumab in mCRC patients according to UGT1A1*28 genotype.  
The secondary purposes of this trial were: 
 to develop and validate a LC-MS/MS method for the quantification of CPT-11 
and its main metabolites (SN-38, SN-38G, and APC) in human plasma samples; 
 to evaluate the variability of CPT-11 PK in patients with *1/*1 and *1/*28 
genotype and the effect of the PK on toxicity and response rate; 
 to evaluate a possible effect of bevacizumab on CPT-11 PK.  
Genotype-guided phase I study of irinotecan administered in combination with 5-
fluorouracil/leucovorin (FOLFIRI) and cetuximab as first-line therapy in metastatic 
colorectal cancer patients 
This second phase I study shares the same aims of the previous one, since it has been 
designed on the basis of the preliminary results obtained: 
 to define the MTD and the DLTs of CPT-11, administered in the FOLFIRI regimen 
plus cetuximab in mCRC patients treated as first-line chemotherapy according 
to UGT1A1*28 genotype; 
 to evaluate the variability of CPT-11 PK in patients with *1/*1 and *1/*28 
genotype and the effect of the PK on toxicity and response rate; 
 to evaluate a possible effect of cetuximab on the CPT-11 PK. 
Genotype-guided phase I study for weekly paclitaxel in ovarian cancer patients 
The primary aim of this study was: 
 to define the MTD and the DLTs of weekly PTX according to the ABCB1-
2677G>T/A polymorphism in epithelial ovarian cancer patients; 
Secondary aims of the study were: 
 to develop and validate a LC-MS/MS method for the quantification of PTX and 
its main metabolite, 6α-OH-PTX, in human plasma samples; 
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 to evaluate the PK of PTX and its 6α-hydroxylated metabolite in human plasma 
and the correlation of PTX PK with the ABCB1-2677G>T/A different genotypes;  
 to define the effect of PTX PK on toxicity and response rate.  
2 Aims  
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3.1 Phase I clinical trials  
3.1.1 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and bevacizumab in advanced colorectal cancer 
patients  
The protocol of this trial (EudraCT n. 2009-012227-28) has been revised and approved 
by the CRO ethical committee, the AIFA (Agenzia Italiana del Farmaco) and the ISS 
(Istituto Superiore di Sanità). It has been conducted in collaboration with University of 
Chicago Medical Center (IL, U.S.A) and San Filippo Neri Hospital of Rome (Italy) and the 
protocol was approved by the ethical committee of each participating site. All patients 
signed a written informed consent before entering the study. The main characteristics 
of this study are briefly described above. 
3.1.1.1 Patients characteristics 
The eligibility criteria for this study are:  
 histologically or cytologically confirmed diagnosis of mCRC;  
 no prior chemotherapy for metastatic disease;  
 age ≥18 or 75 years; 
 Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1;  
 life expectancy > 3 months;  
 measurable or evaluable disease (defined as > 1 cm on spiral computed tomography 
scan);  
 adequate organ function, including bone marrow (absolute neutrophil count (ANC) 
≥l500/µL, haemoglobin ≥9g/dL, platelets ≥100000/µL); hepatic (total bilirubin <1.6 
mg/dL, international normalized ratio or ≤2x for Gilbert’s Syndrome, aspartate 
aminotransferase/alanine aminotransferase <2.5 x upper limit of normal for patients 
without liver metastases, <5 x upper limit of normal for patients with liver 
metastases); and kidneys (serum creatinine ≤1.5 x upper limit of normal) function; 
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 patients who are eligible to be registered in the study, based upon the above 
criteria, will be genotyped for UGT1A1*28 polymorphism and stratified into two 
groups based on the presence of *1/*1 or *1/*28 genotype. Patients with both 
variant alleles *28/*28 will be excluded; 
 for patients valuable for response (secondary end point), at least one measurable 
cancer lesion as defined by RECIST, i.e. lesions that can be accurately measured in 
at least one dimension with the longest diameter ≥20 mm using conventional 
techniques or ≥10 mm using spiral computerized tomography scan;  
 signed informed consent and local ethical committee approval are requested.  
The exclusion criteria are:  
 prior CPT-11 and bevacizumab treatment;  
 chronic enteric diseases (Crohn disease, ulcerous colitis); 
 unresolved diarrhea and bowel obstruction;  
 documented cerebral metastasis;  
 serious active infectious disease;  
 serious functional alteration of visceral and metabolic disease;  
 pregnancy status;  
 radiotherapy or major surgery within 4 weeks; 
 all patients in fertile age must have been under contraceptive treatment;  
 presence of previous or concomitant neoplasm with exclusion of in situ cervical 
cancer;  
 patients who could not attend periodic clinical check-ups. 
3.1.1.2 Drug administration, dose escalation and DLT/MTD definitions 
Patients have been treated with the FOLFIRI regimen plus bevacizumab, where CPT-11 
has been administered at doses higher than the standard dose in patients with the 
UGT1A1 *1/*1 and *1/*28 genotypes. The initial dose of CPT-11 for the two groups of 
patients (the UGT1A1 *1/*1 and *1/*28) was 260 mg/m2 administered as a 120 min 
intravenous infusion every 2 weeks (base on the previous phase I (Toffoli et al., 2010)). 
As per protocol, the CPT-11 dosage could be increased to 310, 370, and 420 mg/m2, and 
further CPT-11 doses would be increased of 14%; 5-FU was administered as 400 mg/m2 
bolus right after the end of the CPT-11 infusion, followed by 2400 mg/m2 over a 46 h 
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continuous infusion plus leucovorin 200 mg/m2 every two weeks. Bevacizumab was 
administered at a dose of 5 mg/kg by 90 min IV on day 3 and 15 during the first 28 day-
cycle of treatment. No dose modification has been performed for 5-FU, LV and 
bevacizumab. Before starting CPT-11, patients have been pre-treated with atropine 0.5 
mg, dexamethasone 8 mg, granisetron 3 mg or ondansetron 8 mg. Diarrhoea has been 
treated promptly with loperamide 4 mg at the onset, and then with 2 mg every 2 h, until 
the patient would be diarrhoea-free for at least 12 h. Growth factors (i.e., G-CSF) have 
been allowed only in patients who had grade 3-4 neutropenia at previous cycles. DLT 
was defined as haematological grade 4 toxicity or non haematological grade 3-4 toxicity 
recorded at cycle 1 that developed or persisted despite supportive measures (i.e. anti-
diarrhoeas or anti-emetics). Toxicity was classified and graded according to the U.S. 
NCI’s Common Terminology Criteria for Adverse Events (version 3.0). Under a “3+3” 
design, three patients have been enrolled at any dose level, they have been treated with 
CPT-11 at 260 mg/m2 and if DLT was observed in <1/3 of them, dose level would be 
escalated and 3 patients would be treated at the next dose level (310 mg/m2). If DLT was 
observed in 1/3 of the patients, 3 additional patients were enrolled at the same dose 
level and the escalation to the next dose level (310 mg/m2) continued if DLT occurred in 
1/6 of the 6 patients treated at 260 mg/m2. If DLT was observed in ≥1/3 or >1/6 patients 
treated at any given dose level, the dose escalation was stopped, and 10 patients total 
were then enrolled at one dose level below to assess the safety and the inter-patient 
pharmacokinetic variability. If DLT was observed in <1/3 of patients enrolled at this dose 
level experience DLT, this dose level was declared as the MTD. The MTD recommended 
for phase II studies has been defined as the dose level immediately below that at which 
1/3 of patients out of three patients or 1/6 out of six patients experienced DLT. 
Therefore at the MTD, 1/3 out of at least 10 patients experienced DLT. No intra-patient 
dose escalation was allowed.  
3.1.1.3 Efficacy and toxicity assessment 
Blood counts were measured at baseline, weekly during cycle 1, and within 48 hours 
before each administration during following cycles. Clinical evaluation, haematological, 
hepatic and renal function tests were performed at baseline and within 48 hours before 
each CPT-11 administration, during which patients were questioned about nausea and 
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vomiting, mucositis, diarrhoea, malaise, and appetite. Computed-tomography (CT) 
scans of measurable lesions were assessed at baseline and repeated every two cycles, 
with a minimum of one on-treatment CT required to be evaluable for efficacy (unless 
there was clinical disease progression). Objective tumour response, limited to those 
patients with measurable disease at enrolment, was assessed according to RECIST 
(version 1.0) (Therasse et al., 2000). The response criteria were: 
 Complete response (CR): Disappearance of all target lesions; 
 Partial response (PR): At least a 30% decrease in the sum of the longest diameter 
(LD) of target lesions, taking as reference the baseline sum LD; 
 Progressive disease (PD): At least a 20% increase in the sum of the LD of target 
lesions, taking as reference the smallest sum LD recorded since the treatment 
started or the appearance of one or more new lesions; 
 Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum LD since the 
treatment started. 
PFS was measured from the time of drug administration to the occurrence of 
progressive disease or death, whichever came first.  
Patients could continue receiving the same dose of CPT-11 in absence of major toxicity 
according to the following criteria: before re-treatment, full recovery from any non 
haematological toxicity, an ANC 1500/µL and platelet count 100000/mm3, were 
required. Chemotherapy was discontinued on evidence of disease progression, or the 
appearance of new lesions on serial magnetic resonance or CT scans. Patients 
experiencing a major toxicity during the first or successive cycles of therapy were 
allowed to receive additional treatment with a 25% reduction in the CPT-11 dose. The 
cumulative haematological and non haematological toxicity as well as the number of 
dose reductions and a delay in starting the next cycle of treatment have been used as 
secondary indicators to differentiate the two genotype cohorts of patients. 
3.1.1.4 Pharmacokinetic study 
To improve current knowledge about the potential PK and PD interaction between 
bevacizumab and CPT-11, the pharmacokinetic profile of CPT-11 has been evaluated in 
absence and presence of bevacizumab in the same patient. In fact, in all patients 
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enrolled in the study and at each dose level the pharmacokinetic profile of CPT-11 alone 
has been evaluated at the first chemotherapy treatment during which bevacizumab was 
administered on day 3 (46h from the end of CPT-11 administration). Instead, CPT-11 PK 
in combination with bevacizumab was performed at day 1 of the second treatment 
where a second dose of bevacizumab was administered concomitantly to CPT-11.  
Thus, serial blood samples were collected into heparinised tubes before drug 
administration, and at 1.0, 2.0, 2.25, 2.50, 3.0, 4.0, 6.0, 8.0, 10.0, 14.0, 26.0, 50.0 h 
following the start of the CPT-11 infusion (Figure 20).  
 
Figure 20 Schematic representation of the sampling times scheduled for the pharmacokinetic study 
during the first (day 1-3) and second administration (day 15-17) of the first chemotherapy cycle. 
Plasma was obtained immediately by centrifugation of the blood samples at 3,000 g for 
15 min at 4°C, and stored at -80°C.  
The quantification of CPT-11 and its main metabolites, SN-38, SN-38G, and APC, in 
patients’ plasma sample has been performed with the validated LC-MS/MS method 
specifically developed for this study (Marangon et al., 2015).  
Non-compartmental analysis was used to generate the PK data, as described in more 
details in Section 3.4. Moreover, the extent of glucuronidation of SN38 to SN38G in 
plasma was defined as the ratio of SN38G AUClast/SN38 AUClast (glucuronidation ratio -
GR). 
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3.1.2 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and cetuximab as first-line therapy in metastatic 
colorectal cancer patients  
This phase I clinical trial has been conducted in collaboration with University of Chicago 
Medical Center (IL, U.S.A).The protocol of this trial (EudraCT n.2013-005618-37) has 
been revised and approved by the ethical committee of each participating site, the AIFA 
(Agenzia Italiana del Farmaco) and the ISS (Istituto Superiore di Sanità). All patients 
signed a written informed consent before entering the study. The main characteristics 
of this study are briefly described above. 
3.1.2.1 Patients characteristics 
The eligibility criteria for this study are:  
 histologically or cytologically confirmed diagnosis of mCRC expressing EGFR;  
 RAS wild-type status;  
 no prior chemotherapy for metastatic disease;  
 age ≥18; 
 ECOG PS of 0 or 1;  
 life expectancy > 3 months;  
 measurable or evaluable disease (defined as > 1 cm on spiral computed tomography 
scan);  
 adequate organ function, including bone marrow ANC ≥1500/µL, haemoglobin 
≥9g/dL, platelets ≥100000/µL); hepatic (total bilirubin <1.6 mg/dL, international 
normalized ratio or ≤2x for Gilbert’s Syndrome, aspartate aminotransferase/alanine 
aminotransferase <2.5 x upper limit of normal for patients without liver metastases, 
<5 x upper limit of normal for patients with liver metastases); and kidneys (serum 
creatinine ≤1.5 x upper limit of normal) function; 
 patients who are eligible to be registered in the study, based upon the above 
criteria, will be genotyped for UGT1A1*28 polymorphism and stratified into two 
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groups based on the presence of *1/*1 or *1/*28 genotype. Patients with both 
variant alleles *28/*28 will be excluded; 
 for patients valuable for response (secondary end point), at least one measurable 
cancer lesion as defined by RECIST, i.e. lesions that can be accurately measured in 
at least one dimension with the longest diameter ≥20 mm using conventional 
techniques or ≥10 mm using spiral computerized tomography scan;  
 signed informed consent and local ethical committee approval are requested.  
The exclusion criteria are:  
 cardiac pathology (cardiac decompensation, infarction during the period of 6 
months preceding the study, atrioventricular block, serious arrhythmia); 
 patients with specific contraindications for the use of EGFR inhibitors (pulmonary 
fibrosis, interstitial pneumonia history); 
 unresolved diarrhoea and bowel obstruction;  
 haemorrhagic syndrome; 
 documented cerebral metastasis;  
 serious active infectious disease;  
 serious functional alteration of visceral and metabolic disease;  
 pregnancy status;  
 radiotherapy or major surgery within 4 weeks; 
 all patients in fertile age must have been under contraceptive treatment;  
 presence of previous or concomitant neoplasm with exclusion of in situ cervical 
cancer;  
 non collaborative and/or unreliable patients;  
 patients with a chronic toxicity ≥grade 2; 
 refusal of informed consent; 
 patients who could not attend periodic clinical check-ups. 
3.1.2.2 Drug administration, dose escalation and DLT/MTD definitions 
Patients are treated with FOLFIRI regimen plus cetuximab, where CPT-11 is 
administered at doses higher than the standard dose in patients with UGT1A1 *1/*1 and 
*1/*28 genotypes. The starting dose of CPT-11 for the two groups of patients (UGT1A1 
*1/*1 and *1/*28  group) is 260 mg/m
2 administered as a 120 min intravenous infusion 
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every 2 weeks. The CPT-11 dosage will be increased to 310, 370, and 420 mg/m2, and 
further CPT-11 doses will be increased of 14%; 5-FU is administered as 400 mg/m2 bolus 
right after the end of the CPT-11 infusion, followed by 2400 mg/m2 over a 46-h 
continuous infusion plus LV 200 mg/m2 every two weeks. Cetuximab is administered as 
an intravenous infusion at a dose of 500 mg/m2 with prophylactic intravenous steroids 
and anti-histaminic agents. Cetuximab is administered every 2 weeks. No dose 
modification will be performed for 5-FU, LV and cetuximab. One cycle is 28 days (two 
CPT-11 administrations). Before starting CPT-11, patients are pre-treated with atropine 
0.5 mg, dexamethasone 8 mg, granisetron 3 mg or ondansetron 8 mg. Diarrhoea will be 
promptly treated with loperamide 4 mg at the onset, and then with 2 mg every 2 h, until 
the patient will be diarrhoea-free for at least a minimum of 12 h. Growth factors (i.e., G-
CSF) is allowed only in patients who will have grade ≥ 3 neutropenia at previous cycles. 
The dosage of CPT-11 is escalated applying a “3 + 3” cohort expansion design to reach 
the MTD. There will be two genotype cohorts of patients: one for each genotype 
(UGT1A1 *1/*1 and *1/*28 groups), and the escalation study will proceed accordingly. 
Three patients will be enrolled and treated with CPT-11 at the starting dose (260 
mg/m2). If DLT is observed in <1/3 of them, the dose level will be escalated and three 
patients more will be treated at the next dose level (310 mg/m2). If DLT is observed in 
1/3 of the patients, 3 additional patients will be enrolled at the same dose level. The 
escalation to the next dose level will continue if DLT occurs in ≤1/6 of the 6 patients 
treated at the first dose level (260 mg/m2). If DLT is observed in >1/3 or >1/6 of the 
patients treated at any given dose level, the dose escalation will be stopped, and 10 
patients in total will then be enrolled at one dose level lower to assess the safety and 
the inter-patient pharmacokinetic variability.  
The MTD recommended for phase II studies will be defined as the dose level 
immediately below the one at which ≥1/3 of patients out of three patients or ≥1/6 out of 
six patients experienced DLT. Therefore at the MTD, ≤1/3 out of at least 10 patients 
experienced DLT. No intra-patient dose escalation is allowed.  
DLT is defined as haematological grade 4 toxicity or non-haematological grade 3-4 
toxicity and developed or persisted despite supportive measures (i.e. anti-diarrhoeas or 
anti-emetics). DLT will be evaluated during the first cycle of chemotherapy (2 
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administrations). Toxicity is classified and graded according to the United States NCI’s 
common toxicity criteria (version 4.03). 
The cumulative haematological and non haematological toxicities as well as the number 
of dose reductions and a delay in starting the next cycle of treatment will be used as 
secondary indicators to differentiate the two genotype cohorts of patients. 
3.1.2.3 Efficacy and toxicity assessment 
See section 3.1.1.3. 
3.1.2.4 Pharmacokinetic study 
To improve the current knowledge about the potential pharmacokinetic and 
pharmacodynamic interactions between cetuximab and CPT-11, this open label drug-
drug interaction study evaluates the pharmacokinetic profile of CPT-11 in absence and 
presence of cetuximab in the same patient within the first chemotherapy cycle. 
In all patients enrolled in the study and at each dose level, the pharmacokinetic profile 
of CPT-11 alone will be evaluated at the first chemotherapy treatment (on days 1-3) 
during which cetuximab will be administered on day 3 (48 h from the end of CPT-11 
administration). Instead, the PK of CPT-11 in combination with cetuximab will be 
performed on days 15-17 of the second treatment of the first cycle of therapy where a 
second dose of cetuximab will be administered concomitantly to CPT-11.  
Thus, serial blood samples are collected into tubes containing K-EDTA (4.9 mL). The 
sampling times is: before drug administration and at 1.0, 2.0, 2.25, 2.50, 3.0, 4.0, 6.0, 
8.0, 10.0, 26.0 and 50.0 h following the start of the CPT-11 infusion during both the 
treatments of the first cycle of therapy, as schematized in Figure 21. Plasma is obtained 
immediately by centrifugation of blood samples (3000 g for 10 min at 4°C), then split 
into 2 aliquots and stored at -80°C in 2 different freezers.  
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Figure 21 Schematic representation of the sampling times scheduled for the pharmacokinetic study 
during the first (day 1-3) and second administration (day 15-17) of the first chemotherapy cycle. 
The quantification of CPT-11 and its main metabolites in patients’ plasma sample has 
been performed with the validated LC-MS/MS method specifically developed for the 
previous phase I study and already published (Marangon et al., 2015). 
3.1.3 Genotype-guided phase I study for weekly paclitaxel in 
ovarian cancer patients 
The protocol of this trial (EudraCT n. 2010-021619-18) has been revised and approved 
by the CRO ethical committee, the AIFA (Agenzia Italiana del Farmaco) and the ISS 
(Istituto Superiore di Sanità). All patients signed a written informed consent before 
entering the study. The main characteristics of this study are briefly described above. 
3.1.3.1 Patients characteristics 
The eligibility criteria for this study are:  
 histologically confirmed diagnosis of relapsed epithelial ovarian cancer;  
 indication for chemotherapy treatment; 
 age ≥18 years and ≤75 years (for patients ≥70 years a multidisciplinary geriatric 
evaluation will be performed); 
 ECOG PS ≤ 2; 
 life expectancy >3 months;  
 pretreatment with adequate dose of platinum based regimens; 
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 measurable disease according to GCIG guidelines (RECIST and/or CA-125 criteria); 
 patients enrolled in the study according to the previous eligibility criteria will be 
genotyped for the ABCB1-2677G>T/A polymorphism and stratified in two groups 
based on the presence of at least one ABCB1-2677T/A variant allele (i.e. group 1: 
ABCB1-2677GG genotype; group 2: ABCB1-2677GT; GA, AA, TT, AT genotypes). 
The exclusion criteria are:  
 cardiac pathology (cardiac decompensation, infarction during the period of 6 
months preceding the study, atrioventricular block, serious arrhythmia); 
 ANC <1,500/µL, platelets <100,000/µL; 
 alterations of renal function (serum creatinine ≥1.25 fold the normal limit); 
 alterations of hepatic function (GOT or GPT ≥1.25 fold the normal limit unless 
clearly due to hepatic metastasis);  
 hemorrhagic syndrome; 
 chronic neuropathy grade ≥2; 
 non collaborative and/or unreliable patients;  
 patients’ impossibility of coming to CRO; 
 patients previously treated with >3 therapy lines for the metastatic disease; 
 patients with a chronic toxicity grade ≥2; 
 refusal of informed consent. 
3.1.3.2 Drug administration, dose escalation and DLT/MTD definitions 
Patients have been treated with weekly PTX starting from an 80 mg/m2 dose for both 
groups: the high risk of toxicity (group 2, ABCB1-2677GT, GA, AA, TT, AT genotypes) 
and the low (group 1, ABCB1-2677GG genotype). Dose escalation steps have been of 10 
mg/m2 for dose level. PTX was administered as 60 minutes intravenous infusion every 
week following anti-hypersensitivity premedication with corticosteroid and anti H1–H2 
histamine receptor. 
DLT was defined as haematological toxicity grade 4 or non-haematological toxicity 
grade ≥ 3. DLTs have been evaluated during the first two cycles of chemotherapy (8 
weekly administrations). Additionally, it has been considered DLT if the recovery from 
any non haematological toxicity, of ANC to 1500/µl and platelet count to 
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100000/mm3 has taken longer than 14 days. Toxicity has been classified and graded 
according to the United States NCI’s common toxicity criteria (version 3).  
Three patients has been treated with PTX at the starting dose and if DLT was observed 
in <1/3 of them, dose level would be escalated and other 3 patients would be treated at 
the next dose level. If DLT was observed in 1/3 of the patients, 3 additional patients 
would be enrolled at the same dose level. The escalation to the next dose level would 
continue if DLT occurred in 1/6 of the 6 patients treated at the first dose level. If DLT 
was observed in >1/3 or >1/6 of the patients treated at any given dose level, the dose 
escalation would be stopped, and a total of 10 would then be enrolled at one dose level 
lower to assess the safety and the inter-patient pharmacokinetic variability. The MTD 
recommended for phase II studies would be defined as the dose level immediately 
below the one at which 1/3 of patients out of three or 1/6 out of six have experienced 
DLT. Therefore at the MTD, 1/3 out of at least 10 patients experienced DLT. No intra-
patient dose escalation is allowed.  
The cumulative haematological and non haematological toxicities, as well as the 
number of dose reductions and a delay in starting the next cycle of treatment, has been 
used as secondary indicators to differentiate the two genotype cohorts of patients. 
3.1.3.3 Efficacy and toxicity assessment 
Blood counts were measured at baseline, weekly during cycle 1, and within 48 hours 
before each administration during following cycles. Clinical evaluation, haematological, 
hepatic and renal function tests were performed at baseline and within 48 hours before 
each PTX administration, during which patients were questioned about nausea and 
vomiting, mucositis, diarrhoea, malaise, and appetite. CT scans of measurable lesions 
were assessed at baseline and repeated every two cycles, with a minimum of one on-
treatment CT required to be evaluable for efficacy (unless there was clinical disease 
progression). Objective tumour response, was assessed according to RECIST (version 
1.0) (Therasse et al., 2000) and/or CA-125 criteria (according to Gynecological Cancer 
Intergroup -GCIG guidelines). PFS was measured from the time of drug administration 
to the occurrence of progressive disease or death, whichever came first.  
Patients could continue receiving the same dose of PTX in absence of major toxicity 
according to the following criteria: before re-treatment, full recovery from any non 
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haematological toxicity, an ANC 1500/µl and platelet count 100000/mm3, were 
required. Chemotherapy was discontinued on evidence of disease progression, or the 
appearance of new lesions on serial magnetic resonance or CT scans.  
Patients experiencing a major toxicity during the first or successive cycles of therapy 
were allowed to receive additional treatment with a 25% reduction in the dose of PTX. 
The cumulative haematological and non haematological toxicity as well as the number 
of dose reductions and a delay in starting the next cycle of treatment will be used as 
secondary indicators to differentiate the two genotype cohorts of patients. 
3.1.3.4 Pharmacokinetics study 
A pharmacokinetic study has been performed to clarify relationship between ABCB1-
2677G>T/A polymorphism and PTX Cl or AUC. In all patients enrolled in the study, the 
PTX pharmacokinetic profile has been evaluated twice during the first chemotherapy 
cycle: on the first PTX administration and on the fourth one, because of the metabolic 
autoinduction effect of this taxane. In fact, it seems that frequent dosing of PTX (i.e. a 
more constant drug exposure) can induce the metabolism and elimination of the drug 
(Gustafson et al., 2005). According with this aim, even the PK of 6α-OH-PTX will be 
determined. 
Thus, serial blood samples will be collected into tubes containing K2EDTA. For what 
concerns the first PTX administration, pharmacokinetic sampling will be done before 
drug infusion, at 59 minutes since its start (just before the end of the infusion, to 
precisely define the Cmax), and at 15 and 30 minutes and 1, 3, 7, 24 and 48 hours after 
the end of the infusion. On the fourth drug administration, the sampling will be done 
before drug infusion, at 59 minutes and at 30 minutes, 1, 4, 10-12, 24 and 48 hours after 
the end of the infusion (Figure 22). Plasma will be obtained immediately by 
centrifugation of blood samples and stored at -80°C. 
The plasma concentration of PTX and its 6α-hydroxymetabolite has been determined 
using a new LC-MS/MS method that has been specifically developed and validated. 
To determine the pharmacokinetic parameters, a non-compartmental analysis has been 
applied (see Section 3.4). 
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Figure 22 Schematic representation of the sampling times scheduled for the pharmacokinetic study 
during the first and fourth administration (adm) of the first chemotherapy cycle. 
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3.2 LC-MS/MS methods: development 
The LC-MS/MS methods have been developed using a HPLC system consisted of a SIL-
20AC XR auto-sampler and LC-20AD UFLC XR pumps (Shimadzu, Tokyo, Japan) 
coupled with an API 4000 triple quadrupole mass spectrometer AB SCIEX 
(Massachusetts, USA). To quantify the chromatographic peaks, data were processed 
with Analyst 1.5.2 (quantification with MultiQuant 2.1) software package (AB SCIEX). 
3.2.1 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
irinotecan and its main metabolites in human plasma 
3.2.1.1 Standards and chemicals 
Analytical reference standards of CPT-11 (7-ethyl-10-[4-(1-piperidino)-1-piperidino]-
carbonyloxycamptothecin, batch 059K1163, purity ≥97%), SN-38 (7-ethyl-10-
hydroxycamptothecin, batch 088K1267, purity ≥98%) and CPT ((S)-(+)-Camptothecin, 
batch SLBB9623V, purity ≥90%), used as Internal Standard (IS), were purchased from 
Sigma-Aldrich Co. (Milan, Italy). APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-
piperidino]-carbonyloxycamptothecin, batch 5-PSB-149-1, purity ≥98%) was purchased 
from Toronto Research Chemicals, Inc. (North York, Ontario, Canada) and SN-38G (7-
ethyl-10-[3,4,5-trihydroxy-pyran-2-carboxylic acid]-camptothecin, batch MS0366) was 
kindly provided by Yakult Honsha Co., Ltd (Tokyo, Japan).  
Dimethyl sulfoxide (DMSO, batch 037K07663) and LC-MS grade acetonitrile were 
purchased from Sigma-Aldrich Co. LC-MS grade methanol and acetic acid were 
supplied by Carlo Erba (Milan, Italy) and Baker (JT Baker, Deventer, NL) respectively. 
Filtered, deionized water was obtained from a Milli-Q Plus system (Millipore, Billerica, 
MA, USA).  
Control human plasma/K2EDTA, used to prepare daily standard calibration curves and 
quality control (QC) samples was provided by the transfusion unit of the National 
Cancer Institute (Aviano, Italy) from healthy volunteers.  
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3.2.1.2 Standards and quality control solutions  
For CPT-11, APC, SN-38 and SN-38G two stock solutions (for standards and QCs) for 
each compound were prepared in DMSO at a concentration of 5000.0 μg/mL for CPT-
11, 1000.0 μg/mL for APC and 100.0 μg/mL for SN-38 and SN-38G. The stock solution 
for the IS was prepared at 5 μg/mL in methanol. These solutions were stored at -80°C. A 
series of working solutions (F to A) to prepare the plasma standard points of the 
calibration curve and the plasma QC samples (L, M and H) were obtained by mixing and 
diluting the stock solutions with methanol in order to obtain the final concentrations 
reported in Table 2. Aliquots of these solutions were kept in polypropylene tubes at -
80°C. The IS working solution was prepared at 0.5 µg/mL by diluting the stock solution 
with methanol. 
Table 2 Standard and quality control working solutions. 
Standards Concentrations (µg/mL) 
F E D C B A QCL QCM QCH 
CPT11 0.20 2.00 20.00 100.00 160.00 200.00 0.50 120.00 180.00 
APC 0.02 0.20 2.00 20.00 50.00 100.00 0.04 40.00 80.00 
SN38 0.02 0.10 0.50 2.00 5.00 10.00 0.04 3.00 8.00 
SN38G 0.02 0.10 0.50 2.00 5.00 10.00 0.04 3.00 8.00 
3.2.1.3 Preparation of standards and quality control samples  
A six-point plasma calibration curve was prepared freshly every day during the 
validation study. Each calibration sample was prepared by adding 5 μL of the respective 
standard solution from F to A (ULOQ) to 95 μL of pooled blank human plasma to obtain 
the final concentrations reported in Table 3. 
Table 3 Final concentrations of calibration curve and QC samples. 
Standards Concentrations (ng/mL) 
F E D C B A QCL QCM QCH 
CPT11 10.00 100.00 1000.00 5000.00 8000.00 10000.00 25.00 6000.00 9000.00 
APC 1.00 10.00 100.00 1000.00 2500.00 5000.00 2.00 2000.00 4000.00 
SN38 1.00 5.00 25.00 100.00 250.00 500.00 2.00 150.00 400.00 
SN38G 1.00 5.00 25.00 100.00 250.00 500.00 2.00 150.00 400.00 
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Each calibration curve included a blank sample (plasma processed without IS) and a 
zero blank sample (plasma processed with the IS). Three QC samples were used for 
each concentration level. To prepare QC samples, 5.7 mL aliquots of control human 
plasma were mixed with 300 μL of each working QC solutions (L, M and H) obtaining 
the QC plasma concentration reported in Table 3. Several 100 μL-aliquots of the three 
QCs were stored at −80°C to check the analytes stabilities and as controls for future 
assays. The calibration curve samples and QCs were processed as described below.  
3.2.1.4 Processing samples 
After have thawed plasma samples in an ice bath, they were vortexed for 10 s and 
centrifuged at 3000 g for 10 min at nominally 4°C. Then 100 μL of the actual sample, 
standard or QC sample were transferred to a 1.5 mL Eppendorf polypropylene tube, and 
5 μL of the IS working solution (0.5 µg/mL) were added and the mixture was vortexed. 
After that, 300 μL of 0.1% CH3COOH/CH3OH were added. Each tube was thoroughly 
vortexed for 10 s and centrifuged at 16000 g for 10 min at nominally 4°C. Then 150 μL of 
the obtained supernatant were transferred to an autosampler glass vial. Different 
amounts (3–5 µL), inversely related to the concentrations, were injected into the HPLC 
system to minimize the carry-over effect. Moreover, after the injection of the ULOQ, 
three samples of mobile phase and one blank sample were injected to demonstrate the 
absence of carry-over effect. This procedure guaranteed that no peak higher than 10% 
of LLOQ was detected. For the same reason, patients’ samples were analyzed on the 
basis of expected concentrations (lowest to highest), and three samples of mobile 
phase were injected between successive test samples. 
3.2.1.5 Chromatographic conditions  
Samples were separated on a Gemini C18 chromatographic column (3 μM 110A, 100 x 
2.0 mm) coupled with a Security Guard Cartridge (Gemini-NX C18 4.0 x 2.0 mm), both 
provided by Phenomenex (Torrance, CA, USA) and thermostatically controlled at 25°C. 
The mobile phases (MP) used for chromatographic separation were 0.1% 
CH3COOH/bidistilled water (MP A) and 0.1% CH3COOH/acetonitrile (MP B). The HPLC 
system was set up with a flow rate of 0.3 mL/min and the following linear gradient: step 
1: the initial condition of 95% MP A held for 1 min; step 2: from 95% MP A to 30% over 
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5.5 min; step 3: constant for 1.5 min; step 4: from 30% MP A to 10% over 0.5 min; step 5: 
kept constant for 1.5 min; step 6: from 10% MP A to the initial condition over 1 min and 
reconditioning for 7 min. The total run time was 18 min. 
3.2.1.6 Mass spectrometry 
Standard solutions prepared in 0.1% CH3COOH acetonitrile/water 1:1 (50 ng/mL) of 
CPT-11, SN-38, SN-38G, APC and IS were infused at a flow rate of 10 µL/min in order to 
optimize all the MS parameters. Positive ion mode was used to obtain the mass spectra 
(MS1) and the product ion spectra (MS2). The instrument was equipped with a Turbo 
IonSpray source operated at 650°C and with ion spray voltage of 5500 V. The biological 
samples were analyzed with ESI, using zero air as nebulizer gas (30 psi) and as heater 
gas (65 psi). Nitrogen was employed as curtain gas (20 psi) and as collision gas at 
medium intensity (CAD). After fragmentation, the characteristic product ions of the five 
compounds were monitored in the third quadrupole at m/z 124.2, m/z 167.2 and m/z 
195.2 for CPT-11, at m/z 349.3, m/z 249.1 and m/z 293.2 for SN-38, at m/z 393.2, m/z 
349.2 and m/z 249.2 for SN-38G, at m/z 393.3, m/z 227.1 and m/z 349.2 for APC and at 
m/z 305.1, m/z 248.9 and m/z 220.1 for IS. Quantification was done in SRM mode using 
the following transitions: m/z 587.4 > 124.2 for CPT-11, m/z 393.3 > 349.3 for SN-38, m/z 
569.3 > 393.2 for SN-38G, m/z 619.2 > 393.3 for APC and m/z 349.2 > 305.1 for the IS 
(CPT).  
3.2.2 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
paclitaxel and its main metabolite 6α-hydroxy-paclitaxel in 
human plasma 
3.2.2.1 Standards and chemicals 
Analytical reference standards of PTX (2α,4α,5β,7β,10β,13α-4,10-Bis(acetyloxy)-13-
{[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoyl]oxy}-1,7-dihydroxy-9-oxo-
5,20-epoxytax-11-en-2-yl benzoate, batch 061M1664V, purity ≥97%), and docetaxel 
(DTX) (1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4,13α-triyl 4-acetate 2-
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benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoate}, 
batch 1425738V, purity ≥97%), used as Internal Standard (IS), were purchased from 
Sigma-Aldrich Co. (Milan, Italy). 6α-OH-PTX (batch 1JAB113-2, purity ≥98%) was 
purchased from Toronto Research Chemicals, Inc. (North York, Ontario, Canada). LC-
MS grade acetonitrile, methanol and formic acid were purchased from Sigma-Aldrich 
Co. Filtered, deionized water was obtained from a Milli-Q Plus system (Millipore, 
Billerica, MA, USA). Control human plasma/K2EDTA, used to prepare daily standard 
calibration curves and QC samples was provided by the transfusion unit of the National 
Cancer Institute (Aviano, Italy) from healthy volunteers.  
3.2.2.2 Standards and quality control solutions  
For PTX and 6α-OH-PTX two stock solutions (for standards and QCs) for each 
compound were prepared in methanol at a concentration of 2000.0 μg/mL for PTX and 
100.0 μg/mL for 6α-OH-PTX. The stock solution for the IS was prepared at 100 μg/mL in 
methanol. These solutions were stored at -80°C. A series of working solutions (G to A) 
to prepare the plasma standard points of the calibration curve and the plasma QC 
samples (L, M and H) were obtained by mixing and diluting the stock solutions with 
methanol in order to obtain the final concentrations: 0.02, 0.20, 1.00, 5.00, 20.00, 
100.00, 200.00 (G to A) and 0.06, 12.50, 150.00 (QCL, M, H) µg/mL for PTX, and 0.02, 
0.10, 0.50, 1.00, 2.00, 10.00, 20.00 (from G to A) and 0.06, 1.50, 15.00 (QCL, M, H) 
µg/mL for 6α-OH-PTX. Aliquots of these solutions were kept in polypropylene tubes at -
80°C. The IS working solution was prepared at 4 µg/mL by diluting the stock solution 
with methanol. 
3.2.2.3 Preparation of standards and quality control samples  
A seven-point plasma calibration curve was prepared freshly every day during the 
validation study. Each calibration sample was prepared by adding 5 μL of the respective 
standard solution from G to A (ULOQ) to 95 μL of pooled blank human plasma to obtain 
the final concentrations: 1.00, 10.00, 50.00, 250.00, 1000.00, 5000.00, 10000.00 (G to A) 
and 3.00, 625.00, 7500.00 (QCL, M, H) ng/mL for PTX, and 1.00, 5.00, 25.00, 50.00, 
100.00, 500.00, 1000.00 (G to A) and 3.00, 75.00, 750.00 (QCL, M, H) ng/mL for 6α-OH-
PTX. Each calibration curve included a blank sample (plasma processed without IS) and 
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a zero blank sample (plasma processed with the IS). Three QC samples were used for 
each concentration level. To prepare QC samples, 5.7 mL aliquots of control human 
plasma were mixed with 300 μL of each working QC solutions (L, M and H), obtaining 
the QC plasma concentration reported above. Several 100 μL-aliquots of the three QCs 
were stored at −80°C to check the analytes stabilities and as controls for future assays. 
The calibration curve samples and QCs were processed as described below.  
3.2.2.4 Processing samples 
After have thawed plasma samples at room temperature, they were vortexed for 10 s 
and centrifuged at 3000 g for 10 min at nominally 4°C. Then 100 μL of the actual 
sample, standard or QC sample were transferred to a 1.5 mL Eppendorf polypropylene 
tube, and 5 μL of the IS working solution (4 µg/mL) were added and the mixture was 
vortexed. After that, 400 μL of 0.1% HCOOH/CH3OH were added. Each tube was 
thoroughly vortexed for 10 s and centrifuged at 16000 g for 15 min at nominally 4°C. 
Then 150 μL of the obtained supernatant were transferred to an autosampler glass vial. 
Different amounts (3–5 µL), inversely related to the concentrations, were injected into 
the HPLC system to minimize the carry-over effect. Moreover, after the injection of the 
ULOQ, three samples of mobile phase and one blank sample were injected to 
demonstrate the absence of carry-over effect. This procedure guaranteed that no peak 
higher than 10% of LLOQ was detected. For the same reason, patients’ samples were 
analyzed on the basis of expected concentrations (lowest to highest), and three 
samples of mobile phase were injected between successive test samples. 
3.2.2.5 Chromatographic conditions  
Samples were separated on a SunFireTM C18 chromatographic column (3.5 μM, 92 Å, 
2,1 x 150 mm) coupled with a Security Guard Cartridge (SunFireTM C18 2.1 x 10 mm), 
both provided by Waters (Milford, MA, USA) and thermostatically controlled at 30°C. 
The mobile phases (MP) used for chromatographic separation were 0.1% 
HCOOH/bidistilled water (MP A) and 0.1% HCOOH/acetonitrile (MP B). The HPLC 
system was set up with a flow rate of 0.2 mL/min and the following linear gradient: step 
1: from the initial condition of 60% MP A to 0% over 12 min; step 2: kept constant for 2 
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min; step 3: from 0% MP A to the initial condition over 1 min; step 4: reconditioning for 6 
min. The total run time was 21 min. 
3.2.2.6 Mass spectrometry 
Standard solutions prepared in 0.1% HCOOH acetonitrile/water 1:1 (50 ng/mL) of PTX, 
6α-OH-PTX and IS were infused at a flow rate of 10 µL/min in order to optimize all the 
MS parameters. Positive ion mode was used to obtain the mass spectra (MS1) and the 
product ion spectra (MS2). The instrument was equipped with a Turbo IonSpray source 
operated at 250°C and with ion spray voltage of 5500 V. The biological samples were 
analyzed with ESI, using zero air as nebulizer gas (50 psi) and as heater gas (50 psi). 
Nitrogen was employed as curtain gas (20 psi) and as collision gas at medium intensity 
(CAD). After fragmentation, the characteristic product ions of the two analytes were 
monitored in the third quadrupole at m/z 569.3, m/z 286.3 and m/z 105.1 for PTX, at m/z 
286.3, m/z 105.1 and m/z 525.3 for 6α-OH-PTX, and at m/z 226.3 and m/z 527.3 for IS. 
Quantification was done in SRM mode using the following transitions: m/z 854.5 > 569.3 
for PTX, m/z 870.5 > 286.3 for 6α-OH-PTX, and m/z 808.5 > 226.3 for the IS (DTX).  
3.2.3 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
sunitinib and its main metabolite N-desethyl sunitinib in 
human plasma 
3.2.3.1 Standards and chemicals 
Analytical reference standard of sunitinib (N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-
oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) was 
purchased from Sigma-Aldrich Co. (Milan, Italy) while N-desethyl sunitinib (N-[2-
(Ethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-
dimethyl-1H-pyrrole-3-carboxamide) and the deuterated internal standard sunitinib 
D10 were purchased from Toronto Research Chemicals, Inc. (North York, Ontario, 
Canada). LC-MS grade methanol and formic acid were supplied by Sigma-Aldrich Co. 
(Milan, Italy) and Baker (JT Baker, Deventer, NL), respectively. Filtered, deionized water 
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was obtained from a Milli-Q Plus system (Millipore, Billerica, MA, USA). The transfusion 
unit of the National Cancer Institute (Aviano, Italy) provided control human 
plasma/K2EDTA, used to prepare daily standard calibration curves and QC samples from 
healthy volunteers. 
3.2.3.2 Standards and quality control solutions  
Two different stock solutions (for standards and QCs) of each compound (sunitinib, N-
desethyl and IS) were prepared in dimethyl sulfoxide (DMSO) at a concentration of 1.00 
mg/mL. Dilution in acetonitrile from the solutions of sunitinib and N-desethyl sunitinib 
(for standards and QC) were prepared at concentration of 100 μg/mL, 10 μg/mL and 1 
μg/mL. A series of working solutions (G to A) to prepare the plasma standard points of 
the calibration curve and the plasma QC samples (L, M and H) were obtained by mixing 
and diluting the stock in order to obtain the final concentrations: 0.002, 0.010, 0.050, 
0.200, 1.000, 5.000, and 10.000 (G to A) and 0.005, 0.500, and 8.000 (L, M and H) µg/mL 
for sunitinib and 0.002, 0.010, 0.050, 0.200, 1.000, 2.000, and 5.000 (G to A) and 0.005, 
0.500, and 4.000 (L, M and H) µg/mL for N-desethyl sunitinib. The IS working solution 
was prepared at 0.1 μg/mL by diluting the stock solution with acetonitrile. All the 
solutions were kept in polypropylene tubes and stored at -80°C. 
3.2.3.3 Preparation of standards and quality control samples  
A seven-point plasma calibration curve was prepared freshly every day during the 
validation study. Each calibration sample was prepared by adding 1.5 μL of the 
respective standard solution from G to A (ULOQ) to 28.5 μL of pooled blank human 
plasma to obtain the following final concentrations: 0.1, 0.5, 2.5, 10.0, 50.0, 250.0, and 
500.0 ng/mL for sunitinib and 0.1, 0.5, 2.5, 10.0, 50.0, 100.0 and 250.0 ng/mL for N-
desethyl sunitinib. Each calibration curve included a blank sample and a zero blank 
sample (plasma processed with the IS). At least three concentrations of QC need to be 
prepared: one within three times the LLOQ (low QC), one in the midrange (middle QC), 
and one approaching the high end (high QC) of the range of the expected study 
concentrations. To prepare QC samples, 1.14 mL aliquots of control human plasma 
were mixed with 60 μL of each working QC solutions (L, M and H) obtaining the 
following QC plasma concentration: 0.25, 25.00, and 400.00 ng/mL for sunitinib and 
3 Materials and Methods: Methods development 
 
89 
0.25, 25.00, and 200.00 ng/mL for N-desethyl sunitinib. Several 30 μL-aliquots of the 
three QCs were stored at −80°C to check the analytes stabilities and as controls for 
future assays.  
3.2.3.4 Processing samples 
After have thawed plasma samples, they were vortexed for 10 s and centrifuged at 3000 
g for 10 min. Then, 30 μL of the actual sample, standard or QC sample were transferred 
to a 1.5 mL Eppendorf polypropylene tube, and 1.5 μL of the IS working solution (0.1 
μg/mL) were added and the mixture was vortexed. Sample treatment was based on a 
simple protein precipitation, made adding 150 μL of CH3OH to the mixture. Each tube 
was thoroughly vortexed for 10 s and centrifuged at 13000 g for 10 min. Then 100 μL of 
the obtained supernatant were transferred to an autosampler glass vial pending 
analysis. Since all the sample handling steps described above occur without any light-
protection, an additional step has been introduced in order to revert the isomerisation 
and thus to obtain only the active Z-isomer to be measured. For this reason, the 
samples were heated at 90°C for 5 min in a thermostatic bath and, then, transferred 
into the autosampler. This last step is the only one in the entire processing procedure 
that needs to be done in the dark (Figure 23). 
 
Figure 23 Schematic representation of the processing sample procedure. 
Different amounts (2–5 μL), inversely related to the concentrations, were injected into 
the HPLC system to minimize the carry-over effect. Moreover, after the injection of the 
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ULOQ, three samples of mobile phase and one blank sample were injected to 
demonstrate the absence of carry-over effect. This procedure guaranteed that no peak 
higher than 10% of LLOQ was detected.  
3.2.3.5 Chromatographic conditions  
Samples were separated on a Synergy Fusion RP C18, 4 μM, 80 Å, 2 x 50 mm (pre-
column: Gemini-NX C18 4.0 x 2.0 mm) and thermostatically controlled at 50°C. The 
mobile phases were 0.1% HCOOH/bidistilled water (MP A) and 0.1% 
HCOOH/acetonitrile (MP B). The HPLC system was set up with a flow rate of 0.3 mL/min 
and the following linear gradient: step 1: the initial condition of 90% MP A held for 0.5 
min; step 2: from 90% MP A to 30% over 1 min; step 3: constant for 1.2 min; step 4: from 
30% MP A to 60% over 0.3 min; step 5: from 60% MP A to the initial condition over 0.5 
min and reconditioning for 4 min. The total run time was 7.5 min. 
3.2.3.6 Mass spectrometry 
Standard solutions prepared in 0.1% CH3COOH acetonitrile/ water 1:1 (50 ng/mL) of 
sunitinib, N-desethyl sunitinib, and IS were infused at a flow rate of 10 μL/min in order 
to optimize all the MS parameters. Positive ion mode was used to obtain the mass 
spectra (MS1) and the product ion spectra (MS2). The instrument was equipped with a 
Turbo Ion Spray source operated at 625°C and with ion spray voltage of 5000 V. The 
biological samples were analyzed with ESI, using zero air as nebulizer gas (30 psi) and as 
heater gas (70 psi). Nitrogen was employed as curtain gas (20 psi) and as collision gas at 
medium intensity (CAD). After fragmentation, the characteristic product ions of the 
compounds were monitored in the third quadrupole at m/z 326.2, m/z 283.2 and m/z 
238.2 for each analyte. Quantification was done in SRM mode using the following 
transitions: m/z 399.2 > 326.2 for sunitinib, m/z 371.2 > 283.2 for N-desethyl sunitinib, 
and m/z 409.2 > 328.2 for IS.  
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3.3 LC-MS/MS methods: validation study 
All the three methods above described have been validated in accordance with the EMA 
and the FDA guidance on bio-analytical method validation (EMA, 2011) (FDA, 2013) 
(FDA, 2001). In particular, the validation study was conducted by examining the 
following parameters: recovery, linearity, intra- and inter-day precision and accuracy, 
reproducibility, limit of detection (LOD), LLOQ, selectivity, matrix effect, and stability. 
3.3.1 Recovery 
The percentage extraction recovery was determined for each analyte at three plasma 
concentrations (QCL, QCM and QCH) prepared in quintuplicate. The peak areas of each 
analyte extracted from plasma QC samples were compared to those from external 
standards prepared in methanol.  
The recovery of IS was evaluated in the same way at the specific plasma concentration 
chosen for each method. Recovery of the analyte and the IS need not to be 100%, but it 
is important that the extent of recovery is consistent, precise and reproducible. 
3.3.2 Linearity 
The linearity of calibration curves was validated on five different working days. For each 
standard point, the ratio of the HPLC–MS/MS peak area for each analyte to the IS was 
calculated and plotted against the nominal concentration of each analyte in the sample. 
A weighted quadratic regression function (1/x2) was applied to generate calibration 
curves.  
The linearity of the standard curves was checked by regression analysis and the 
goodness of the regression by calculating the Pearson’s determination coefficient R2 
and by comparison of the true and back-calculated concentrations of the calibration 
standards.  
The accuracy of back-calculated values of an individual point had to be within 85–115% 
of the theoretical concentration (80–120% at the LLOQ), and a minimum of five 
standards had to meet these criteria, including the LLOQ and highest calibrator, ULOQ. 
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3.3.3 Intra-day and inter-day precision and accuracy and reproducibility 
The precision of an analytical method describes the closeness of individual measures of 
an analyte when the procedure is applied repeatedly to multiple aliquots of a single 
homogeneous volume of biological matrix. The accuracy of an analytical method 
describes the closeness of mean test results obtained by the method to the actual value 
(concentration) of the analyte. This parameter was determined by expressing the mean 
calculated QC concentration as percentage of the nominal concentration.  
Precision and accuracy were evaluated on five different days by measuring the analytes 
in three replicates at the three QC levels. To analyze the QC samples, different standard 
calibration curves were plotted and processed on each of the five days of the validation 
study. The precision of the method at each concentration was reported as the 
coefficient of variation (CV%), expressing the standard deviation as a percentage of the 
mean calculated concentration. The accuracy was determined by expressing the mean 
calculated concentration as a percentage of the nominal concentration. In each run, the 
measured concentration for at least six out of nine QC samples had to be within 15% of 
the nominal value. Only one QC sample could be excluded at each concentration level. 
As indicated in the FDA Draft Guidance for Industry on Bioanalytical Method Validation 
-September 2013-(Biopharmaceutics, Revision 1) (FDA, 2013), a revised version of the 
guidance published in May 2001 (FDA, 2001) taking into account the AAPS/FDA 
Workshop on Incurred Sample Reanalysis (Fast et al., 2009), evaluation of bioanalytical 
methods by re-analysis of incurred samples should be performed and can be considered 
as an additional measure of assay reproducibility. Incurred Sample Reanalysis (ISR) is a 
necessary component of bioanalytical method validation and is intended to verify the 
reliability of the reported subject sample analyte concentrations. ISR is conducted by 
repeating the analysis, with the same bioanalytical method procedures, of a subset of 
subject samples from a given study in separate runs on different days to critically 
support the precision and accuracy measurements established with spiked QCs. 
Therefore, the accuracy of the present method was assessed by re-analyzing the 
incurred plasma samples of one patient from the pharmacokinetic study in a further 
analytical session. The selection of samples for reanalysis was done guaranteeing 
adequate coverage of the pharmacokinetic profile in its entirety including a sample 
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around the maximum concentration (Cmax) and in the elimination phase. The analyses 
can be considered equivalent if two-thirds (67%) of the percentage difference [(repeat-
original)*100/mean] of the results is within 20%.  
3.3.4 Limit of detection, limit of quantification, and selectivity  
The LOD is the concentration at which the signal-to-noise ratio (S/N) is at least 3. The 
LLOQ of the bioanalytical method is the concentration of the lowest standard. The 
analyte response at the LLOQ should be at least 5 times the response compared to 
blank response. The LLOQ of the present method was assessed by adding F working 
solution to six samples of blank human plasma. Selectivity was proved using six 
independent sources of blank human plasma, which were individually analyzed and 
evaluated for interference: a single 95 µL-aliquot from each of the six matrices was 
spiked with the analytes at the LLOQ. Both LLOQ and selectivity had to have 
acceptable accuracy (≤20%) and precision (between 80% and 120%).  
3.3.5 Matrix effect 
Matrix effects arise due to effects of endogenous components of the plasma matrix on 
the ionization of the analytes of interest and IS. In the ESI source a process of charging 
and desolvation transforms the analytes in the liquid phase into gas ions that are 
introduced in MS analyzer. It seems clear that the coeluting compounds interfering with 
either the desolvation or the charging step alter the ionization of the analyte (González 
et al., 2014). Although they are generally the principal cause, not only endogenous 
components in the biological matrix (e.g. salts, amines, triglycerides) cause matrix 
effect, also some exogenous compounds (plasticizers from sample containers or 
anticoagulants in case of plasma) are susceptible to alter the ionization process (Mei et 
al., 2003). Furthermore, other substances can be present in the mobile phase and can 
alter the signal of the analyte by causing ion suppression or enhancement. Nevertheless 
this is not considered a matrix effect source since it is not sample specific (González et 
al., 2014).  
Current FDA requirements underline the importance to assess this phenomenon in 
mass spectrometry, because it may compromise the precision, the accuracy, the 
sensitivity and the selectivity of the developed method and, consequently, the 
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reliability of analytical data produced. The same definition reported in the FDA 
guidance for matrix effect is given by EMA in the Guideline on bioanalytical method 
validation of 2011 (EMA, 2011). Both guides agree that the variability in the matrix 
effect, which would cause lack of reproducibility in the method, should be studied using 
six lots of blank matrix from individual donors. Indeed, a quantitative evaluation of 
matrix effect should be achieved by comparing the response of the analyte in solvent to 
the response obtained by spiking the analyte into six extracted independent sources of 
black human plasma. The matrix effect is calculated as the ratio of the peak area in the 
presence of matrix to the peak area in absence of matrix at the three different QC 
concentrations (L, M and H) of each analyte. The CV should be within 15%.  
In addition, a common method to evaluate qualitatively the matrix effect is the post-
column infusion, described by Bonfiglio and colleagues (Bonfiglio et al., 1999), which 
permits to identify the chromatographic region where the matrix effect manifests itself 
(González et al., 2014). A constant concentration of the analyte is introduced in the ion 
source of the mass spectrometer by using an infusion pump connected with a zero-
dead-volume “T” junction after the HPLC column, while a blank extracted sample is 
injected onto the chromatographic system. The signal of the infused drug, followed in a 
SRM scan mode, is steady, unless endogenous components eluting from the column 
cause a reduction or a gain of the response. To assure the reliability of the results, it is 
important that these ion suppression or enhancement effects do not happen near the 
analyte retention time. To perform the post-column infusion experiments standard 
solutions, prepared in 0.1% CH3COOH acetonitrile/water 1:1 (50 ng/mL) for each 
analyte and IS, were infused by a syringe pump. 
3.3.6 Stability  
Studying the stability of the analyte in stock solutions and matrix is vital to ensure the 
reliability of the results provided by the analytical method. These include assesses that 
cover all the situations that can be encountered during the whole analytical procedure 
such as freeze-thaw stability, short and long term stability, stock stability and post 
preparative stability. 
Plasma stability each analyte was assessed by analyzing QC samples for each standard 
at the three different concentrations (L, M and H) during sample storage and handling. 
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Bench-top stability was determined after 2- or 4 h at room temperature (or in ice bath in 
the case of the CPT-11 method) and the stability of the processed samples in the 
autosampler was determined repeatedly analyzing the processed QC samples 24, 48 
and 96 h after the first injection. To check freeze/thaw stability, a freshly prepared 
aliquot of each QC sample concentration was processed and analyzed, and then again 
after one and two freeze/thaw cycles. Long-term stability was assessed in plasma and in 
working solutions stored at approximately −80°C. Each analyte was considered stable 
at each concentration when the differences between the freshly prepared samples and 
the stability of testing samples did not deviate more than 15% from the nominal 
concentrations. 
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3.4 Calculation of the pharmacokinetic parameters 
Pharmacokinetic parameters were calculated with Phoenix® WinNonlin™ 6.4, 
Pharsight, Certara Company (Princeton, New Jersey, USA). Data were fitted using the 
non-compartmental model (Urso et al., 2002) (Gabrielsson and Weiner, 2012). 
A linear-log trapezoidal numerical integration method was used to calculate the area 
under the drugs and their main metabolites plasma concentration-time curve (AUC0-last) 
from time 0 to the last sampling time: 
(1) 
 
The closer time points are, the closer the trapezoids reflect the actual shape of the 
concentration-time curve. For this reason is very important to have tight samples time 
points especially near the Cmax.  
The extrapolation of the AUC from the last measurable concentration to infinity (AUC0-
∞) was computed assuming that the wash-out in the terminal phase follows a 
monoexponential profile. Despite often in PK the drug profile is not monoexponential, 
it has been observed that the log-concentrations of many drugs in plasma and tissues 
decay linearly in the terminal phase.  
A monoexponential function can be written as: 
(2)  
Where C(t) is the drug concentration at time t and C0 and λ (the elimination constant 
rate) are the parameters to be estimated. Ideally, to obtain a reliable estimate of the 
terminal slope, 3–4 half-lives would need to have elapsed. However, sometimes this is 
not possible and in this case it is allowed to consider 3–4 observations for the terminal 
slope to consider the estimation accurate. For this reason, the points used in the 
estimation should always be declared when the estimate of the terminal half-life is 
presented. 
Integrating the equation (2) between 0 and infinity, we get: 
(3) 
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Starting from the monoexponential function (2) and taking into account that at t1/2 the 
drug plasma concentration helves its value respect to the C0, the following equation is 
obtained for the elimination half-life: 
(4) 
 
The most useful parameter for the evaluation of an elimination mechanism is the Cl 
that, in the non-compartmental analysis, represents the sum of all organs clearance, 
especially hepatic and renal clearance, the two major organs of elimination. Clearance 
can be defined as the drug amount eliminated per unit of time, which is the rate of 
excretion (Xe), over drug concentration in plasma: 
(5) 
 
Integrating the equation (5) between 0 and infinity it is possible to obtain:  
(6) 
 
Where D is the total amount of drug that enters into the systemic circulation that is, 
after an intravenous administration, the dose. 
The Vd is the apparent volume into which the total amount of drug needs to be 
dissolved to maintain the same concentration as the plasma. This parameter it is useful 
to correlate the drug in the body to the measured concentration in the plasma, in fact 
Vd can be defined as: 
(7) 
 
Using monoexponential function to redefine Co (2) and making the integration between 
0 and infinity of the equation obtained, it is possible to express the Vd on the basis of the 
dose (D), AUC0-∞ and λz: 
(8) 
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3.5 Statistics  
Differences in the pharmacokinetic parameters of the drugs and their metabolites 
between the different administrations (day1-3 vs day15-17 in the case of CPT-11, and I vs 
IV administration in case of PTX) were tested by the non-parametric Wilcoxon signed 
rank matched pairs test.  
The correlation between CPT-11/PTX dose and pharmacokinetic parameters was tested 
by Spearman’s rank correlation test. 
The effects of drugs doses and patient’s genotype on PFS were estimated using the 
Kaplan-Meier estimator, and differences were tested using the log-rank test. ORRs 
(complete + partial response) between groups were compared using Fisher’s exact test 
for count data. For all comparisons, a two-sided p value <0.05 was considered 
significant, not adjusted for multiple comparisons due to the exploratory nature of the 
analyses. 
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4.1 LC-MS/MS methods: development and validation 
4.1.1 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
irinotecan and its main metabolites in human plasma 
4.1.1.1 HPLC-MS/MS 
To optimize the mass spectrometer conditions, an infusion of each standard solution at 
50 ng/mL in mobile phases (50:50) was used. The source and compound dependent 
parameters so optimized are reported in Table 4, together with the ion transitions of 
each analyte used for the mass spectrometer method.  
Table 4 Source- and compound-dependent parameters and ion transitions of each analyte and IS used for 
the mass spectrometer method. The dwell time of each transition was set up at 50 msec. DP: declustering 
potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential. 
Precursor Ion Daughter Ion 
Analyte Q1 (amu) DP (volts) EP (volts) Q3 (amu) CE (volts) CXP (volts) 
CPT-11 587.4 125 11 
124.2 51 6 
167.2 58 10 
195.2 44 13 
SN-38 393.3 103 13 
349.3 35 8 
249.1 68 15 
293.2 47 13 
SN-38G 569.3 113 11 
393.2 40 8 
349.2 60 7 
249.2 104 16 
APC 619.2 115 12 
393.3 45 9 
227.1 36 14 
349.2 62 7 
CPT (IS) 349.2 75 10 
305.1 33 15 
248.9 43 16 
220.1 48 13 
The fragmentation patterns are represented in Figure 24. For each compound, the 
daughter ion with the highest signal was used as quantifier, as follows: 587.4 >124.2 for 
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CPT-11, 393.3>349.3 for SN-38, 569.3>393.2 for SN-38G, 619.2>393.3 for APC and 
349.2>305.1 for IS, all expressed in m/z.  
 
Figure 24 MS/MS mass spectra of CPT-11, SN-38, SN-38G and APC with chemical structures and 
identification of the main fragment ions. The fragment ion at *248 m/z of SN-38G is not shown in the 
MS/MS mass spectrum because it requires, for its formation, a higher collision energy than the other 
fragments. 
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Figure 25 presents typical SRM chromatograms, using the quantifier transitions noted 
above. 
 
Figure 25 Representative SRM chromatograms. Panel A: SRM chromatograms of a human blank plasma 
sample; Panel B: SRM chromatograms of a human blank plasma sample with IS added; Panel C: S/N of 
SN-38, SN-38G, CPT-11 and APC at the LLOQ (10 ng/mL for CPT-11 and 1 ng/mL for SN-38, SN-38G and 
APC); Panel D: SRM chromatograms of an extracted plasma sample of a treated patient showing IS, SN-
38, SN-38G, CPT-11 and APC. 
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Panel A shows an extracted blank plasma sample; Panel B displays an extracted blank 
plasma sample with IS added; Panel C shows an extracted plasma sample at the LLOQ 
with IS added and Panel D displays an extracted plasma sample of a patient, drawn 26 h 
after the drug dose of 310 mg/m2. The peaks correspond to a concentration of 80.27, 
7.42, 16.57 and 12.91 ng/mL of CPT-11, SN-38, SN-38G, APC, respectively. The elution 
of the analytes was rapid and selective with adequate separation of all the peaks within 
9 min: CPT-11, SN-38, SN-38G, APC and IS were eluted at approximately 5.05, 6.43, 7.9, 
5.07 and 6.57 min, respectively. No interfering peaks were observed at these retention 
times, and the peaks were completely resolved from plasma matrix, with a good shape. 
The specificity of the method was confirmed by analyzing six independent sources of 
blank human plasma. 
4.1.1.2 Validation of the method  
Recovery. The extraction method is based on simple deproteinization with three 
volumes of 0.1% CH3COOH/CH3OH relative to plasma sample (Table 5).  
Table 5 Recovery of the analytes and the IS from human plasma. 
Analyte Nominal concentration (ng/mL) Recovery (%) ± SD CV % 
CPT-11 
25.00 66.4 ± 5.7 8.6 
6000.00 68.3 ± 1.6 2.3 
9000.00 68.8 ± 1.6 2.3 
SN-38 
2.00 77.2 ± 7.3 9.4 
150.00 83.8 ± 2.8 3.4 
400.00 84.1 ± 1.0 1.2 
SN-38G 
2.00 58.6 ± 7.1 12.1 
150.00 54.8 ± 2.6 4.8 
400.00 56.4 ± 0.8 1.4 
APC 
2.00 44.0 ± 4.7 10.6 
2000.00 47.6 ± 2.3 4.7 
4000.00 49.1 ± 0.9 1.9 
CPT (IS) 25.00 30.6 ± 2.1 6.9 
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The recovery, evaluated in five replicates at three QC concentrations, was in the range 
66.4-68.8% (CV ≤8.6%) for CPT-11, 77.2-84.1% (CV ≤9.4%) for SN-38, 54.8-58.6% (CV 
≤12.1%) for SN-38G and within 44.0-49.1% (CV ≤10.6%) for APC. The recovery of IS was 
30.6% (CV 6.9%).  
Calibration Curves. Table 6 reports the results for the calibration curves of CPT-11 and 
its main metabolites freshly prepared every day during the validation study, and the 
accuracy and precision for each standard (Figure 26). 
Table 6 Linearity, accuracy and precision data for calibration curves of CPT-11 and its main metabolites. 
Analyte 
Nominal conc. 
(ng/mL) 
Mean ± SD Precision % Accuracy % 
CPT-11 
10.00 9.88 ± 0.03 0.3 98.8 
100.00 111.90 ± 3.18 2.8 111.9 
1000.00 1070.91 ± 61.18 5.7 107.1 
5000.00 4671.81 ± 114.51 2.5 93.4 
8000.00 7568.46 ± 500.11 6.6 94.6 
10000.00 9420.12 ± 513.90 5.5 94.2 
SN-38 
1.00 1.00 ± 0.01 1.0 99.8 
5.00 5.01 ± 0.29 5.9 100.2 
25.00 25.70 ± 0.86 3.4 102.8 
100.00 99.35 ± 5.09 5.1 99.4 
250.00 251.99 ± 10.01 4.0 100.8 
500.00 484.99 ± 31.86 6.6 97.0 
SN-38G 
1.00 1.00 ± 0.01 1.5 100.1 
5.00 4.98 ± 0.38 7.7 99.6 
25.00 24.67 ± 0.86 3.5 98.7 
100.00 101.40 ± 3.48 3.4 101.4 
250.00 253.43 ± 14.12 5.6 101.4 
500.00 494.14 ± 34.95 7.1 98.8 
APC 
1.00 1.00 ± 0.01 0.7 99.7 
10.00 10.38 ± 0.68 6.5 103.8 
100.00 105.44 ± 5.01 4.8 105.4 
1000.00 943.42 ± 39.02 4.1 94.3 
2500.00 2469.92 ± 207.95 8.4 98.8 
5000.00 4935.06 ± 264.42 5.4 98.7 
The calibration curves prepared on five different days showed good linearity and 
acceptable results of the back-calculated concentrations over the validated range of 
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10.00-10000.00 ng/mL for CPT-11, of 1.00-500.00 ng/mL for SN-38 and SN-38G and of 
1.00-5000.00 ng/mL for APC. Pearson’s coefficient of determination R2 was ≥0.9962 for 
each run, the mean accuracy was always close to 100% (range 93.4-111.9% for CPT-11, 
97.0-102.8% for SN-38, 98.7-101.4% for SN-38G and 94.3-105.4% for APC) and the 
precision, expressed as CV%, ranged from 0.3% for the lowest calibrator (10.00 ng/mL) 
to 6.6% for CPT-11, from 1.0 to 6.6% for SN-38, from 1.5 to 7.7% for SN-38G and from 
0.7 to 8.4% for APC. In order to quantify patients’ samples, a calibration curve was 
freshly prepared every analysis run and the samples’ concentrations were back-
calculated from the calibration curve. 
 
Figure 26 Calibration curve of CPT-11 and its main metabolites SN-38, SN-38G and APC in human plasma. 
Intra-day and inter-day Precision and Accuracy and Reproducibility. The precision and 
accuracy of the method were evaluated by analysing three replicates of QC samples 
(QCL, QCM and QCH) within a single-run analysis for intra-day assessment and over 
five consecutive runs for inter-day assessment. The accuracy and precision (CV%) 
obtained are shown in Table 7. The method was very precise, with intra- and inter-day 
CV ≤8.9% and ≤8.7% for CPT-11, ≤11.6% and ≤9.9% for SN-38, ≤9.0% for SN-38G and 
≤10.7% and ≤12.2% for APC.  
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Table 7 Intra and inter-day precision and accuracy of the method for the analysis of CPT-11 and its main 
metabolites in human plasma samples. 
 Analyte 
Nominal 
conc. (ng/mL) 
Mean ± SD Precision % Accuracy % 
Intra-
day 
(N=5) 
CPT-11 
25.00 25.42 ± 2.26 8.9 101.7 
6000.00 6379.41 ± 520.23 8.2 106.3 
9000.00 9090.55 ± 369.12 4.1 101.0 
SN-38 
2.00 2.17 ± 0.14 6.5 108.7 
150.00 163.43 ± 18.97 11.6 109.0 
400.00 384.85 ± 14.03 3.6 96.2 
SN-38G 
2.00 1.85 ± 0.17 9.0 92.3 
150.00 169.52 ± 3.73 2.2 113.0 
400.00 405.40 ± 15.15 3.7 101.3 
APC 
2.00 2.10 ± 0.22 10.7 105.2 
2000.00 1788.03 ± 83.27 4.7 89.4 
4000.00 4242.35 ± 170.47 4.0 106.1 
Inter-
day 
(N=14) 
CPT-11 
25.00 24.77 ± 2.16 8.7 99.1 
6000.00 5986.95 ± 483.98 8.1 99.8 
9000.00 8667.00 ± 580.72 6.7 96.3 
SN-38 
2.00 2.02 ± 0.20 9.9 101.2 
150.00 158.78 ± 13.97 8.8 105.9 
400.00 387.53 ± 21.46 5.5 96.9 
SN-38G 
2.00 1.98 ± 0.18 9.0 98.9 
150.00 153.45 ± 11.89 7.8 102.3 
400.00 393.07 ± 20.94 5.3 98.3 
APC 
2.00 2.06 ± 0.25 12.2 103.2 
2000.00 1881.31 ± 158.89 8.4 94.1 
4000.00 3984.00 ± 346.26 8.7 99.6 
Moreover, the method showed intra- and inter-day accuracy within the range 101.0-
106.3% and 96.3-99.8% for CPT-11, 96.2-109.0% and 96.9-105.9% for SN-38, 92.3-
113.0% and 98.3-102.3% for SN-38G and 89.4-106.1% and 94.1-103.2% for APC. The 
good reproducibility and accuracy of the method were further demonstrated by re-
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analysis of incurred plasma samples of one patient treated at the dose of 260 mg/m2 
(Figure 27).  
 
Figure 27 Re-analysis of incurred plasma samples of one patient treated at the dose of 260 mg/m
2
 during 
the first (C1D1, on the left) and the second (C1D15, on the right) of the first chemotherapy cycle. 
The concentrations of CPT-11 and its main metabolites determined on the two 
analytical runs were very similar in all samples, being the percentage difference of the 
results within 20% for more than 71% of the total amount of samples re-analyzed. This 
range encompasses the accepted variability of the analytical method; hence, the two 
measurements can be considered equivalent. 
Limit of Detection, Limit of Quantification, Selectivity and Matrix Effect. The LOD 
was defined as the concentration at which the S/N was at least 3. The LOD was 58 
pg/mL for SN-38, 105 pg/mL for SN-38G, 116 pg/mL for CPT-11 and 75 pg/mL for APC. 
As shown in Panel C of Figure 25, with the high S/N obtained (S/N range: 28.5-258.5), it 
would have been possible to fix a lower LLOQ for each analyte. However, the LLOQ 
values were chosen on the basis of the concentration range expected in plasma samples 
of patients enrolled in the phase I study. Therefore, the LLOQ was fixed at 1 ng/mL for 
SN-38, SN-38G and APC and at 10 ng/mL for CPT-11 and was validated through analysis 
of six replicates. The accuracy and precision at the LLOQ were determined by analyzing 
six replicates of the sample at the LLOQ concentration. The accuracy and CV% were, 
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respectively, 91.0% and 4.9% for CPT-11, 111.4% and 5.2% for SN-38, 94.2% and 7.9% 
for SN-38G and 98.3% and 11.2% for APC. The method was not affected by endogenous 
components in the matrix or other components in the sample; on spiking six different 
sources of human plasma with CPT-11 and its main metabolites at a concentration 
corresponding to the LLOQ the precision was 4.9, 5.2, 7.9 and 11.2% for CPT-11, SN-38, 
SN-38G and APC, respectively and the accuracy was 91.0, 111.4, 94.2 and 98.3%, 
respectively. There were no significant variations (<15%) in the peak area of each 
analyte in the six lots of matrix, therefore it was possible to exclude the presence of any 
matrix effect of ion suppression or enhancement. The absence of the matrix effects has 
been determined also by the post column infusion test and by comparing the peak area 
of the analyte extracted from plasma QC samples with the peak area of the extracted 
matrix prepared in five replicates and added with the same amount of the analyte (data 
not shown). 
Stability. CPT-11 and its main metabolites resulted stable for 2 h in ice bath and for 96 h 
in the autosampler at 4°C after extraction (Table 8).  
CPT-11 and its main metabolites were stable in human plasma over two freeze/thaw 
cycles: precision as CV% and accuracy for freeze/thaw samples were ≤5.3% and within 
86.7-97.6% for CPT-11, ≤6.5% and within 101.3-105.4% for SN-38, ≤3.2% and within 
88.1-90.7% for SN-38G and ≤11.0% and within 94.6-95.3% for APC (Table 9).  
After 4 months of storage in human plasma, at approximately -80°C, precision (CV%) 
and accuracy obtained were ≤9.9% and within 94.4-102.2% for CPT-11, ≤8.3% and 
within 93.5-103.6% for SN-38, ≤8.6% and within 85.2-92.0% for SN-38G and ≤8.3% and 
within 92.5-104.5% for APC (Table 9).  
The standard working solutions of CPT-11, SN-38, SN-38G and APC used for calibration 
curve and QC samples, prepared in methanol and stored at −80°C, were stable after 9 
months: CV% and accuracy were ≤5.9% and within 107.1-108.9% for CPT-11, ≤4.4% and 
within 100.3-104.9% for SN-38, ≤6.5% and within 99.0-109.1% for SN-38G and ≤14.4% 
and within 97.1-111.3% for APC (Table 10).  
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Table 8 Short term stability of CPT-11 and its main metabolites in human plasma samples. 
Analytes 
Nominal 
conc. 
(ng/mL) 
T = 2 h T = 96 h in autosampler (4°C) 
Mean ± SD Prec % Acc % Mean ± SD Prec % Acc % 
CPT-11 
25.00 23.93 ± 2.83 11.8 95.7 22.71 ± 0.80 3.5 90.8 
6000.00 5983.16 ± 268.62 4.5 99.7 5443.19 ± 270.24 5.0 90.7 
9000.00 8645.98 ± 303.46 3.5 96.1 8337.48 ± 963.60 11.6 92.6 
SN38 
2.00 1.96 ± 0.02 1.2 98.1 1.89 ± 0.25 13.4 94.6 
150.00 154.21 ± 2.16 1.4 102.8 136.06 ± 7.51 5.5 90.7 
400.00 402.43 ± 17.77 4.4 100.6 360.09 ± 26.21 7.3 90.0 
SN-38 G 
2.00 1.90 ± 0.02 1.1 95.2 1.80 ± 0.11 6.1 90.2 
150.00 147.04 ± 2.68 1.8 98.0 127.55 ± 0.84 0.7 85.0 
400.00 379.76 ± 24.29 6.4 94.9 360.82 ± 34.01 9.4 90.2 
APC 
2.00 2.08 ± 0.19 8.9 103.9 1.84 ± 0.12 6.8 91.9 
2000.00 1864.57 ± 86.08 4.6 93.2 1715.93 ± 13.10 0.8 85.8 
4000.00 3955.31 ± 235.24 5.9 98.9 3716.48 ± 424.53 11.4 92.9 
Table 9 Stability of CPT-11 and its metabolites after 2 freeze-thaw cycles and after 4 months at -80°C. 
Analytes 
Nominal 
conc. 
(ng/mL) 
After 2 freeze-thaw cycles Stored at -20ºC over 4 months 
Mean ± SD Prec % Acc % Mean ± SD Prec % Acc % 
CPT-11 
25.00 21.67 ± 0.12 0.6 86.7 25.55 ± 2.53 9.9 102.2 
6000.00 5853.32 ± 237.66 4.1 97.6 5941.81 ± 322.04 5.4 99.0 
9000.00 8381.75 ± 445.81 5.3 93.1 8496.65 ± 605.20 7.1 94.4 
SN38 
2.00 2.11 ± 0.06 2.8 105.4 2.07 ± 0.17 8.3 103.6 
150.00 151.97 ± 9.86 6.5 101.3 154.76 ± 3.98 2.6 103.2 
400.00 412.38 ± 16.19 3.9 103.1 374.05 ± 30.58 8.2 93.5 
SN-38 G 
2.00 1.81 ± 0.05 2.8 90.5 1.84 ± 0.16 8.6 92.0 
150.00 136.10 ± 3.72 2.7 90.7 130.48 ± 2.60 2.0 87.0 
400.00 352.52 ± 11.30 3.2 88.1 340.69 ± 0.28 0.1 85.2 
APC 
2.00 1.91 ± 0.21 11.0 95.3 2.09 ± 0.17 8.3 104.5 
2000.00 1891.29 ± 160.58 8.5 94.6 1870.85 ± 136.92 7.3 93.5 
4000.00 3791.48 ± 280.50 7.4 94.8 3699.92 ± 254.86 6.9 92.5 
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Table 10 Stability of the working solutions of CPT-11 and its main metabolites stored at -80ºC over 9 
months. 
Analytes 
Nominal conc. 
(ng/mL) 
Stored at -80ºC over 9 months 
Mean ± SD Prec. % Acc. % 
CPT-11 
25.00 26.78 ± 1.08 4.0 107.1 
6000.00 6533.20 ± 388.29 5.9 108.9 
9000.00 9798.46 ± 396.30 4.0 108.9 
SN38 
2.00 2.01 ± 0.06 2.8 100.3 
150.00 154.57 ± 6.09 3.9 103.0 
400.00 419.47 ± 18.31 4.4 104.9 
SN-38 G 
2.00 1.98 ± 0.05 2.5 99.0 
150.00 149.18 ± 9.72 6.5 99.5 
400.00 436.51 ± 21.69 5.0 109.1 
APC 
2.00 1.94 ± 0.28 14.4 97.1 
2000.00 2058.05 ± 74.43 3.6 102.9 
4000.00 4451.13 ± 107.37 2.4 111.3 
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4.1.2 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
paclitaxel and its main metabolite 6α-hydroxy-paclitaxel in 
human plasma  
4.1.2.1 HPLC-MS/MS 
An infusion of each standard solution at 50 ng/mL in mobile phases (50:50) was used to 
optimize the mass spectrometer parameters, reported in the following table (Table 11). 
Table 11 Source- and compound-dependent parameters and ion transitions of each analyte and IS used 
for the mass spectrometer method The dwell time of each transition was set up at 50 msec. DP: 
declustering potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential. 
Precursor Ion Daughter ion 
Analyte Q1 (amu) DP (volts) 
EP 
(volts) 
Q3 (amu) CE (volts) 
CXP 
(volts) 
PTX 854.5 63 9 
569.3 15 18 
286.3 23 7 
105.1 95 19 
6α-OH-PTX 870.5 63 8 
286.3 23 7 
105.1 94 18 
525.3 22 16 
DTX 808.5 50 7 
226.3 23 22 
527.3 14 16 
The fragmentation patterns are represented in Figure 28. For each compound, the 
daughter ion with the highest signal was used as quantifier, as follows: 854.5 >569.3 for 
PTX, 870.5>286.3 for 6α-OH-PTX, and 808.5>226.3 for IS, all expressed in m/z. Figure 29 
presents typical SRM chromatograms, using the quantifier transitions noted above. 
Panel A shows an extracted blank plasma sample; Panel B displays an extracted blank 
plasma sample with IS added; Panel C shows an extracted plasma sample at the LLOQ 
with IS added and Panel D displays an extracted plasma sample of a patient, drawn at 
the end of the 1-h intravenous infusion of 80 mg/m2 of PTX. The peaks correspond to a 
concentration of 1997.39 and 93.67 ng/mL of PTX and 6α-OH-PTX, respectively. The 
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elution of the analytes was rapid and selective with adequate separation of all the peaks 
within 10 min: PTX, 6α-OH-PTX and IS were eluted at approximately 8.40, 7.15 and 8.04 
min, respectively. No interfering peaks were observed at these retention times, and the 
peaks were completely resolved from plasma matrix, with a good shape. The specificity 
of the method was confirmed by analyzing six independent sources of blank human 
plasma. 
 
Figure 28 MS/MS mass spectra of PTX and 6α-OH-PTX with chemical structures and identification of the 
main fragment ions. 
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Figure 29 Representative SRM chromatograms. Panel A: SRM chromatograms of a human blank plasma 
sample; Panel B: SRM chromatograms of a human blank plasma sample with IS added; Panel C: S/N of 
PTX and 6α-OH-PTX at the LLOQ (1 ng/mL for both analytes); Panel D: SRM chromatograms of an 
extracted plasma sample of a treated patient showing IS, PTX and 6α-OH-PTX.  
4.1.2.2 Validation of the method  
Recovery. The extraction method is based on simple deproteinization with four 
volumes of 0.1%HCOOH/CH3OH relative to plasma sample. The recovery, evaluated in 
five replicates at three QC concentrations, was in the range 92.4-95.7% (CV ≤6.9%) for 
PTX and 93.4-97.7% (CV ≤5.5%) for 6α-OH-PTX, as shown in Table 12. The recovery of 
IS was 101.2% (CV 4.4%).  
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Table 12 Recovery of the analytes and the IS from human plasma. 
Analyte 
Nominal 
concentration 
(ng/mL) 
Recovery (%) ± SD CV % 
PTX 
3 95.7 ± 6.4 6.6 
625 92.4 ± 6.4 6.9 
7500 93.8 ± 1.3 1.4 
6α-OH-PTX 
3 94.2 ± 1.9 2.0 
75 97.7 ± 5.4 5.5 
750 93.4 ± 2.6 2.8 
DTX (IS) 200 101.2 ± 4.5 4.4 
Calibration Curves. Table 13 reports the results for the calibration curves of PTX and its 
main metabolite 6α-OH-PTX freshly prepared every day during the validation study, 
and the accuracy and precision for each standard.  
Table 13 Linearity, accuracy and precision data for calibration curves of PTX and its metabolite 6α-OH-
PTX. 
Analytes 
Nominal conc. 
(ng/mL) 
Mean ± SD Precision % Accuracy % 
PTX 
1 0.99 ± 0.01 0.6 99.4 
10 10.59 ± 0.68 6.4 105.9 
50 50.91 ± 1.74 3.4 101.8 
250 269.00 ± 9.05 3.4 107.6 
1000 1020.79 ± 52.28 5.1 102.1 
5000 4488.84 ± 161.87 3.6 89.8 
10000 9292.7 ± 736.14 7.9 92.9 
6α-OH-PTX 
1 1.01 ± 0.01 0.8 100.8 
5 4.82 ± 0.27 5.7 96.5 
25 21.74 ± 0.48 2.2 87.0 
50 53.40 ± 3.63 6.8 106.8 
100 102.43 ± 4.12 4.0 102.4 
500 512.77 ± 17.90 3.5 102.6 
1000 1011.36 ± 71.36 7.1 101.1 
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The calibration curves (Figure 30) prepared on five different days showed good linearity 
and acceptable results of the back-calculated concentrations over the validated range 
of 1.00-10000.00 ng/mL for PTX and of 1.00-1000.00 ng/mL for 6α-OH-PTX. Pearson’s 
coefficient of determination R2 was ≥0.9948 for each run, the mean accuracy was 
always close to 100% (range 89.8-107.6% for PTX and 87.01-106.8% for 6α-OH-PTX) 
and the precision, expressed as CV%, ranged from 0.6% for the lowest calibrator (1.00 
ng/mL) to 7.9% for PTX and from 0.8 to 7.1% for 6α-OH-PTX. In order to quantify 
patients’ samples, a calibration curve was freshly prepared every analysis run and the 
samples’ concentrations were back-calculated from the calibration curve. 
 
Figure 30 Calibration curve of PTX and its main metabolite 6α-OH-PTX in human plasma. 
Intra-day and inter-day Precision and Accuracy and Reproducibility. The precision and 
accuracy of the method were evaluated by analysing three replicates of QC samples 
(QCL, QCM and QCH) within a single-run analysis for intra-day assessment and over 
five consecutive runs for inter-day assessment. The accuracy and precision (CV%) 
obtained are shown in Table 14. The method was very precise, with intra- and inter-day 
CV ≤9.2% and ≤7.0% for PTX and ≤7.9% and ≤9.9% for 6α-OH-PTX. Moreover, the 
method showed intra- and inter-day accuracy within the range 91.1-98.4% and 94.0-
104.8% for PTX and 92.8-103.3% and 99.5-104.0% for 6α-OH-PTX. The good 
reproducibility and accuracy of the method were further demonstrated by re-analysis of 
incurred plasma samples of one patient treated at the dose of 100 mg/m2. The 
concentrations of PTX and its main metabolite determined on the two analytical runs 
were very similar in all samples, being the percentage difference of the results within 
20% for more than 94.1 and 91.7% of the total amount of samples re-analyzed for PTX 
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and 6α-OH-PTX, respectively. This range encompasses the accepted variability of the 
analytical method; hence, the two measurements can be considered equivalent. 
Table 14 Intra and inter-day precision and accuracy of the method for the analysis of PTX and its 
metabolite 6α-OH-PTX in human plasma samples. 
 Analytes 
Nominal 
concentration 
(ng/mL) 
Mean ± SD Precision % Accuracy % 
Intra-
day 
(N=5) 
PTX 
3 3.18 ± 0.29 9.2 94.4 
625 685.97 ± 40.72 5.9 91.1 
7500 7619.62 ± 370.09 4.9 98.4 
6α-OH-PTX 
3 2.91 ± 0.23 7.9 103.3 
75 80.85 ± 4.24 5.2 92.8 
750 808.02 ± 50.47 6.2 92.8 
Inter-
day 
(N=15) 
PTX 
3 3.14 ± 0.19 5.9 104.8 
625 644.20 ± 45.22 7.0 103.1 
7500 7047.92 ± 477.06 6.8 94.0 
6α-OH-PTX 
3 2.99 ± 0.29 9.9 99.5 
75 77.99 ± 5.73 7.3 104.0 
750 766.42 ± 58.58 7.6 102.2 
 
Figure 31 Re-analysis of incurred plasma samples of one patient treated at the dose of 100 mg/m
2
 during 
the first (I ADM, left) and the fourth (IV ADM, right) of the first chemotherapy cycle. 
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Limit of Detection, Limit of Quantification, Selectivity and Matrix Effect. The LOD, 
defined as the concentration at which the S/N was at least 3, was 0.13 ng/mL for PTX 
and 0.19 ng/mL for 6α-OH-PTX. As shown in Panel C of Figure 29, reporting the S/N 
values obtained (22.5 and 15.5 for PTX and 6α-OH-PTX, respectively), the LLOQ was 
fixed at 1 ng/mL for both PTX and its metabolite 6α-OH-PTX and was validated through 
analysis of six replicates. The accuracy and precision at the LLOQ were determined by 
analyzing six replicates of the sample at the LLOQ concentration. The accuracy and 
CV% were, respectively, 109.8% and 5.0% for PTX and 106.5% and 8.1% for 6α-OH-
PTX.  
The method was not affected by endogenous components in the matrix or other 
components in the sample; on spiking six different sources of human plasma with PTX 
and 6α-OH-PTX at a concentration corresponding to the LLOQ the precision was 12.5 
and 6.5 % for PTX and 6α-OH-PTX, respectively and the accuracy was 107.5 and 
104.0%, respectively. There were no significant variations (<15%) in the peak area of 
each analyte in the six lots of matrix, therefore it was possible to exclude the presence 
of any matrix effect of ion suppression or enhancement. The absence of the matrix 
effects has been determined also by the post column infusion test and by comparing 
the peak area of the analyte extracted from plasma QC samples with the peak area of 
the extracted matrix prepared in five replicates and added with the same amount of the 
analyte (data not shown). 
Stability. The stability of PTX and its metabolite 6α-OH-PTX, under different 
conditions, was assessed by analyzing QC samples, prepared in triplicate. All these 
analytes in human plasma were stable for 4 h at room temperature and for 72 h in the 
autosampler at 4°C after extraction (Table 15). PTX and 6α-OH-PTX were stable in 
human plasma over two freeze/thaw cycles: precision as CV% and accuracy for 
freeze/thaw samples were ≤3.1% and within 102.4-107.1% for PTX and ≤12.8% and 
within 94.0-112.2% for 6α-OH-PTX (Table 16). After 7 months of storage in human 
plasma, at approximately -80°C, precision (CV%) and accuracy obtained were ≤4.5% 
and within 94.6-103.2% for PTX, and ≤4.9% and within 89.6-102.8% for 6α-OH-PTX 
(Table 16).The standard working solutions of PTX and 6α-OH-PTX used for calibration 
curve and QC samples, prepared in methanol and stored at −80°C, were stable after 27 
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months: CV% and accuracy were ≤3.6% and within 106.6-113.3% for PTX and ≤8.8% and 
within 105.6-113.6% for 6α-OH-PTX (Table 17).  
Table 15 Short term stability of PTX and its metabolite 6α-OH-PTX in human plasma samples. 
Analytes 
Nominal 
conc. 
(ng/mL) 
T = 4h (RT) T = 72h in autosampler (4°C) 
Mean ± SD Prec. % Acc. % Mean ± SD Prec. % Acc. % 
PTX 
3 2.71 ± 0.21 7.7 90.2 3.03 ± 0.03 1.1 101.1 
625 561.64 ± 26.83 4.8 89.9 617.20 ± 15.39 2.5 98.8 
7500 6658.95 ± 378.35 5.7 88.8 6703.78 ± 435.30 6.5 89.4 
6α-OH-
PTX 
3 2.58 ± 0.02 0.7 86.0 2.74 ± 0.19 7.1 91.4 
75 66.60 ± 1.64 2.5 88.8 76.88 ± 1.55 2.0 102.5 
750 666.35 ± 36.97 5.5 88.8 725.84 ±25.13 3.5 96.8 
Table 16 Stability of PTX and 6α-OH-PTX, in human plasma samples, after 2 freeze-thaw cycles and after 
7 months of storage at -80°C. 
Analytes 
Nominal 
conc. 
(ng/mL) 
After 2 freeze-thaw cycles Stored at -80ºC over 7 months 
Mean ± SD 
Prec. 
% 
Acc. 
% 
Mean ± SD 
Prec. 
% 
Acc. 
% 
PTX 
3 3.21 ± 0.03 0.9 107.1 2.97 ± 0.11 3.8 99.0 
625 706.72 ± 15.66 2.2 113.1 591.47 ± 8.31 1.4 94.6 
7500 7683.00 ± 236.01 3.1 102.4 7739.55 ± 354.80 4.5 103.2 
6α-OH-PTX 
3 2.82 ± 0.36 12.8 94.0 2.69 ±0.1 3.8 89.6 
75 84.19 ± 2.57 3.1 112.2 76.19 ± 2.35 3.1 101.6 
750 814.86 ± 2.24 0.3 108.6 771.01 ± 37.96 4.9 102.8 
Table 17 Stability of the working solutions of PTX and 6α-OH-PTX stored at -80ºC over 27 months. 
Analytes Nominal conc. (ng/mL) 
Stored at -80ºC over 27 months 
Mean ± SD Prec. % Acc. % 
PTX 
3 3.20 ± 0.12 3.6 106.6 
625 704.35 ± 4.68 0.7 112.7 
7500 8499.14 ± 153.41 1.8 113.3 
6α-OH-PTX 
3 3.17 ± 0.28 8.8 105.6 
75 83.78 ± 0.28 0.3 111.7 
750 851.94 ± 4.27 0.5 113.6 
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4.1.3 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
sunitinib and its main metabolite N-desethyl sunitinib in 
human plasma 
4.1.3.1 Study on the Z/E isomerization 
Most of the published analytical methods developed for the quantification of sunitinib 
and its main metabolite describe the sample handling under strict light protection, 
which is time-consuming and requires a dark room. Thus, in order to obtain a fast, 
specific, and easy to use method, we set up a processing procedure able to avoid the 
light protection relying on the peculiar characteristics of sunitinib isomerization. Sistla 
et al.(Sistla and Shenoy, 2005), indeed, showed that the E isomer of the sunitinib 
precursor semaxanib reverted to the Z-isomer following storage in the dark with an 
increase in the reconversion rate at higher temperatures (lnK vs. 1/T: r2=0.96). This 
observation indicates that the E- to Z-isomer reversion is a thermal reversion. Based on 
these data we have studied the reversion kinetics of sunitinib in the dark at different 
temperatures (Figure 32).  
 
Figure 32 E/Z-isomer conversion of sunitinib (0.9 µg/mL) under different temperature conditions. The 
samples were analyzed at T0, without any heating process (blue line), and respectively after 5 (pink line), 
10 (dark green line), 15 (red line), and 20 min (light green line) at 60°C. 
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During these initial experiments on the sunitinib reversion kinetics, a provisional and 
non optimized LC-MS/MS method has been used. More in detail, at first, an extracted 
sample of sunitinib (1 µg/mL), after light exposure, (for the extraction method, see 
“Material and Methods” Section) was split in five different glass vials: four aliquots were 
put in a heated bath, at 60°C for 5 (T1), 10 (T2), 15 (T3) and 20 (T4) min, while one 
aliquot was directly analyzed without heating process (T0).The peak area of the two 
isomers obtained after the heated bath step (T1,2,3,and 4 samples) were compared to 
those obtained from the same extracted light-exposed sample without heating process 
(T0 sample). Figure 32 shows the differences in terms of peak area of the samples 
treated at the different conditions. Already after 5 min at 60°C the peak area of E-
isomer was more than 5-fold lower than T0 sample while the peak area of the Z-isomer 
resulted proportionally increased. Table 18 shows the area of E- and Z-isomers at 
different time points and the sum of the two isomers areas.  
Table 18 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas, together with the 
percentages respect to the total area, measured at T0 (without any heating process), T1, T2, T3, and T4 at 
60°C. 
Time E-isomer Area·105 (%) Z-isomer Area·105 (%) Total Area·105 (%) 
T0 6.94 (44.12) 8.79 (55.87) 15.73 (100) 
T1 (5 min) 1.34 (8.69) 14.14 (91.30) 15.48 (100) 
T2 (10 min) 0.36 (2.27) 15.72 (97.72) 16.08 (100) 
T3 (15 min) 0.23 (1.44) 16.00 (98.55) 16.23 (100) 
T4 (20 min) 0.30 (1.95) 15.53 (98.04) 15.83 (100) 
The peak area percentage of the two isomers respect to the total peak area is also 
reported. The reproducibility of the total area guaranteed that the decrease of the E-
isomer area was due to its conversion in the active isomer and excluded the possibility 
of analyte degradation. After 10 min at 60°C, the equilibrium between E- and Z-isomers 
was reached and no variations in their areas were observed prolonging the time of 
incubation in the heated bath. 
In order to further decrease the E-isomer signal and to reduce the time required for the 
treatment, additional experiments have been planned and the heated bath 
temperature has been progressively scaled up to 90°C. The best performance in terms 
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of E-isomer reconversion and time required for the treatment, has been obtained with 
highest temperature evaluated (90°C), which allowed a reduction of the sample 
treatment time to 5 min. Thus, further experiments have been performed in order to 
study the reconversion kinetics that takes place into the autosampler (i.e. in the dark 
and at 40°C), in order to understand if prolonging the time in the autosampler could 
further increase the Z- to E-isomers ratio. Therefore, extracted samples were heated at 
90°C for 5 min and then placed in the autosampler to be analyzed by means of LC-
MS/MS. Repeated analyses have been conducted to investigate the kinetics of the 
isomer reconversion for about 3 hours. Moreover, with the aim to test whether the 
kinetics depends on the sunitinib concentration, the following experiments were 
performed at 50 and 500 ng/mL.  
In Figure 33, the peaks of Z-and E-isomers of samples prepared at the concentration of 
50 ng/mL are reported. 
 
Figure 33 Panel A: Z- and E-isomer peaks of sunitinib at a concentration of 50 ng/mL after different 
intervals in dark condition and 40°C. The sample was analyzed at T0, immediately after the step at 90°C 
for 5 min (blue line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 200 (T20) min 
in the autosampler. Panel B: enlargement of the E-isomer peaks. 
As clear by the previous figure, at 50 ng/mL, the signal of the E-isomer was barely 
noticeable from the noise signal, anyway, an attempt of quantification was done and 
the results are reported in the following table (Table 19). 
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Table 19 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of sunitinib at a 
concentration of 50 ng/mL. The percentages of E- and Z-isomers respect to the total areas are reported. 
The samples were analyzed immediately after the step at 90°C for 5 min (T0), and after 10 (T1), 20 (T2), 
30 (T3), 100 (T10), and 200 (T20) min in the autosampler (dark and at 40°C). 
Sunitinib 50 ng/mL 
Time E-isomer Area·105 (%) Z-isomer Area·105 (%) Total Area·105 (%) 
T0 0.004 (0,67) 0,582 (99,33) 0,586 (100) 
T1 (10 min) 0.003 (0,41) 0,681 (99,59) 0,684 (100) 
T2 (20 min) 0.003 (0,41) 0,697 (99,59) 0,700 (100) 
T3 (30 min) 0.003 (0,38) 0,692 (99,62) 0,695 (100) 
T10 (100 min) 0.002 (0,32) 0,706 (99,68) 0,708 (100) 
T20 (200 min) 0.003 (0,35) 0,766 (99,65) 0,769 (100) 
 
The results obtained using the concentration of 500 ng/mL are reported in Figure 34 and 
Table 20. 
 
Figure 34 Panel A: Z- and E-isomer peaks of sunitinib at a concentration of 500 ng/mL after different 
intervals in dark condition and at 40°C. The sample was analyzed at T0, immediately after the step at 
90°C for 5 min (blue line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 (T10), and 200 (T20) min 
in the autosampler. Panel B: enlargement of the E isomer peaks. 
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Table 20 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of sunitinib at a 
concentration of 500 ng/mL. The percentages of E- and Z-isomers respect to the total areas are reported. 
The samples were analyzed immediately after the step at 90°C for 5 min (T0), and after 10 (T1), 20 (T2), 
30 (T3), 100 (T10), and 200 (T20) min in the autosampler (dark and at 40°C). 
Suntinib 500 ng/mL 
Time E-isomer Area·105 (%) Z-isomer Area·105 (%) Total Area·105 (%) 
T0 0.049 (0.73) 6.669 (99.26) 6.718 (100) 
T1 (10 min) 0.048 (0.67) 7.084 (99.33) 7.132 (100) 
T2 (20 min) 0.046 (0.64) 7.106 (99.35) 7.152 (100) 
T3 (30 min) 0.042 (0.59) 7.083 (99.41) 7.125 (100) 
T10 (100 min) 0.027 (0.37) 7.240 (99.63) 7.267 (100) 
T20 (200 min) 0.023 (0.32) 7.247 (99.68) 7.270 (100) 
 
The increasing of the temperature from 60 to 90°C augmented the E- to Z-isomer 
reconversion, thus increasing the Z-isomer signal and decreasing the E-isomer signal at 
both the investigated concentrations (50 and 500 ng/mL). In fact, the percentage of the 
E-isomer even after 20 min at 60°C was equal to 1.95% (T4, Figure 32), while after only 5 
min at 90°C it resulted reduced to 0.67 and 0.73% at 50 (T0, Figure 33) and 500 ng/mL 
(T0, Figure 34), respectively. Moreover, the maintenance of the samples into the 
autosampler, thus in dark condition and at 40°C, resulted to be not worth of 
consideration for the set up of the method due to the very slightly difference between 
different re-injected samples. In fact, the E-isomer percentage decreased from 0.67% to 
0.35% and from 0.73 to 0.32% in about 3 hours at 50 and 500 ng/mL, respectively. 
However, in each analytical run a series of samples, collectively called system suitability 
test, are requested to be analyzed before samples injection to verify instrument 
conditions. The system suitability test requires about 1 hour and, from these results, it is 
reliable to assume that this period is enough for stabilize the Z- to E-isomer ratio. 
The same set of tests have been performed in samples at low (50 ng/mL) and high (500 
ng/mL) concentration of the metabolite N-desethyl sunitinib heated at 90°C for 5 min. 
The results obtained are comparable with those observed with sunitinib samples: the E-
isomer signal was indeed barely observable from the noise signal after the heated bath, 
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and it resulted even lower than the sunitinib one (Figure 35 and Figure 36, Table 21 and 
Table 22). 
 
 
Figure 35 Panel A: Z- and E-isomer peaks of N-desethyl sunitinib at a concentration of 50 ng/mL after 
different intervals in dark condition and at 40°C. The sample was analyzed at T0, immediately after the 
step at 90°C for 5 min (blue line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 
200 (T20) min in the autosampler. Panel B: enlargement of the E-isomer peaks. 
 
 
Table 21 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of N-desethyl sunitinib at a 
concentration of 50 ng/mL. The percentages of E- and Z-isomers respect to the total areas are reported. 
The samples were analyzed immediately after the step at 90°C for 5 min (T0), and after 10 (T1), 20 (T2), 
30 (T3), 100 (T10), and 200 (T20) min in the autosampler (dark and at 40°C). 
N-desethyl sunitinib 50 ng/mL 
Time E-isomer Area·105 (%) Z-isomer Area·105 (%) Total Area·105 (%) 
T0 0.004 (0.89) 0.480  (98.61) 0.484  (100) 
T1 (10 min) 0.004 (0.75) 0.478  (99.24) 0.482  (100) 
T2 (20 min) 0.002  (0.53) 0.476  (99.47) 0.478  (100) 
T3 (30 min) 0.002  (0.36) 0.481  (99.64) 0.483  (100) 
T10 (100 min) 0.001  (0.30) 0.468  (99.70) 0.469  (100) 
T20 (200 min) 0.001  (0.23) 0.472  (99.77) 0.473  (100) 
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Figure 36 Panel A: Z- and E-isomer peaks of N-desethyl sunitinib at a concentration of 500 ng/mL after 
different intervals in dark condition and at 40°C. The sample was analyzed at T0, immediately after the 
step at 90°C for 5 min (blue line), and then re-analyzed after 10 (T1), 20 (T2), 30 (T3), 100 min (T10), and 
200 (T20) min in the autosampler. Panel B: enlargement of the E isomer peaks. 
 
Table 22 Areas of E-isomer, Z-isomer, and the sum of the two isomers areas of N-desethyl sunitinib at a 
concentration of 500 ng/mL. The percentages of E- and Z-isomers respect to the total areas are reported. 
The samples were analyzed immediately after the step at 90°C for 5 min (T0), and after 10 (T1), 20 (T2), 
30 (T3), 100 (T10), and 200 (T20) min in the autosampler (dark and at 40°C). 
N-desethyl sunitinib 500 ng/mL 
Time E-isomer Area·105 (%) Z-isomer Area·105 (%) Total Area·105 (%) 
T0 0.022  (0.40) 5.473  (99.60) 5.495  (100) 
T1 (10 min) 0.019  (0.37) 5.257  (99.63) 5.276  (100) 
T2 (20 min) 0.015  (0.29) 5.324  (99.71) 5.339  (100) 
T3 (30 min) 0.014  (0.26) 5.398  (99.74) 5.412  (100) 
T10 (100 min) 0.010  (0.19) 5.472  (99.81) 5.482  (100) 
T20 (200 min) 0.010  (0.19) 5.456  (99.81) 5.466  (100) 
 
Also in the case of N-desethyl sunitinib, the maintenance of the samples into the 
autosampler resulted to be not worth of consideration in the E-isomer reconversion 
process and can be neglected.  
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To conclude, the conditions chosen for E-isomer reconversion to Z-isomer consisted of 
a heating process at 90°C for 5 min. At these conditions, it is possible to assume the E-
isomer peak to be negligible, respect to the Z-isomer.  
4.1.3.2 HPLC-MS/MS 
To optimize the mass spectrometer conditions, an infusion of each standard solution 
and IS at 50 ng/mL in mobile phases (50:50) was used. The response of sunitinib and its 
main metabolite was assessed in positive and negative ion mode but the better one was 
obtained in positive mode. Using an ESI source in positive ion mode, sunitinib and its 
main metabolite formed mainly a protonated molecule [M+H]+. The precursor ion of 
sunitinib, N-desethyl sunitinib, and sunitinib D-10 as IS (m/z 399.2, m/z 371.2, and m/z 
409.3 respectively) passed through the first quadrupole into the collision cell and the 
collision energy (CE) and the Collision Cell Exit Potential (CXP) were optimized to obtain 
their product ions with a high signal (Table 23).  
Table 23 Source- and compound-dependent parameters and ion transitions of each analyte and IS used 
for the mass spectrometer method. The dwell time of each transition was set up at 50 msec. DP: 
declustering potential; EP: entrance potential; CE: collision energy; CXP: collision cell exit potential. 
Compound Q1 (m/z) DP (V) EP (V) Q3 (m/z) CE (V) CXP (V) 
sunitinib 399 72 11 
326.2 28 21 
283.1 36 18 
238.1 60 14 
N-desethyl-
sunitinib 
371 57 10 
283.2 27 14 
326.2 22 18 
238.2 54 21 
sunitinib-D10 (IS) 409 67 11 
326.2 30 21 
283.2 39 18 
238.2 63 14 
 
The fragmentation pattern of sunitinib is represented in Figure 37, the same 
fragmentation pattern has been observed for its metabolite and IS. 
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Figure 37 MS/MS mass spectra of sunitinib, N-desethyl sunitinib and sunitinib D10 (IS) with chemical 
structures and identification of the main fragment ions. The fragment ion at 238 m/z of the three 
compounds is not shown in the MS/MS mass spectra because it requires, for its formation, a higher CE 
than the other fragments. 
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For each compound, the daughter ion with the highest signal was used as quantifier, as 
follows: 399.2>326.2 for sunitinib, 371.2>283.2 for N-desethyl sunitinib, 409.3>326.2 for 
IS, all expressed in m/z. Two additional daughter ions, for each analyte and IS, were 
chosen as qualifiers and the details of the transitions and the correspondent CE and CXP 
were reported in Table 23. 
Figure 38 presents typical SRM chromatograms, using the quantifier transitions noted 
above.  
 
Figure 38 Representative SRM chromatograms. Panel A: SRM chromatograms of a human blank plasma 
sample; Panel B: SRM chromatograms of a human blank plasma sample with IS added; Panel C: S/N of 
sunitinib and N-desethyl sunitinib at the LLOQ (0.1 ng/mL for both the analytes); Panel D: SRM 
chromatograms of an extracted plasma sample of a calibration curve point (B: 250 ng/mL for sunitinib 
and 100 ng/mL for N-desethyl sunitinib). 
Panel A shows an extracted blank plasma sample; Panel B displays an extracted blank 
plasma sample with IS added; Panel C shows an extracted plasma sample at the LLOQ 
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with IS added, and Panel D displays a point of the calibration curve at a concentration 
equal to 250 ng/mL for sunitinib and 100 ng/mL for N-desethyl sunitinib. The elution of 
the analytes was rapid and selective with adequate separation of all the peaks within 2.5 
min: sunitinib, N-desethyl sunitinib and IS were eluted at approximately 2.61, 2.55, and 
2.61 min, respectively. No interfering peaks were observed at these retention times, 
and the peaks were completely resolved from plasma matrix, with a good shape. 
4.1.3.3 Validation of the method 
The validation process has not yet been concluded. In fact, for a completely validation it 
is necessary to test the method in real patients samples and to conduct the ISR to verify 
the reliability of the reported subject sample analyte concentrations, as reported in 
Section 3.3 (Materials and Methods Section). At present, a request for plasma samples 
from patients treated with sunitinib has been presented at the internal ethical 
committee of the CRO institute. As soon as patients plasma samples will be available, 
these final assessment will be performed and the validation will be concluded.  
Recovery. The extraction method is based on simple deproteinization with five volumes 
of CH3OH relative to plasma sample. The recovery, evaluated in five replicates at three 
QC concentrations, was in the range 93.9-111.1% (CV ≤ 9.2%) for sunitinib and 95.7-
108.1% (CV≤ 12.3%) for N-desethyl sunitinib, as shown in Table 24. The recovery of IS 
was evaluated in five replicates at a concentration of 100 ng/mL and it was 104.9 % (CV 
5.2 %).  
Table 24 Recovery of the analytes and the IS from human plasma. 
Analyte Nominal conc. (ng/mL) Recovery (%) ± SD CV % 
sunitinib 
0.25 100.5±9.3 9.2 
25 93.9±5.4 5.8 
400 111.1±1.0 0.9 
N-desethyl 
sunitinib 
0.25 104.6±12.9 12.3 
25 95.7±5.9 6.1 
200 108.1±2.9 2.7 
sunitinib-D10 (IS) 100 104.9±5.4 5.2 
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Calibration Curves. Table 25 reports the results for the calibration curves of sunitinib 
and its main metabolite freshly prepared every day during the validation study, and the 
accuracy and precision for each standard.  
Table 25 Linearity, accuracy, and precision data for calibration curves of sunitinib and N-desethyl 
sunitinib. 
Analytes 
Nominal conc. 
(ng/mL) 
Mean ± SD 
Precision 
% 
Accuracy 
% 
sunitinib 
0.1 0.10±0.00 1.6 101.0 
0.5 0.48±0.04 7.7 95.8 
2.5 2.41±0.14 5.6 96.5 
10 10.25±0.47 4.6 102.5 
50 49.38±2.04 4.1 98.8 
250 256.67±12.29 4.8 102.7 
500 514.50±16.16 3.1 102.9 
N-desethyl 
sunitinib 
0.1 0.10±0.00 0.8 101.2 
0.5 0.47±0.02 3.9 94.2 
2.5 2.31±0.11 4.8 92.3 
10 9.72±1.05 10.8 97.2 
50 51.48±2.96 5.7 103.0 
100 104.93±9.07 8.6 104.9 
250 265.41±19.16 7.2 106.2 
 
The calibration curves prepared on five different days showed good linearity and 
acceptable results of the back-calculated concentrations over the validated range of 
0.1–500 ng/mL for sunitinib and 0.1-250 ng/mL for N-desethyl sunitinib (Figure 39). 
Pearson’s coefficient of determination R2 was ≥0.9931 for each run, the mean accuracy 
was always close to 100% (range from 95.8% to 102.9% for sunitinib and from 92.3 to 
106.2% for N-desethyl sunitinib) and the precision, expressed as CV%, ranged from 1.6 
to 7.7 % for sunitinib and from 0.8 to 10.8% for N-desethyl sunitinib. The carry-over 
effect was minimized injecting three samples of mobile phase between successive test 
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samples and after the injection of the ULOQ. This action guaranteed peak response no 
higher than 10% of LLOQ. 
 
Figure 39 Calibration curves of sunitinib and N-desethyl sunitinib in human plasma. 
Intra-day and inter-day Precision and Accuracy. The precision and accuracy of the 
method were evaluated by analyzing three replicates of QC samples (QCL, QCM and 
QCH) within a single-run analysis for intra-day assessment and over five consecutive 
runs for inter-day assessment. The accuracy and precision (CV%) obtained are shown in 
Table 26. 
Table 26 Intra and inter-day precision and accuracy of the method for the analysis of sunitinib and its 
main metabolite in human plasma samples. 
 Analytes Nominal conc. (ng/mL) Mean ± SD Prec. % Acc. % 
Intra-
day 
(N=5) 
sunitinib 
0.25 0.25±0.03 11.0 98.5 
25 25.93±0.69 2.7 103.7 
400 447.86±5.10 1.1 112.0 
N-desethyl 
sunitinib 
0.25 0.26±0.03 11.7 103.7 
25 26.71±2.57 9.6 106.9 
200 223.30±6.28 2.8 111.7 
Inter-
day 
(N=15) 
sunitinib 
0.25 0.26±0.02 6.1 102.5 
25 25.40±1.27 5.0 101.6 
400 423.48±29.23 6.9 105.9 
N-desethyl 
sunitinib 
0.25 0.25±0.02 9.1 99.1 
25 24.18±1.76 7.3 96.7 
200 214.45±14.17 6.6 107.2 
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The method was very precise, with intra- and inter-day CV ≤ 11.0 % and ≤ 6.9% for 
sunitinib, ≤11.7% and ≤9.1% for N-desethyl sunitinib. Moreover, the method showed 
intra- and inter-day accuracy within the range from 98.5 ad 112.0% and from 101.6 and 
105.9% for sunitinib, from 103.7 to 111.7% and from 96.7 and 107.2% for N-desethyl 
sunitinib.  
Limit of Detection, Limit of Quantification, Selectivity and Matrix Effect. The LOD 
was defined as the concentration at which the S/N was at least 3. On the basis of the 
S/N ratio obtained and reported in Figure 38, the LOD was 32 pg/mL for sunitinib and 29 
pg/mL for N-desethyl sunitinib. The LLOQ was fixed at 0.1 ng/mL for both sunitinib and 
N-desethyl sunitinib and the accuracy and precision were determined by analyzing six 
replicates of the sample at the LLOQ concentration. The accuracy and CV% were, 
respectively, 87.4% and 14.7% for sunitinib, 107.8% and 8.0% for N-desethyl sunitinib. 
The method was not affected by endogenous components in the matrix or other 
components in the sample. In fact, spiking six different sources of human plasma with 
sunitinib and its main metabolite at a concentration corresponding to the LLOQ, the 
precision was 8.4% for sunitinib and 5.9% for N-desethyl sunitinib, respectively, and the 
accuracy was 89.5% for sunitinib and 114.9% for N-desethyl sunitinib, respectively. 
There were no significant variations (<15%) in the peak area of each analyte in the six 
lots of matrix, therefore it was possible to exclude the presence of any matrix effect of 
ion suppression or enhancement. The absence of the matrix effect has been 
determined, for sunitinib and N-desethyl sunitinb, also by the post column infusion test 
and by comparing the peak area of the analyte extracted from plasma QC samples with 
the peak area of the extracted matrix prepared in five replicates and added with the 
same amount of the analyte (data not shown). 
Stability. The stability of sunitinib and its main metabolite, under different conditions, 
was assessed by analyzing QC samples, prepared in triplicate. Both the analytes in 
human plasma were stable for 4 h at room temperature (Table 27). For the peculiarity of 
this method, it was particularly important to assess the stability in the autosampler 
after the extraction. In fact, the autosampler temperature was set at 40°C in order to 
enhance and stabilize the conversion to the active Z-isomer, while usually the 
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autosampler temperature is fixed at 4°C. Therefore, we demonstrated the stability of 
the extracted samples up to 48 h in the autosampler at 40°C (Table 27). 
Table 27 Short term stability of sunitinib and its main metabolite in human plasma samples at room 
temperature (RT) and in autosampler (40°C). 
Analytes 
Nominal 
conc. 
(ng/mL) 
T = 4h (RT) T = 48h in autosampler (40°C) 
Mean ± SD Prec. % Acc. % Mean ± SD Prec. % Acc. % 
sunitinib 
0.25 0.23±0.01 5.9 90.6 0.23±0.02 8.4 90.6 
25 23.37±0.86 3.7 93.5 23.94±1.95 8.1 95.8 
400 440.84±22.23 5.0 110.2 418.56±24.90 5.9 104.6 
N-
desethyl 
sunitinib 
0.25 0.25±0.03 12.6 101.0 0.25±0.02 7.2 101.3 
25 22.81±1.12 4.9 91.2 25.20±0.45 1.8 100.8 
200 227.44±4.10 1.8 113.7 209.57±7.56 3.6 104.8 
 
Sunitinib and N-desethyl sunitinib were stable in human plasma over two freeze/thaw 
cycles: precision as CV% and accuracy for freeze/thaw samples were ≤8.6% and within 
99.9–108.2% for sunitinib and ≤12.4% and within 101.9–106.1% for N-desethyl 
sunitinib, (Table 28).  
Table 28 Stability of sunitinib and its main metabolite, in human plasma samples, after 2 freeze-thaw 
cycles. 
Analytes 
After 2 freeze-thaw cycles 
Nominal conc. (ng/mL) Mean ± SD Prec. % Acc. % 
sunitinib 
0.25 0.26±0.02 6.5 105.9 
25 24.97±0.74 3.0 99.9 
400 432.80±37.20 8.6 108.2 
N-desethyl sunitinib 
0.25 0.26±0.02 9.2 104.8 
25 26.52±0.26 1.0 106.1 
200 203.82±25.24 12.4 101.9 
Several aliquots of QC plasma samples have been stored at -80°C in order to complete 
the assessment of the long-term stability. This part of the validation will be conducted 
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in the next months in order to define the stability of the analytes in plasma at 6 months 
(after 5 months at -70°C have been already verified by Rodamer et al. (Rodamer et al., 
2011). Moreover, the long term stability of standard working solutions of sunitinib and 
N-desethyl sunitinib used for the calibration curves and QC samples prepared in 
methanol and stored at −80°C will be assessed in the next months. 
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4.2 Phase Ib clinical trials 
4.2.1 Collection and storage of the samples 
The collection and storage of the samples from the three clinical trials followed the 
same procedures. Patients were hospitalized for 3 days during the two treatments (I and 
II administration for the phase I of FOLFIRI in combination with bevacizumab and 
cetuximab; I and IV administration for the phase I of weekly PTX) of the first therapy 
cycle and the drug administration and sampling were strictly monitored by the 
dedicated staff (MD clinical staff and research nurses dedicated to clinical studies). 
The blood samples were collected into tubes containing K2-EDTA and plasma was 
obtained immediately by centrifugation of the blood samples at 3000 g for 10 min at 
4°C. Then the plasma was separated, split into 2 polypropylene tubes and stored as two 
independent aliquots at -80°C pending analysis. All blood samples were collected under 
the full ethical approval of the ethics committee of the participating centers and only 
after the signature of informed consent from all the enrolled patients. 
The samplings were recorded, in details, in forms suitable to indicate the correct timing 
and any possible variation from it. Some basic information of the patient, such as the 
performance status (PS), the BSA, the scheduled treatment, the CPT-11/PTX dose, and 
the date and time of the therapy start were also reported (Appendix 1).  
4.2.2 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and bevacizumab in advanced colorectal cancer 
patients 
4.2.2.1 Patients characteristics and dose escalation 
This dose finding study was concluded in December 2014. A total of 48 patients were 
enrolled in the trial, 25 with UGT1A1 *1/*1 genotype and 23 with *1/*28 genotype. The 
main characteristics of the patients enrolled are shown in Table 29.  
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Table 29 Patients characteristics (n=48 patients who received at least one dose of protocol therapy).
 
*
One patient was not evaluable for safety because his treatment was delayed for personal reasons in the 
absence of DLT. 
Number of evaluable patients 
For safety* 
For pharmacokinetics 
For efficacy 
47 
47 (43 for interaction with bevacizumab) 
33 
Accrual site 
Aviano, Italy 
Chicago, USA 
Rome, Italy 
28 (58%) 
17 (35%) 
3 (6%) 
Age, years 
Median, range 56, 32-76 
Sex 
Male 
Female 
28 (58%) 
20 (42%) 
Race 
White 
Black 
Asian 
41 (85%) 
6 (13%) 
1 (2%) 
Body-surface area (BSA), m2 
Median, range 1.80, 1.42-2.52 
ECOG performance status 
0 
1 
45 (94%) 
3 (6%) 
Primary site 
Colon 
Rectum 
37 (77%) 
11 (23%) 
Number of metastatic sites 
1 
≥2 
29 (60%) 
19 (40%) 
 
 
The dose of CPT-11 was escalated from 260 mg/m2 to 310 mg/m2 and eventually to 370 
mg/m2 in both *1/*1 and *1/*28 patients, as reported in Table 30 where the overall 
results of the dose escalation are schematized. 
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Table 30 Dose escalation of CPT-11 and observed DLTs in patients treated with FOLFIRI plus 
bevacizumab. 
CPT-11 dose (mg/m2) *1/*1 patients (DLTs) *1/*28 patients (DLTs) 
260 10 (1) 
Grade 3 diarrhoea 
10 (2) 
Grade 3 arrhythmia 
Grade 4 neutropenia 
310 10 (2) 
Grade 3 diarrhoea x 2 
10 (4) 
Grade 3 diarrhoea 
Grade 3 mucositis 
Grade 4 neutropenia x 2 
370 4 (2) 
Grade 3 nausea/vomiting 
Grade 5 neutropenic sepsis 
3 (2) 
Grade 3 diarrhoea 
Grade 4 neutropenia x 2 
 
In the *1/*28 patients, 370 mg/m2 was not tolerated (2 DLTs out of 3 patients), and the 
310 mg/m2 cohort was expanded to 10 patients, where 4 DLTs were observed. Hence, 
the 260 mg/m2 cohort was expanded to 10 patients, and because 2 DLTs were observed 
among those 10 patients, 260 mg/m2 was declared the MTD in *1/*28 patients. In the 
*1/*1 patients, 2 DLTs occurred among the first 3 patients treated at 310 mg/m2. The 
260 mg/m2 was expanded to 10 patients and only 1 DLT was observed. Therefore, the 
310 mg/m2 cohort was expanded and no additional patients had a DLT (total 2 DLTs out 
of 10 patients). Thus, the dose was escalated to 370 mg/m2, but 2 DLTs occurred among 
the first 4 patients treated, including a death from neutropenic sepsis. Hence, the 310 
mg/m2 dose was declared the MTD in *1/*1 patients.  
The most common DLTs were neutropenia (6 of 13; 46%) and diarrhoea (5 of 13; 38%). 
Three of 6 neutropenia DLTs were febrile neutropenia. The other two DLTs were grade 
3 mucositis and grade 3 arrhythmia (Table 30). Common (> 10% of patients) and/or 
severe toxicities during the first cycle of therapy are reported in Table 31. The median 
number of treatment cycles was 6 (range 0.5-10.5) in all treated patients. In the 20 *1/*1 
and *1/*28 patients treated at the MTD, the median number of treatment cycles was 6 
(range 1.5-10), and 65% of the patients treated at the MTD did not require a dose 
reduction of CPT-11. The doses of 5-FU and bevacizumab were not modified. 
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Table 31 Toxicities during the first cycle of FOLFIRI plus bevacizumab. Number of patients (%) is 
indicated. Toxicities were included if they occurred in at least 10% of patients or if they were grade 3 or 
greater, and if they were at least possibly related to treatment. 
  Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 
Anaemia 13 (27) 9 (19) 1 (2) 0  0 
Leukopenia 7 (15) 8 (17) 2 (4) 0 0 
Neutropenia 4 (8) 12 (25) 10 (21) 5 (10) 1 (2) 
Febrile neutropenia 0 0  1 (2)  1 (2) 1 (2) 
Thrombocytopenia 3 (6) 0  0 0 0 
Abdominal pain 12 (25) 2 (4) 0 0 0 
Alopecia 3 (6) 3 (6) 1 (2) 0 0 
Anorexia 6 (13) 0 0 0  0 
Arrhythmia 0 0 1 (2) 0 0 
Asthenia 16 (33) 1 (2) 0 0 0 
Constipation 19 (40) 2 (4) 0 0 0 
Diarrhoea 15 (31) 6 (13) 5 (10) 0  0 
Elevated ALT 14 (29) 2 (4) 0 0 0 
Elevated AST 24 (50) 4 (8) 0 0 0 
Epistaxis 5 (10) 0 0 0 0 
Fatigue 11 (23) 2 (4) 0 0 0 
Fever 4 (8) 0 0 0 0 
Mucositis 7 (15) 2 (4) 1 (2) 0  0 
Nausea/Vomiting 26 (54) 7 (15) 5 (10) 0  0 
Pain (from mucositis) 1 (2) 0 1 (2) 0 0 
4.2.2.2 Pharmacokinetics of irinotecan and its main metabolites and 
interaction with bevacizumab 
Pharmacokinetic data were obtained from 47 patients applying the LC-MS/MS method 
for the quantification of CPT-11 and its main metabolites in plasma samples (for the 
development and validation of the method see Section 4.1.1).  
As examples of the pharmacokinetic profiles obtained, Figure 40 (Panel A and B) shows 
the plasma concentration-versus-time curves of CPT-11, SN-38, SN-38G and APC 
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determined, during the first cycle of therapy in two patients receiving respectively 310 
(Panel A) and 370 (Panel B) mg/m2 of CPT-11.  
 
Figure 40 Plasma concentration-versus-time profiles of CPT-11 and its main metabolites: SN-38, SN-38G 
and APC. Panel A: Plasma concentration-versus-time profiles of CPT-11, SN-38, SN-38G and APC in one 
patient receiving 310 mg/m
2
 of CPT-11 during the I and the II administration of the first therapy cycle; 
Panel B: Plasma concentration-versus-time profiles of CPT-11, SN-38, SN-38G and APC in one patient 
receiving 370 mg/m
2
 of CPT-11 during the I administration of the first therapy cycle. BV: bevacizumab. 
Panel A shows two pharmacokinetic profiles for each analyte because the patient 
received both the administrations of the first cycle whereas Panel B shows just one 
profile (referring to the first treatment) for analyte because the patient experienced 
DLTs. Therefore, he received additional treatment with a 25% reduction in the dose of 
CPT-11 and, consequently, blood samples were not drawn during the second 
administration.  
For both the patients, CPT-11 plasma concentrations appeared to decline in a bi-
exponential manner, with a rapid initial phase and an extended terminal phase. 
Moreover, it is possible to observe that APC presents a curve very similar to CPT-11 
while the two regarding SN-38 and SN-38G show the same multi-exponential manner 
to decline with a very prolonged terminal phase. The principal pharmacokinetic 
parameters determined by the profiles reported in Figure 40 and related to the two 
patients treated with 310 or 370 mg/m2 of CPT-11 are reported in Table 32 and Table 33, 
respectively.  
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Table 32 Pharmacokinetic parameters obtained from one patient treated at 310 mg/m
2
 of CPT-11 during 
the first (Day 1-3) and the second (Day 15-17) treatment of the first chemotherapy cycle. 
Days 1-3 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
AUCinf 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
CPT-11 3003.21 2.00 21298.29 21475.55 8.00 16.66 14.43 
SN-38 30.70 4.00 415.40 452.34 16.81 - - 
SN-38G 94.36 4.00 1128.51 1263.11 18.31 - - 
APC 194.08 4.00 1994.79 2028.70 8.67 - - 
Days 15-17 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
AUCinf 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
CPT-11 3682.62 2.08 25613.15 25967.08 8.92 15.37 11.94 
SN-38 24.12 3.08 375.22 449.63 24.31 - - 
SN-38G 104.41 3.08 1304.04 1491.75 19.44 - - 
APC 131.36 3.08 1714.92 1751.17 9.19 - - 
 
Table 33 Pharmacokinetic parameters obtained from one patient treated at 370 mg/m
2
 of CPT-11 during 
the first (Day 1-3) treatment of the first chemotherapy cycle. 
Days 1-3 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
AUCinf 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/hrm2) 
CPT-11 2370.47 2.00 17759.90 18194.43 10.27 30.12 20.34 
SN-38 65.95 3.00 515.52 601.46 21.04 - - 
SN-38G 100.72 3.00 1130.06 1330.56 19.07 - - 
APC 155.16 3.00 1817.06 1842.21 8.14 - - 
 
As reported in Table 33, in comparison with the patient treated at 310 mg/m2, the 
patient treated at 370 mg/m2 reached a SN-38 Cmax that was more than double (65.95 
vs. 30.70 ng/mL) and the SN-38 AUClast was almost 25% higher (515.42 h vs. 415.40 
ng/mL). This could explain the development of DLTs as CPT-11 is just a pro-drug rapidly 
converted to the active metabolite (SN-38).  
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Moving from a specific to a more general view of the pharmacokinetic results, in Figure 
41, the mean plasma concentrations versus time profiles of CPT-11, SN-38, SN-38G and 
APC per dose level are reported.  
 
Figure 41 Mean plasma concentrations versus time profiles of CPT-11, SN-38, SN-38G and APC per dose 
level in patients enrolled in the phase I study. 
Only the concentrations found during the first administration, with no effect derived by 
bevacizumab, have been used for the calculation of the mean values, and they include 
both the two genotype cohorts (Table 34). For all the quantifications of each patient, 
the highest concentrations found were within the dynamic range of the assay without 
the need for further dilution steps even if the independence of analysis from the dilution 
was previously assessed at the dilution factors of 1:10 and 1:100 (data not shown). If the 
blood sample at T=14 h should be done during the night, our policy was not to collect it 
for patient’s respect. For this reason, for some patients the T=14 h sample was missed. 
In particular, this was the case of the seven patients treated at 370 mg/m2. 
4 Results: Phase Ib clinical trials 
143 
Table 34 Data used for the generation of the mean plasma concentrations versus time profiles of CPT-11, 
SN-38, SN-38G and APC. 
CPT-11 APC 
Time 
(h) 
260 
(mg/m2) 
310  
(mg/m2) 
370 
(mg/m2) 
260  
(mg/m2) 
310  
(mg/m2) 
370  
(mg/m2) 
1 1395.28 ± 
657.24 
1454.00 ± 
473.00 
2232.70 ± 
831.02 
33.93 ±  
23.62 
45.31 ±  
62.95 
125.09 ±  
117.60 
2 2069.36 ± 
876.71 
1821.89 ± 
562.43 
3233.45 ± 
1203.40 
124.92 ± 
71.46 
142.18 ± 
152.84 
413.65 ±  
332.28 
2.25 1643.80 ± 
696.46 
1512.78 ± 
477.03 
3040.31 ± 
1090.12 
142.70 ± 
82.58 
166.92 ± 
187.63 
534.96 ±  
473.18 
2.5 1486.28 ± 
601.02 
1399.62 ± 
437.10 
2857.57 ± 
1122.81 
167.01 ± 
100.36 
176.80 ± 
187.31 
490.45 ±  
402.79 
3 1305.00 ± 
558.31 
1224.16 ± 
394.26 
2814.81 ± 
1107.33 
178.51 ± 
112.01 
185.17 ± 
191.76 
660.27 ±  
596.25 
4 
1103.07 ± 
502.06 
1001.99 ± 
419.86 
2227.54 ± 
930.41 
179.30 ± 
127.07 
176.58 ± 
159.47 
619.02 ±  
503.22 
6 
719.76 ± 
341.02 
658.09 ± 
235.26 
1488.96 ± 
657.65 
146.63 ± 
86.74 
157.52 ± 
139.76 
557.56 ±  
434.17 
8 
573.98 ± 
245.75 
499.16 ± 
166.92 
792.76 ± 
312.69 
123.59 ± 
65.35 
146.55 ± 
151.60 
319.98 ±  
367.70 
10 
383.99 ± 
167.82 
328.24 ±  
88.63 
646.42 ± 
329.15 
95.03 ± 
 64.20 
87.54 ±  
79.08 
305.92 ±  
391.86 
14 
181.51 ± 
64.80 
171.52 ± 
21.93 
- 
46.83 ± 
41.21 
58.73 ±  
7.95 
- 
26 
81.19 ±  
61.51 
64.89 ±  
27.18 
188.72 ± 
147.36 
24.55 ± 
19.61 
20.98 ± 
22.18 
106.23 ± 
116.89 
50 
20.94 ± 
18.31 
15.55 ± 
10.63 
34.52 ±  
26.23 
6.23 ±  
8.01 
4.41 ±  
5.94 
16.24 ±  
20.39 
SN-38 SN-38G 
1 
10.47 ± 
4.85 
14.06 ±  
6.00 
27.32 ±  
23.11 
28.96 ± 
17.95 
44.69 ± 
34.58 
65.76 ±  
61.53 
2 
12.77 ±  
6.13 
18.35 ±  
8.16 
34.32 ±  
29.55 
56.68 ± 
28.77 
91.86 ± 
61.52 
113.59 ± 
83.89 
2.25 
12.50 ± 
6.44 
18.28 ±  
8.00 
35.16 ±  
29.57 
60.21 ± 
30.79 
97.04 ± 
64.39 
125.84 ±  
96.19 
2.5 
12.25 ± 
6.87 
17.37 ± 
8.02 
33.67 ±  
28.14 
65.24 ± 
34.09 
104.42 ± 
72.69 
112.52 ± 
79.66 
3 
11.91 ± 
7.26 
17.28 ±  
9.13 
32.42 ±  
21.93 
62.38 ± 
33.35 
97.65 ± 
58.10 
139.95 ± 
105.97 
4 
10.38 ± 
5.01 
15.09 ±  
8.56 
25.13 ±  
12.46 
55.74 ± 
30.30 
85.35 ± 
45.37 
129.10 ± 
90.03 
6 
8.25 ±  
4.77 
11.47 ±  
7.41 
18.13 ± 
 6.97 
43.84 ± 
23.07 
71.71 ± 
47.55 
110.48 ±  
77.32 
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8 
6.87 ±  
3.22 
6.83 ±  
4.76 
7.96 ±  
4.36 
34.98 ± 
15.50 
48.51 ± 
39.85 
66.54 ±  
76.62 
10 
5.62 ±  
3.16 
5.65 ±  
3.39 
9.33 ±  
4.28 
29.06 ± 
14.64 
35.03 ± 
30.28 
63.30 ±  
77.49 
14 
5.94 ±  
4.46 
6.35 ±  
5.78 
- 
18.25 ± 
7.78 
18.22 ± 
13.40 
- 
26 
3.33 ±  
1.59 
3.54 ±  
1.59 
8.48 ±  
7.34 
18.36 ± 
11.54 
22.27 ± 
15.58 
44.12 ±  
37.04 
50 
1.72 ±  
1.12 
1.77 ±  
0.84 
3.62 ±  
2.42 
9.39 ±  
7.75 
9.43 ±  
7.47 
19.93 ±  
14.50 
 
The same considerations about the shape of the pharmacokinetic profiles of CPT-11, 
SN-38, SN-38G, and APC reported above can be done for the mean plasma 
concentrations versus time curves. CPT-11 and APC present a curve very similar each 
other, with concentrations declining in a bi-exponential manner, with a rapid initial 
phase and an extended terminal phase. At the same time, SN-38 and SN-38G show the 
same multi-exponential manner to decline with a very prolonged terminal phase.  
In Figure 41 the standard deviation was not reported for major clarity. In fact, in Table 
34 it is possible to see the huge variability, in term of standard deviation, obtained from 
the pharmacokinetic profiles of patients enrolled. In the following tables (Table 35, 
Table 36) the mean values of the principal pharmacokinetic parameters obtained from 
all the patients enrolled in the phase I study are reported, divided by administrations (I 
administration, i.e. without bevacizumab; II administration, i.e. with bevacizumab) and 
genotype group. In these tables dose adjustments were made for both Cmax and AUClast. 
Even in this case, looking at the standard deviation values, a great interindividual 
variability in the pharmacokinetic parameters has been observed.  
The glucuronidation ratio (GR), defined as the ratio of SN38G AUClast and SN38 AUClast, 
has been calculated between the two genotype groups. Once more, in order to 
overcome the different concentrations among patients, the dose adjustment has been 
done for AUClast values. No difference between the two cohorts has been obtained in 
GR values: indeed, GR equal to 6.10 ± 3.42 and 5.89 ± 4.02 has been obtained for *1/*1 
patients and *1/*28 patients, respectively. These data suggest no pharmacokinetic 
differences between the two genotype groups. 
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Table 35 Summary of the main pharmacokinetic parameters of CPT-11, SN-38, SN-38G and APC without 
bevacizumab (I adm) obtained in the two genotype groups (*1/*1 and *1/*28 patients) during the I 
administration of the first chemotherapy cycle. Dose adjustments were made for Cmax and AUClast. 
I adm (days 1-3)  
Genotype  
group 
compound 
Cmax  
(ng/mL)/ 
dose (mg/m2) 
tmax 
(h) 
AUClast 
(h·ng/mL)/ 
dose (mg/m2) 
t1/2 
(h) 
Cl 
(L/h/m2) 
*1/*1 
CPT-11 8.12 ± 3.43 2.14 ± 0.55 59.64 ± 30.18 8.70 ± 1.41 20.77 ± 10.54 
SN-38 0.09 ± 0.05 2.89 ± 1.14 1.09 ± 0.46 18.43 ± 6.63 
 
SN-38G 0.41 ± 0.23 3.19 ± 0.84 5.92 ± 3.22 20.05 ± 11.05 
 
APC 1.09 ± 1.11 3.37 ± 0.98 13.46 ± 13.85 9.20 ± 3.00 
 
*1/*28 
CPT-11 6.59 ± 2.26 2.03 ± 0.20 49.09 ± 18.02 9.10 ± 1.92 22.65 ± 8.07 
SN-38 0.06 ± 0.04 2.18 ± 1.18 0.83 ± 0.37 32.54 ± 31.77 
 
SN-38G 0.26 ± 0.17 2.95 ± 0.87 4.66 ± 2.95 23.85 ± 10.00 
 
APC 0.75 ± 0.66 3.59 ± 1.25 9.81 ± 7.64 9.03 ± 1.57 
 
Table 36 Summary of the main pharmacokinetic parameters of CPT-11, SN-38, SN-38G and APC with 
bevacizumab (II adm) obtained in the two genotype groups (*1/*1 and *1/*28 patients) during the II 
administration of the first chemotherapy cycle. Dose adjustments were made for Cmax and AUClast. 
II adm (days 15-17) 
Genotype 
group 
compound 
Cmax  
(ng/mL)/ 
Dose 
 (mg/m2) 
tmax 
(h) 
AUClast 
(h·ng/mL)/ 
dose 
(mg/m2) 
t1/2 
(h) 
Cl 
(L/h/m2) 
*1/*1 
CPT-11 8.74 ± 4.89 1.97 ± 0.43 63.80 ± 41.96 9.11 ± 1.29 20.21 ± 10.34 
SN-38 0.08 ± 0.04 2.39 ± 1.17 1.02 ± 0.52 24.72 ± 10.25 
 
SN-38G 0.37 ± 0.18 2.89 ± 0.86 6.16 ± 3.95 20.99 ± 8.20 
 
APC 0.62 ± 0.58 3.64 ± 1.12 8.87 ± 7.31 9.65 ± 2.52 
 
*1/*28 
CPT-11 6.81 ± 2.26 1.90 ± 0.52 49.78 ± 20.80 9.20 ± 1.60 25.83 ± 22.33 
SN-38 0.05 ± 0.03 1.83 ± 1.12 0.70 ± 0.32 32.99 ± 34.45 
 
SN-38G 0.26 ± 0.18 2.71 ± 0.61 4.01 ± 3.02 22.96 ± 10.91 
 
APC 0.42 ± 0.29 3.02 ± 0.59 6.56 ± 4.05 9.45 ± 2.13 
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To conclude, as it is shown in Figure 42, CPT-11 Cl seems to be constant across the 
different dose levels (Spearman correlation coefficient = -0.02432, p = 0.8210), thus 
indicating a linear PK. 
 
Figure 42 CPT-11 clearance (Cl) versus the doses  (mg/m
2
) in each patients. 
Interaction with bevacizumab 
In order to analyse the interaction between CPT-11 and bevacizumab, it has been 
considered only the PK of CPT-11 and SN-38, because of their clinical interest. 
Moreover, 4 out of the 47 patients enrolled were excluded because they did not receive 
a second dose of CPT-11 due to DLTs. In Table 37, the summary of CPT-11 and SN-38 
pharmacokinetic parameters with and without bevacizumab is reported.  
Table 37 CPT-11 and SN-38 pharmacokinetic parameters with and without bevacizumab (BV)  
  
Mean, range 
(% CV) 
without  BV 
Mean, range 
(% CV) 
With BV 
p 
CPT-11 
Cmax (ng/mL)/Dose (mg/m
2) 7.2, 3.3-14.1 (39) 7.8, 1.2-27.4 (50) 0.08 
Tmax (h) 2.1, 1.0-4.0 (21) 1.9, 1.0-3.0 (24) 0.23 
AUClast (h·ng/mL)/Dose (mg/m
2) 53.2, 21.6-129 (45) 57.0, 8.2-213 (59) 0.05 
t1/2 (h) 8.8, 5.3-14.3 (18) 9.2, 5.4-12.0 (16) 0.48 
CL (L/h/m2) 22.4, 7.7-46.3 (42) 23.5, 4.7-122 (76) 0.06 
SN-38 
Cmax (ng/mL)/Dose (mg/m
2) 0.07, 0.02-0.22 (57) 0.06, 0.02-0.17 (58) 0.10 
Tmax (h) 2.5, 1.0-6.0 (49) 2.1, 1.0-6.0 (55) 0.05 
AUClast (h·ng/mL)/Dose (mg/m
2) 0.93, 0.33-2.3 (46) 0.86, 0.31-2.6 (53) 0.03 
t1/2 (h) 25.4, 7.8-148 (96) 28.8, 8.4-178 (88) 0.02 
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No major differences were observed in all the pharmacokinetic parameters of CPT-11 
and SN-38 in the presence or absence of bevacizumab. CPT-11 Cl was slightly higher 
when administered with bevacizumab compared to without bevacizumab (p = 0.06). 
The presence of bevacizumab was also associated with very small changes in the dose-
adjusted AUClast of CPT-11 (increased, p = 0.05) and SN-38 (reduced, p = 0.03). This is 
even graphically shown in the following figure (Figure 43). 
 
Figure 43 AUClast of CPT-11 (A) and SN-38 (B) normalized for the CPT-11 dose, with and without 
concomitant treatment with bevacizumab. Each black line represents an individual subject, while the red 
lines connect the means for the two groups. 
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The overall median PFS was 9.0 months (95% CI = 6.6 - 13.1 months). PFS curves do not 
clearly separate by UGT1A1 genotype, and a trend of PFS with CPT-11 dose is not 
evident (Table 38 and Figure 44).  
Anyway, one patient with extensive liver and lymph node metastases and *1/*1 
genotype treated at 310 mg/m2 (dose reduced to 233 mg/m2 after a DLT of grade 3 
diarrhoea) had a complete response that has been durable for 5 years since the start of 
therapy (as of CT scan dated September 21, 2015). 
 
 
Table 38 Response rate, overall and by CPT-11 dose and UGT1A1*28 genotype. CR: complete response; 
PD: progressive disease; PR: partial response; SD: stable disease. Response rates between groups were 
compared using Fisher’s exact test for count data. *One patient with *1/*1 genotype treated at 310 
mg/m
2
 (the MTD) had a CR that has been durable for 5 years since the start of chemotherapy. 
 Patients 
CR+PR  
(responders) 
SD+PD  
(non-responders) 
p value and odds 
ratio (95% CI)  
Overall 33 
13 (39%) 2 CR* + 11 
PR 
20 (61%) 15 SD + 5 
PD 
 
 
260 mg/m2 13 6 (46%) 1 CR + 5 PR 7 (54%) 6 SD + 1 PD 
p = 0.61 310 mg/m2 16 5 (31%) 1 CR* + 4 PR 
11 (69%) 9 SD + 2 
PD 
370 mg/m2 4 2 (50%) 2 PR 2 (50%) 2 PD 
 
*1/*1 16 
6 (38%) 2 CR* + 4 
PR 
10 (63%) 7 SD + 3 PD p = 1 
OR = 0.86 (0.17 - 
4.3) *1/*28 17 7 (41%) 7 PR 
10 (59%) 8 SD + 2 
PD 
 
Below MTD 6 2 (33%) 1 CR + 1 PR 4 (67%) 3 SD + 1 PD p = 1 
OR = 0.73 (0.06 - 
6.2) 
At or above 
MTD 
27 
11 (41%) 1 CR* + 10 
PR 
16 (59%) 12 SD + 4 
PD 
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Figure 44 Progression-free survival (PFS) overall (A), by UGT1A1 genotype (B), and by CPT-11 dose (C). 
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4.2.3 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and cetuximab as first-line therapy in metastatic 
colorectal cancer patients  
4.2.3.1 Patients characteristics and dose escalation 
To be eligible for this study, patients have to be UGT1A1 wild type or heterozygous and 
RAS wild type. More in detail, the mutational analysis for K-RAS/N-RAS/B-RAF is 
necessary to assess that the patient is wild-type for all the mutations present in the 
exons 2, 3 and 4 of K-RAS and N-RAS in correspondence of the amino acid residues 12, 
13, 59, 61, 117, and 146 (AIOM and SIAPEC-IAP, 2015). 
Moreover, the wild-type status needs to be assessed for the B-RAF mutation within the 
exon 15 at the residue 600.  
In the two centers involved in this ongoing study, seven patients were screened for the 
panel of mutations within the RAS and RAF genes family but, due to the relative high 
frequencies of these mutations in CRC patients and to the additional step of the 
UGT1A1*28 screening, the enrollment is quite low and, at the moment, only two 
patients resulted eligible for this study. 
The details of the enrollment status of this trial are summarized in Table 39. 
Table 39 Genotype information about the seven screened patients. 
Patient Eligible 
UGT1A1 EXON 2 EXON 3 EXON 4 EXON 15 
UGT1A1*28 K-RAS N-RAS K-RAS N-RAS K-RAS N-RAS B-RAF 
1 Yes *1/*1 wt wt wt wt wt wt wt 
2 No *28/*28 wt wt wt wt wt wt wt 
3 No *1/*1 wt wt wt Q61H wt wt wt 
4 No *28/*28 wt wt wt wt wt wt wt 
5 Yes *1/*28 wt wt wt wt wt wt wt 
6 No *1/*1 G12S wt wt wt wt wt wt 
7 No *1/*1 wt G12S wt wt wt wt wt 
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4.2.3.2 Pharmacokinetic analysis 
Till now, just two patients completed both the treatments of the first therapy cycle and 
the PK followed during the days 1-3 and the days 15-17, accordingly to the protocol 
design. Even if, during the validation process, the stability of CPT-11 and its main 
metabolites was assessed at 4 months in plasma, patients’ samples are analyzed as 
soon as possible after the collection. For this reason, the data regarding the first patient 
enrolled in this study are already available. In Figure 45 the plasma concentration-
versus-time curves of CPT-11, SN-38, SN-38G, and APC are shown. They were 
determined, using the validated LC-MS/MS method (Marangon et al., 2015), described 
in the Section 4.1.1 in the first patient enrolled and receiving 260 mg/m2 (first dose 
level) of CPT-11 as a 2-h continuous intravenous infusion. 
 
Figure 45 Plasma concentration-versus-time profiles of CPT-11 and its main metabolites (SN-38, SN-38G, 
and APC) in one patient receiving 260 mg/m
2
 of CPT-11 during the I (C1D1) and the II (C1D15) 
administration of the first therapy cycle. 
As regards the pharmacokinetic profiles of CPT-11 and its main metabolites, a good 
agreement between these curves and those obtained during the previous study has 
been observed, both in terms of shape and intensity. In fact, CPT-11 plasma 
concentrations appeared to decline in a bi-exponential manner, with a rapid initial 
phase and an extended terminal phase. The same trend has been shown with APC, 
which presents a curve very similar to CPT-11. As already observed, the two profiles 
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regarding SN-38 and SN-38G have shown the same multi-exponential manner to 
decline with a very prolonged terminal phase.  
In order to define the pharmacokinetic interaction between CPT-11 and cetuximab, 
CPT-11 PK was evaluated in absence and presence of the monoclonal antibody in the 
same patient. The pharmacokinetic profile of CPT-11 alone was assessed at the first 
chemotherapy treatment in which cetuximab was administered on day 3 (50 h after the 
start of CPT-11 infusion). Whereas, CPT-11 PK in combination with cetuximab was 
performed during the second treatment of the first cycle, when the antibody was 
administered before CPT-11 dosage. 
In the following tables (Table 40, Table 41) the main pharmacokinetic parameters of 
CPT-11 and its metabolites, obtained during the first and the second treatment 
respectively, are reported. They were determined applying a non-compartmental 
analysis. 
Table 40 PK parameters obtained in one patient receiving 260 mg/m
2
 of CPT-11 as a 2-h continuous 
intravenous infusion during the first administration (Day 1-3) of the first chemotherapy cycle. 
Days 1-3 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
AUCinf 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
CPT-11 2599.96 1.08 16968.01 17448.08 10.60 227,85 14,90 
SN-38 8.20 1.08 164.16 426.44 75.66 - - 
SN-38G 33.97 1.92 767.06 1652.60 58.24 - - 
APC 507.14 2.47 6576.38 6732.95 9.31 - - 
Table 41 PK parameters obtained in one patient receiving 260 mg/m
2
 of CPT-11 as a 2-h continuous 
intravenous infusion during the second administration (Day 15-17) of the first chemotherapy cycle. 
Days 15-17 
Compound 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
AUCinf 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
CPT-11 1933.13 2.25 14420.32 14667.84 9.15 234,10 17,73 
SN-38 10.93 0.97 198.31 277.22 23.57 - - 
SN-38G 22.18 2.25 521.74 722.15 24.05 - - 
APC 304.92 2.58 3644.86 3700.01 8.07 - - 
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4.2.4 Genotype-guided phase I study for weekly paclitaxel in 
ovarian cancer patients 
4.2.4.1 Patients characteristics and dose escalation 
This third dose finding study is still on-going. Until now, a total of 37 patients were 
enrolled in the trial but only 35 patients were evaluable: 10 in the group 1 (ABCB1-
2677GG genotype) and 25 in the group 2 (ABCB1-2677GT; GA, AA, TT, AT genotypes). 
The overall results of the dose escalation are schematized in Table 42.  
Table 42 Dose escalation and observed DLTs in patients treated with weekly PTX. Group 1: ABCB1-
2677GG genotype; group 2: ABCB1-2677GT; GA, AA, TT, AT genotypes. 
PTX (mg/m2)  group 1 patients (DLT) group 2 patients (DLT) 
80  3 (0)  3 (0)  
90  /  3 (0)  
100  3 (0)  3 (0)  
110  4 (1) 
Prolonged G3 
neutropenia  
3 (0)  
120   10 (0)  
130   3 (2) 
Prolonged G3 neutropenia; 
Dermatological toxicity  
The patients’ enrollment in the group 2 was concluded: the dose of PTX was escalated 
from 80 to 130 mg/m2, with steps of 10 mg/m2. The dose of 130 mg/m2 was not 
tolerated (2 patients out of 3 experienced DLTs), thus the 120 mg/m2 dose level has 
been expanded to 10 patients, and due to no DLTs were observed among them, 120 
mg/m2 was declared the MTD for the group 2. In the group 1 patients, 1 DLT occurred 
among the first 3 patients treated at 110 mg/m2. Hence, the 110 mg/m2 cohort needs to 
be expanded to 6 patients before escalating the dose to the next dose level (120 mg/m2) 
if no additional DLT will be observed. As reported in Table 42, the dose escalation 
conducted in this cohort was modified and the dose level of 90 mg/m2 was omitted, 
thanks to a protocol emendation. Since 3 patients belonging to the group 2 
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characterized, according to the protocol rationale, by high risk of toxicity, were treated 
at the dose level of 100 mg/m2 and no one exhibited DLT, it has been proposed to pass 
over the dose level of 90 mg/m2 in patients belonging to group 1 (low risk of toxicity). 
Therefore, for this group of patients, the dose escalation passed directly from 80 mg/m2 
to 100 mg/m2. Up to now, two of the three DLTs occurred were prolonged G3 
neutropenia (67%), while the other DLT was a dermatological toxicity (Table 42). 
4.2.4.2 Pharmacokinetics of paclitaxel and its 6α-hydroxy metabolite 
Pharmacokinetic data were obtained from 34 out of the 35 patients (for one patient the 
PK was not performed) enrolled and evaluable till now in the phase I study. For this 
purpose, the validated LC-MS/MS method specifically developed for the quantification 
of PTX and its 6α-hydroxy metabolite in plasma samples (for the development and 
validation of the method see Section 4.1.2) has been applied. Figure 46 (Panel A and B) 
shows, as an example, the plasma concentration-versus-time curves of PTX and 6α-OH-
PTX determined, during the first cycle of therapy, in two patients receiving respectively 
the lowest (80 mg/m2, Panel A) and the highest (130 mg/m2, Panel B) dose level of PTX 
as 1-h continuous intravenous infusion. In each panel, the two pharmacokinetic profiles 
of each analyte related to the first and fourth administration of PTX were shown.  
 
Figure 46 Plasma concentration-versus-time profiles of PTX and 6α-OH-PTX. Panel A: Plasma 
concentration-versus-time profiles of PTX and 6α-OH-PTX in one patient receiving 80 mg/m
2
 of PTX 
during the I and the IV administration; Panel B: Plasma concentration-versus-time profiles of PTX and 6α-
OH-PTX in one patient receiving 130 mg/m
2
 of PTX during the I and the IV administration. 
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The principal pharmacokinetic parameters related to these two patients are reported in 
the following tables (Table 43 and Table 44). 
Table 43 PK parameters obtained in one patient receiving 80 mg/m
2
 of PTX during the first (I adm) and 
the fourth (IV adm) administration. 
I adm 
compounds 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
t1/2 
(h) 
Vz 
(L/m2) 
Cl 
(L/h/m2) 
PTX 2467.60 1.20 5740.15 18.31 328.41 12.43 
6α-OH-PTX 85.40 1.45 228.87 15.64 
  
IV adm 
PTX 2920.76 1.00 6169.61 22.40 364.02 11.26 
6α-OH-PTX 95.20 1.00 256.76 18.49 
  
Table 44 PK parameters obtained in one patient receiving 130 mg/m
2
 of PTX during the first (I adm) and 
the fourth (IV adm) administration. 
I adm 
compounds 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
t1/2 
(h) 
Vz 
(L/m2) 
Cl 
(L/h/m2) 
PTX 4302.20 1.08 10644.14 12.34 210.62 11.83 
6α-OH-PTX 576.86 1.33 1359.89 10.56 
  
IV adm 
PTX 6817.95 1.00 11325.75 15.65 248.99 11.03 
6α-OH-PTX 580.35 1.53 1439.60 10.60 
  
 
In order to have a more general view of the pharmacokinetic profiles determined for 
PTX and 6α-OH-PTX in all the patients enrolled in this phase I study, the mean plasma 
concentrations versus time profiles of the two compounds per dose level have been 
calculated and they are reported in Table 45. 
For all the quantifications of each patient, the highest concentration found in plasma 
samples was within the dynamic range of the assay without the need for further dilution 
steps even if the independence of analysis from the dilution was previously assessed at 
the dilution factors of 1:10 and 1:100 (data not shown).  
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Table 45 Data used for the generation of the mean plasma concentrations versus time profiles of PTX and 
6α-OH-PTX. 
PTX (ng/mL) 
Dose 
(mg/m2) 
Time (h) 
1 1.25 1.5 2 4 8 25 49 
80 
n=6 
2377.67 ± 
562.23 
948.74 ± 
239.36 
551.20 ± 
98.34 
309.22 ± 
59.68 
138.16 ± 
30.46 
74.25 ± 
30.99 
23.61 ± 
7.83 
11.07 ± 
7.87 
90 
n=3 
1836.46 ± 
905.99 
834.41 ± 
452.56 
514.71 ± 
339.84 
442.73 ± 
158.96 
208.37 ± 
53.33 
91.89 ± 
28.11 
29.45 ± 
7.45 
13.15 ± 
1.72 
100 
n=6 
3576.32 ± 
549.40 
1713.80 
± 80.89 
984.62 ± 
109.63 
499.79 ± 
36.63 
213.13 ± 
25.96 
102.36 
± 26.10 
29.77 ± 
6.36 
12.13 ± 
5.87 
110 
n=7 
3941.74 ± 
891.07 
1900.47 
± 311.48 
1166.74 ± 
198.76 
625.43 ± 
126.73 
236.87 ± 
64.95 
119.20 
± 35.98 
25.47 ± 
10.34 
11.62 
± 3.24 
120 
n=9 
5634.44± 
764.94 
2689.76 
± 814.16 
1690.66 
± 475.60 
984.84 ± 
317.74 
373.53 ± 
128.54 
146.24 
± 49.82 
34.82 ± 
11.44 
15.24 
± 4.10 
130 
n=3 
5254.80 ± 
2341.28 
3013.22 ± 
1613.81 
2323.08 ± 
1339.06 
1367.46 ± 
896.90 
440.83 ± 
240.02 
198.32 
± 87.69 
56.13 ± 
28.93 
19.28 
± 5.16 
6α-OH-PTX (ng/mL) 
Dose 
(mg/m2) 
Time (h) 
1 1.25 1.5 2 4 8 25 49 
80 
n=6 
75.32 ± 
12.24 
73.72 ± 
18.72 
48.99 ± 
19.24 
22.87 ± 
12.87 
4.22 ± 
1.92 
1.76 ± 
0.97 
0.70 ± 
0.22 
0.25 ± 
0.27 
90 
n=3 
92.20 ± 
58.21 
92.20 ± 
58.21 
66.71 ± 
57.49 
52.43 ± 
38.38 
7.55 ± 
3.25 
2.53 ± 
0.34 
0.79 ± 
0.26 
0.33 ± 
0.29 
100 
n=6 
205.48 ± 
81.28 
228.62 
± 120.05 
163.42 ± 
113.18 
65.34 ± 
49.15 
10.18 ± 
8.78 
3.07 ± 
2.79 
0.82 ± 
0.64 
0.27 ± 
0.47 
110 
n=7 
300.25 ± 
212.77 
348.85 ± 
268.06 
245.86 ± 
188.00 
83.67 ± 
42.80 
13.13 ± 
8.88 
4.39 ± 
2.53 
0.78 ± 
0.34 
0.17 ± 
0.29 
120 
n=9 
279.19 ± 
144.78 
327.14 ± 
161.05 
236.40 ± 
98.07 
110.36 ± 
44.13 
16.03 ± 
6.36 
4.36 ± 
1.70 
0.71 ± 
0.30 
0.23 ± 
0.27 
130 
n=3 
365.12 ± 
116.25 
468.40 
± 196.19 
453.05 ± 
234.17 
269.73 ± 
193.42 
36.01 ± 
27.24 
9.30 ± 
5.68 
1.70 ± 
0.72 
0.66 ± 
0.22 
Noteworthy, in 24 out of 34 patients (70.6%), during the IV administration, the T0 
sample (collected immediately before the PTX infusion) presented a residual presence 
of PTX at the mean concentration of 7.93 ± 12.82 ng/mL, thus indicating that with the 
weekly schedule, PTX may not be completely cleared from the bloodstream. 
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The mean plasma concentrations versus time profiles seem to augment with the dose 
increasing. Even in the case of PTX, a notable interindividual variability in plasma 
concentration levels has been observed. Thus, the standard deviations, reported in 
Table 45, have been omitted in Figure 47 for major clarity.  
 
Figure 47 Mean plasma concentrations versus time profiles of PTX and 6α-OH-PTX per dose level 
determined in patients enrolled in the phase I study. 
 
As reported for CPT-11 study, also in this case only the concentrations found during the 
first administration have been used for the calculation of the mean values, and they 
include both the two genotype cohorts. 
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In Table 46 and Table 47 the mean values of the principal pharmacokinetic parameters 
of PTX and 6α-OH-PTX per dose level are reported, respectively. No distinction 
between the two genotype groups has been done for these calculations.  
Table 46 Summary of the mean pharmacokinetic parameters of PTX per dose level obtained during the 
first (I adm) and fourth (IV adm) administration. 
PTX, I adm 
Dose 
(mg/m2) 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
80 
2452.67 ± 
550.26 
1.03 ± 
0.08 
4221.73 ±  
927.97 
14.87 ± 
2.18 
394.55 ± 
71.06 
18.72 ± 
4.23 
90 
2343.92 ± 
310.70 
1.00 ± 
0.00 
5064.95 ± 
994.85 
15.12 ± 
4.17 
379.27 ± 
162.02 
17.01 ± 
2.73 
100 
3514.83 ± 
527.26 
1.00 ± 
0.01 
6045.01 ± 
542.59 
13.42 ± 
2.63 
308.01 ± 
50.12 
16.05 ± 
1.59 
110 
3941.74 ± 
891.07 
1.02 ± 
0.05 
6830.04 ± 
1409.31 
12.76 ± 
1.52 
302.09 ± 
93.86 
16.32 ± 
4.10 
120 
5175.00 ± 
1552.96 
1.06 ± 
0.14 
9339.32 ± 
2337.45 
13.09 ± 
1.24 
249.31 ± 
67.91 
13.21 ± 
3.47 
130 
5254.80 ± 
2341.28 
1.03 ± 
0.05 
11843.56 ± 
6246.63 
12.72 ± 
1.28 
243.16 ± 
147.05 
12.82 ± 
6.53 
PTX, IV adm 
Dose 
(mg/m2) 
Cmax  
(ng/mL) 
tmax 
(h) 
AUClast 
(h·ng/mL) 
t1/2 
(h) 
Vd 
(L/m2) 
Cl 
(L/h/m2) 
80 
2202.36 ± 
448.63 
1.01 ± 
0.03 
4109.80 ± 
1112.49 
20.39 ± 
4.90 
528.47 
±90.58 
18.71 ± 
4.75 
90 
2441.84 ± 
915.05 
1.00 ± 
0.00 
4513.99 ± 
820.20 
20.85 ± 
0.71 
555.34 ± 
100.38 
18.41 ± 
2.76 
100 
3478.81 ± 
1046.64 
1.03 ± 
0.04 
5696.28 ± 
1092.13 
18.87 ± 
2.46 
458.63 ± 
83.24 
17.05 ± 
3.86 
110 
3936.11 ± 
859.69 
1.01 ± 
0.02 
6508.20 ± 
1283.91 
16.12 ± 
2.68 
387.32 ± 
81.12 
16.89 ± 
4.10 
120 
5367.92 ± 
1739.55 
1.01 ± 
0.04 
9138.38 ± 
3256.79 
17.02 ± 
2.75 
352.38 ± 
167.33 
14.15 ± 
5.54 
130 
7342.52 ± 
3231.71 
1.00 ± 
0.00 
12297.64 ± 
6345.87 
16.80 ± 
1.80 
306.10 ± 
191.85 
12.21 ± 
6.37 
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Table 47 Summary of the mean pharmacokinetic parameters of 6α-OH-PTX per dose level obtained 
during the first (I adm) and fourth (IV adm) administration. 
6α-OH-PTX, I adm 
Dose (mg/m2) Cmax (ng/mL) tmax (h) AUClast (h·ng/mL) t1/2 (h) 
80 79.60 ± 16.08 1.14 ± 0.18 154.15 ± 51.62 14.58 ± 7.56 
90 119.51 ± 29.73 1.19 ± 0.17 249.36 ± 82.52 14.49 ± 7.27 
100 251.83 ± 122.42 1.14 ± 0.14 466.22 ± 281.68 10.15 ± 5.34 
110 352.70 ± 264.97 1.23 ± 0.10 573.30 ± 364.34 7.91 ± 3.64 
120 332.19 ± 158.48 1.23 ± 0.14 589.40 ± 237.63 9.32 ± 6.22 
130 490.40 ± 218.48 1.42 ± 0.22 1138.57 ± 607.86 12.03 ± 2.93 
6α-OH-PTX, IV adm 
Dose (mg/m2) Cmax (ng/mL) tmax (h) AUClast (h·ng/mL) t1/2 (h) 
80 74.17 ± 19.90 1.01 ± 0.03 149.08 ± 53.37 16.23 ± 13.71 
90 99.30 ± 23.00 1.17 ± 0.29 236.84 ± 95.70 11.05 ± 4.04 
100 176.55 ± 76.31 1.03 ± 0.04 350.30 ± 198.93 11.45 ± 8.88 
110 233.44 ± 27.39 1.09 ± 0.19 436.66 ± 84.72 9.68 ± 6.92 
120 263.60 ± 115.09 1.07 ± 0.18 532.47 ± 249.39 10.80 ± 5.45 
130 495.92 ± 172.14 1.35 ± 0.31 1112.68 ± 490.56 8.86 ± 3.09 
Differences between the first and the fourth administration 
Although these data are not final due to the enrollment is still on-going, a preliminary 
comparison between the pharmacokinetic parameters obtained during the I and the IV 
administration has been performed among the patients enrolled till now, in order to 
investigate the possible autoinduction effect of PTX metabolism when administered in 
the weekly schedule (Gustafson et al., 2005). Thirty-two patients were evaluable in this 
analysis since in two patients the second PK was not performed due to DLT experience 
and venflon malfunction. Applying the Wilcoxon signed-rank test, no statistical 
differences were obtained in PTX Cmax, tmax, AUClast, and Cl (p>0.05) between the two 
administrations. These results, along with a significant increased of the PTX t1/2 (from 
13.61 ± 2.07 to 18.25 ± 3.38 h for the I and the IV administration, respectively) and a 
decreased Vd (from 316.51 ± 108.51 to 430.50 ± 139.19 L/m
2 for the I and the IV 
administration, respectively) during the IV administration (p<0.0000 in both the 
parameters), seem to exclude the autoinduction of PTX metabolism. As an example, in 
Figure 48 the mean PTX AUClast obtained during the I and the IV administration are 
reported, divided per dose level for major clarity.  
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Furthermore, a significant decreasing in 6α-OH-PTX Cmax (p=0.0028) and AUClast 
(p=0.0455) has been observed during the IV administration. These results are in line 
with what reported for PTX. 
Anyway, it should be considered that, in order to improve the patients’ compliance, less 
sample time points were performed during the IV administration and, thus, the 
pharmacokinetic profile resulted less defined (Figure 22, Materials and methods 
Section). The sample time points omitted were specifically chosen in order to not 
invalidate the PTX PK. However, it is possible that during the IV administration the Cmax 
of the metabolite has been missed in some patients, confirmed also by the variation of 
its tmax observed between the two administrations (decreased during the IV adm, 
p=0.0029). No difference in the t1/2 value of the metabolite has been observed (p>0.05). 
 
Figure 48 Comparison between the mean PTX AUClast obtained during the I and the IV administration per 
dose level. 
Differences between the two genotype groups 
The effect of the patient’s genotype on the PK of PTX and its main metabolite was also 
been investigated. As shown in the dose escalation scheme reported in Table 42, only 
the dose levels of 80, 100, and 110 mg/m2 could be included for this analysis.  
No significant (p>0.05) genotype-dependent differences in the main pharmacokinetic 
parameters of both PTX and 6α-OH-PTX have been obtained from this preliminary test.  
PTX pharmacokinetics: linearity vs non linearity 
In the literature, a disproportional increase in Cmax and AUC at the increasing of the dose 
has been reported due to the saturation of both elimination and distribution processes 
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at higher concentrations of PTX (Henningsson et al., 2001) (Mross et al., 2000) (Gianni 
et al., 1995). The critical threshold for non-linear kinetics has not univocally determined. 
The evaluation of the PTX PK at different dose levels during this phase I study allowed 
us to investigate the drug’s pharmacokinetic behaviour in a weekly schedule. Moreover, 
the closeness of the dose steps (10 mg/m2) used for this dose escalation design could 
permit a precise definition of the critical threshold for non-linear PTX kinetics. 
In Figure 49 the mean PTX AUClast values, obtained during the first administration, 
versus the dose are reported. 
 
Figure 49 Mean PTX AUClast obtained during the first administration versus the drug dose. The single 
AUClast value of each patient treated at 130 mg/m
2
 of PTX are reported (in red those related to patients 
experienced DLT; in green concerning the patient who did not experience DLT). 
Looking at the blue line, it seems that the increasing of PTX AUClast with the augment of 
the dose followed two distinct trends, one from 80 to 110 mg/m2 and the other from 110 
to 130 mg/m2. In order to quantify this increase, the percentages of the dose and the 
relative AUClast increment are reported in Table 48. 
Table 48 PTX mean AUClast values per dose level obtained during the first administration. For each dose 
level, the percentages of dose and relative AUClast increasing, respect to the previous level, are reported. 
Dose (mg/m2) AUClast (h·ng/mL) Dose increment % AUClast increment % 
80 4221.73 ± 927.97 0 0 
90 5064.95 ± 994.85 12.5 19.9 
100 6045.01 ± 542.59 11.1 19.3 
110 6830.04 ± 1409.31 10.0 13.0 
120 9339.32 ± 2337.45 9.1 36.7 
130 11843.56 ± 6246.63 8.3 26.8 
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Although the low number of patients per dose level represents a limitation, it seems 
that PTX AUClast increased proportionally with the increment of the dose up to 110 
mg/m2. On the contrary, for doses higher than 110 mg/m2, the increment is 
disproportionate respect to the dose increasing.  
Looking at the single AUClast value of each patient treated at 130 mg/m
2 (a total of 3 
patients: 2/3 experienced DLT), as reported in Figure 49, it is clear that the huge AUClast 
standard deviation observed at this dose level was due to the only patient who did not 
experience DLT. This patient exhibited indeed a particularly low AUClast respect to the 
other two patients who experienced severe toxicity after the treatment. Excluding this 
patient from the calculation of the mean AUClast at 130 mg/m
2, the increment respect to 
120 mg/m2 should be even greater than that reported in Table 48, thus emphasizing the 
non-linear behaviour of the PTX PK when doses higher than 110 mg/m2 are 
administered. This result is in line with the literature that reports a variation of PTX 
kinetics from linear to non-linear with the increasing of the dose administered. 
Moreover, in our case, the critical threshold for non-linear kinetics seems to be the dose 
of 110 mg/m2. 
This consideration has been confirmed also by the Cl variations across the different 
dose levels, reported in Figure 50. 
 
Figure 50 Mean PTX Cl obtained during the first administration versus the dose level. The single Cl value 
of each patient treated at 130 mg/m
2
 of PTX is reported (in red those related to patients experienced DLT; 
in green concerning the patient who did not experience DLT). 
Even in this case the Cl seems to follow two different trends, and the turning point 
seems to be the 110 mg/m2 dose level: for doses lower than that the Cl can be 
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considered constant (linear PK), while for higher doses a decreased was observed (non-
linear PK). This effect would be even stronger whether, as for AUClast, the single Cl value 
of each patient treated at 130 mg/m2 are considered. Even in this case, the large 
standard deviation was due to the only patient who did not experience DLT after the 
treatment. 
More in general, the Spearman’s rank correlation test was applied to analyse the overall 
correlation between PTX Cl and the dose. An inverse correlation has been found 
(Spearman correlation coefficient equal to -0.5191 and -0.4050 during the I and the IV 
administration, respectively), meaning that the Cl decreases with the increasing of the 
dose, and this trend is statistically significant (p = 0.0012 and 0.0175 during the I and the 
IV administration, respectively).  
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5.1 LC-MS/MS methods: development and validation 
5.1.1 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
irinotecan and its main metabolites in human plasma 
The purpose of this work was to set up and validate a method to quantify irinotecan and 
its main metabolites (SN-38, SN-38G, and APC), in plasma of patients treated with both 
the standard doses, defined by different treatment protocols, and higher doses as 
expected in a dose escalation study.  
Several methods are currently employed for the determination of CPT-11 and its 
metabolites in human plasma, most of them based on the use of fluorescence 
detectors, as reviewed by Chen et al. (Chen et al., 2012) and, more recently, by Crotti et 
al. (Crotti et al., 2015). 
Anyway, to our knowledge, no method was available to simply measure irinotecan and, 
in particular, SN-38G with a high degree of sensitivity and in a wide concentration 
range. Among these methods, indeed, just few could quantify SN-38G but two 
(Sparreboom et al., 1998) (Owens et al., 2003) exploit a chromatographic runtime 
longer than 35 minutes and a too limited range (Owens et al.: 2-25 ng/mL for SN-38, 
SN-38G and APC and 5-300 ng/mL for CPT-11; Sparreboom et al.: 2-200 ng/mL for all 
the analytes). Since it has been mentioned the importance of quantifying SN-38G 
concentration, the method developed by Sai et al. (Sai et al., 2002) seemed not suitable 
because of a SN-38G lower limit of quantification (LLOQ) of 10 ng/mL that appears not 
fitting to accurately determine the elimination phase of the pharmacokinetic profile of 
this metabolite. Among the LC-MS/MS methods, just one, developed by our group, is 
suitable for simultaneously analyzing CPT-11, SN-38, SN-38G and APC (Corona et al., 
2010) but the upper limit of quantification (ULOQ) (2 µg/mL for CPT-11) seemed not 
suitable for the quantification of samples collected by patients treated with high-dose 
irinotecan regimens (> 180 mg/m2). 
For this reason, a sensitive, specific and rapid method to quantify irinotecan and its 
main metabolites in human plasma has been developed and validated. The developed 
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method requires a small volume of plasma sample (100 µL), only simple treatment with 
methanol added with acetic acid (0.1% v/v) and a reasonable time of analysis (18 min). 
High selectivity and sensitivity was guaranteed by working in SRM mode (Kaye et al., 
1992). In addition, as irinotecan and its main metabolites concentration needed to be 
determined on plasma collected by pluri-treated patients, more than one transition for 
each analyte (one used as quantifier and two as qualifiers) have been followed, in order 
to avoid interferences. Lastly, this method was developed using the reference standard 
of SN-38G avoiding any interferences related to the enzymatic conversion of SN-38. 
SN-38G reference compound, indeed, is not easy to find commercially available and 
many alternatives have been proposed: standard custom-synthesized by the analytical 
laboratory (Chen et al., 2012), biosynthesis of SN-38G from SN-38 precursor and the 
uridine-diphosphate (UDP) glucuronic acid substrate through the action of the UDP-
glucuronosyl transferase 1A1 isoform enzyme (Corona et al., 2010), and hydrolysis of 
SN-38G in plasma by β-glucuronidase (Zhang et al., 2009). In this last case, the 
quantification of SN-38G was obtained through the increase of SN-38 after the 
hydrolysis.  
We investigated a range of concentrations (10-10000 ng/mL for CPT-11, 1-500 ng/mL 
for SN-38 and SN-38G and 1-5000 ng/mL for APC) that we expected to cover those 
found in the patients’ plasma even though, on the basis of our signal to noise ratio, we 
could have validated a lower LLOQ. Chromatographic separation was done on a Gemini 
C18 column (3 μM, 100 mm x 2.0 mm) using 0.1% acetic acid/bidistilled water and 0.1% 
acetic acid/acetonitrile as mobile phases. The mass spectrometer worked with 
electrospray ionization in positive ion mode. The method has been successfully 
validated according to the FDA-EMA guidance on bioanalytical method validation. The 
standard curves were linear (R2 ≥0.9962) over the concentration ranges and had good 
back-calculated accuracy and precision. The intra- and inter-day precision and accuracy, 
determined on three quality control levels for all the analytes, were always <12.3% and 
between 89.4% and 113.0%, respectively. Moreover, we evaluated this bioanalytical 
method by re-analysis of incurred samples as an additional measure of assay 
reproducibility. The concentrations of irinotecan and its main metabolites determined 
on the two analytical runs were very similar in all samples, being the percentage 
difference of the results within 20% for more than 71% of the total amount of samples 
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re-analyzed. Finally, the present method was applied to a pharmacokinetic study in 
patients with metastatic CRC enrolled in a genotype-guided phase I study (dose-
escalation study) of irinotecan administered in combination with 5-FU/leucovorin 
(FOLFIRI) and bevacizumab. The successful application of our method to a dose-
escalation study, such as a phase I study, guarantees to have the possibility to employ 
this method to all irinotecan dosages currently used in clinical practice. 
5.1.2 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
paclitaxel and its main metabolite 6α-hydroxy-paclitaxel in 
human plasma 
With the always stronger need of quantifying taxanes in samples derived from clinical 
studies or from treated patients due to the great inter-patient variability, and thanks to 
the identification of liquid chromatography coupled with mass spectrometry as the 
Gold Standard of drug testing, many LC-MS/MS assays have been developed and 
validated. In Table 49 a list of the published methods for the quantification of paclitaxel 
in human plasma is reported.  
Noteworthy, the extraction procedure more frequently described in literature to 
quantify paclitaxel is surely LLE. The alternative sample treatment proposed in these 
published methods is the SPE, in some cases as on-line (Yamaguchi et al., 2013) or 
automatic (Sottani et al., 1998) SPE. Furthermore, in two assays the SPE has been 
associated to PP (Gardner et al., 2008) (Sottani et al., 1998). Instead, none of the 
published methods designed a sample treatment based on only PP, which is the fastest 
extraction method. The best LLOQs (0.1 ng/mL (Alexander et al., 2003)) in paclitaxel 
quantification were obtained applying LLE but this procedure is certainly more time-
consuming than PP and on-line SPE. Thus, the first challenge in developing this method 
was to obtain a reasonable, from a clinical point of view, LLOQ concentration 
employing as sample treatment only PP in order to develop an analytical assay more 
suitable for a routine clinical application. 
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Table 49 List of publications related to the quantification of paclitaxel in human samples. (o)=on-line; 
(a)=automatic; (sa)=semi-automatic; DTX: docetaxel. 
Ref. Compound(s) 
Sample 
(µL) 
Sample 
prep 
LLOQ 
 (ng/mL) 
ULOQ  
(ng/mL) 
Runtime 
(min) 
(Fernández-
Peralbo et 
al., 2014) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
200 LLE 
0.125, 0.5, 
0.125 
100 17.5 
(Yamaguchi 
et al., 2013) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
90 (o)SPE 5, 0.87, 0.87 
5000, 870, 
435 
30 
(Zhang et 
al., 2011) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
100 LLE 0.5 500 7 
(Zhang and 
Chen, 2008) 
PTX 200 LLE 102.1 20420 2 
(Gardner et 
al., 2008) 
PTX 100 PP/SPE 10 2500 4 
(Gao et al., 
2006) 
PTX 200 LLE 1 1000 4 
(Gardner et 
al., 2006) 
PTX 100 LLE 2 2500 8 
(Gréen et 
al., 2006) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
500 SPE 0.5 7500,750,400 9 
(Vainchtein 
et al., 2006) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
200 LLE 0.25 
1000, 100, 
100 
9 
(Mortier et 
al., 2004) 
PTX 500 LLE 10 1000 2 & 0.8 
(Stokvis et 
al., 2004) 
PTX 200 LLE 0.25 1000 9 
(Basileo et 
al., 2003) 
PTX 100 (sa)LLE 1 1000 6 
(Alexander 
et al., 2003) 
PTX, 6α-OH-PTX, 
p-3’-OH-PTX 
400 LLE 0.1, 0.1, 0.1 100, 100, 100 5 
(Sottani et 
al., 1998) 
PTX 500 
PP/ 
(a)SPE 
5 500 8 
(Mortier et 
al., 2005) 
DTX, PTX,  
6α-OH-PTX,  
p-3’-OH-PTX 
250 LLE 2  1000  11 
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Among the methods reported in Table 49, seven assays have been developed for the 
simultaneous quantification of the drug and its main metabolites, 6α-OH-PTX and p-3’-
OH-PTX, while the other eight consider only the quantification of paclitaxel. Looking 
only at former seven, some of them employ a sample volume that ranges from 0.2 to 
0.5 mL (Fernández-Peralbo et al., 2014) (Gréen et al., 2006) (Vainchtein et al., 2006) 
(Alexander et al., 2003) (Mortier et al., 2005). We could not employ these methods 
because we aimed at using a reduced volume of plasma (100 μL). 
Another crucial feature was represented by the linearity range. Since we needed a 
method to be applied to a phase I study, the ULOQ had to be suitable for the 
quantification of samples collected by patients treated with higher than standard PTX 
doses, as expected in a dose escalation study. Most of the methods for the 
quantification of PTX and its main metabolites showed an ULOQ not appropriate for 
our purpose, being PTX upper limit of quantification equal or less than 2500 ng/mL 
(Fernández-Peralbo et al., 2014) (Zhang et al., 2011) (Alexander et al., 2003) (Mortier et 
al., 2005). The two methods with the highest ULOQs (5000 ng/mL (Yamaguchi et al., 
2013) and 7500 ng/mL (Gréen et al., 2006)) have, instead, several other limitations, such 
as an unsatisfactory LLOQ (5 ng/mL) for paclitaxel (Yamaguchi et al., 2013) or a large 
plasma volume requirement (Gréen et al., 2006) together with a time-consuming 
sample treatment process (SPE). 
Thus, due to the previously discussion on the methods already published, an LC-MS/MS 
assay has been developed and validated for the quantification of paclitaxel and its 
principal metabolite, 6α-OH-PTX. Our method requires a small volume of plasma 
sample (100 µL), only simple treatment with methanol added with formic acid (0.1% 
v/v) and a reasonable time of analysis (21 min). Chromatographic separation was done 
on a SunFireTM C18 column (3.5 μM, 92 Å, 2,1 x 150 mm) using 0.1% formic 
acid/bidistilled water and 0.1% formic acid/acetonitrile as mobile phases. The mass 
spectrometer worked with electrospray ionization in positive ion mode and selected 
reaction monitoring. The method has been fully validated according to the FDA-EMA 
guidance on bioanalytical method validation. The standard curves were linear (R2 
≥0.9948) over the concentration ranges of 1-10000 and 1-1000 ng/mL for PTX and 6α-
OH-PTX, respectively, and had good back-calculated accuracy and precision. The intra- 
and inter-day precision and accuracy, determined on three quality control levels for all 
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the analytes, were always <9.9% and between 91.1% and 104.8%, respectively. 
Moreover, we evaluated this bioanalytical method by re-analysis of incurred samples as 
an additional measure of assay reproducibility. The concentrations of PTX and its main 
metabolite determined on the two analytical runs were very similar in all samples, being 
the percentage difference of the results within 20% for more than 91.7% of the total 
amount of samples re-analyzed. Finally, the present method was successfully applied to 
a pharmacokinetic study in advanced ovarian cancer patients in a genotype-guided 
phase I study (dose-escalation study) of weekly paclitaxel. 
5.1.3 High-performance liquid chromatography–tandem mass 
spectrometry method for the simultaneous determination of 
sunitinib and its main metabolite N-desethyl sunitinib in 
human plasma 
Sunitinib is an oral multi-targeted tyrosine kinase inhibitor with antiangiogenic and 
antitumor activities attributable to the inhibition of several related tyrosine kinase 
receptors, including VEGF receptors types 1 and 2 (FLT1 and FLK1/KDR), platelet-
derived growth factor receptors (PDGFR- α and PDGFR-β), stem cell factor receptor (c-
KIT), and FMS-related tyrosine kinase 3 (FLT-3), which are implicated in tumour 
proliferation, angiogenesis, and metastasis (Giamas et al., 2010; Sawyers, 2004). Target 
total plasma concentrations of sunitinib plus active metabolite (N-desethyl sunitinib) 
are in the range of 50-100 ng/mL, as deduced from PK/PD relationship data (Faivre, 
2006). Total trough concentrations <50 ng/mL have been associated with decreased 
therapeutic efficacy, whereas concentrations >100 ng/mL have been associated with an 
increased risk for toxicity. Taking into account the low therapeutic index, the large 
interindividual variability in the systemic exposure among patients treated with 
sunitinib, and the positive exposure-efficacy relationship of sunitinib, there is a strong 
rationale for TDM of this drug.  
In the literature, previously published LC-MS/MS methods were developed for the 
detection of sunitinib alone or with its active metabolite. The main characteristics of 
these methods are reported in Table 50. 
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Table 50 List of publications related to the quantification of sunitinib and its active metabolite N-desethyl 
sunitinib.  
Referenc
e  
Sunitinib 
and 
metabolites 
analized 
Other analytes 
analized 
Sampl
e 
Volum
e (mL) 
Extractio
n Method 
LLOQ 
(ng/mL
) 
ULOQ 
(ng/mL) 
Runtim
e (min) 
(Minkin et 
al., 2008) 
Sunitinib   0.2 LLE  0.2  500  3  
(Haouala 
et al., 
2009) 
Sunitinib  
Imatinib, nilotinib, 
dasatinib, sorafenib, 
lapatinib 
0.1 PP 1  500  20  
(de Bruijn 
et al., 
2010) 
Sunitinib, N-
desethyl 
sunitinib 
 0.1 LLE  0.2  50  4  
(Zhou and 
Gallo, 
2010) 
Sunitinib   0.01 PP 1.37  1000  3.2  
(Honeywe
ll et al., 
2010) 
Sunitinib  
Erlotinib, sorafenib, 
gefitinib 
0.02 PP 5  4000  <4  
(Rodamer 
et al., 
2011) 
Sunitinib, N-
desethyl 
sunitinib 
 0.1 PP 0.06  100  4  
(Lankheet 
et al., 
2013) 
Sunitinib   
Dasatinib, erlotinib 
gefitinib, imatinib, 
lapatinib, nilotinib, 
sorafenib 
0.05 PP 5  2500  10  
(Rais et 
al., 2012) 
Sunitinib, N-
desethyl 
sunitinib 
 0.05 LLE  
0.1 
sunitini
b,  
0.2 N-
desethy
l 
sunitini
b 
100 
sunitinib, 
200 N-
desethyl 
sunitinib 
5  
(Qiu et 
al., 2013) 
Sunitinib,  
N-desethyl 
sunitinib,  
N,N 
didesethyl  
 0.05 PP 0.1  100  4  
(Götze et 
al., 2012) 
Sunitinib  
Erlotinib, imatinib, 
lapatinib, nilotinib, 
sorafenib 
0.1 PP 10  1000  12  
(Andriam
anana et 
al., 2013) 
Sunitinib  
Bortezomib, 
dasatinib, erlotinib, 
imatinib, lapatinib, 
nilotinib, sorafenib, 
vandetanib 
0.05 PP 2  250  10 
(Lankheet 
et al., 
2013a) 
Sunitinib, N-
desethyl 
sunitinib 
 0.5 PP 2.5  500  10  
(Musijows
ki et al., 
2014) 
Sunitinib , N-
desethyl 
sunitinib 
 0.5 LLE  0.1  150  6  
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Only six published methods considered the quantification of both sunitinib and N-
desethyl sunitinib. One of the pivotal characteristics of a good method to be applicable 
to the clinical routine is the use of limited quantity of biological samples. The published 
methods employed a quantity of plasma that ranges from 50 μL (Lankheet et al., 2013a) 
(Qiu et al., 2013) to 500 μL (Musijowski et al., 2014). Instead, our method requires only 
30 μL of plasma. 
Another crucial point to consider in the development of a TDM method is surely the 
ease and the rapidity of the processing procedure. Three published methods use protein 
precipitation, whereas the other three require a more complex liquid-liquid extraction. 
Our processing method consists of an easy protein precipitation (PP) with 150 μL of 
methanol. Moreover, the major part of the methods aims to avoid the light exposure in 
any step, from the collection to the analysis of the sample, in order to prevent the 
conversion of the Z- to the unwanted E-isomer. This is a clear limit in the perspective of 
the applicability of the method to the clinical practice. For this reason, the method 
presented in this thesis does not require the protection from the light during the sample 
preparation but only a heating step with a heated water bath at 90°C for 5 min. The 
incubation of the sample, just before their introduction into the autosampler for the 
analysis, allows the rapid reconversion of the E-isomer, formed during the sample 
preparation, to the Z-form. Despite the additional heating step of 5 min little extends 
the processing time, it strongly facilitates the handling of the samples avoiding the 
necessity of sodium or UV-light (de Bruijn et al., 2010) and the setting of suitable dark 
rooms. Some authors (Lankheet et al., 2013a) found a way to bypass the light 
protection: as the two isomers showed equal mass spectrometry response, to process 
the data, the sum of single reaction monitoring responses of both separated isomers of 
each analyte was used. Consequently, protection from light during shipment, handling 
and processing of samples was not necessary employing the method developed by 
Lankheet et al. However, in order to apply this method, a quantifiable peak of both the 
isomers is necessary in any analytical run and this consideration could explain the LLOQ 
at 2.5 ng/mL. In our method, the LLOQ is 25 fold lower for both the analytes and the 
calibration range was 0.1-500 ng/mL for sunitinib and 0.1-250 ng/mL for N-desethyl 
sunitinib. Considering that the trough plasma concentration during the sunitinib 
therapy is typically in a range from 10 to 200 ng/mL for sunitinib and from 5 to 100 
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ng/mL for N-desethyl sunitinib, our method generously covered the clinical range and 
could be suitable also for pharmacokinetic studies in which really low concentrations 
should be detected in order to very accurately determine parameters as half-life. 
Chromatographic separation was done on a Synergy Fusion RP C18 (4 μM, 80 Å, 2 x 50 
mm) using 0.1% formic acid/bidistilled water and 0.1% formic acid/acetonitrile as 
mobile phases. The method resulted rapid, with retention times of the analytes at 2.61 
and 2.55 min for sunitinib and N-desethyl sunitinib, respectively and a total analytical 
run, including the recondition time, of only 7 min. The mass spectrometer worked with 
electrospray ionization in positive ion mode and selected reaction monitoring. The 
method has been successfully validated according to the FDA-EMA guidance on 
bioanalytical method validation, although the long term stability and the incurred 
samples reanalysis still need to be performed in order to conclude this process. The 
standard curves were linear (R2 ≥0.9931) over the concentration ranges and had good 
back-calculated accuracy and precision. The intra- and inter-day precision and accuracy, 
determined on three quality control levels for both the analytes, were always <11.7% 
and between 96.7% and 111.7%, respectively.  
In conclusion, our method described an innovative approach to overtake the 
troublesome step of the light protection and a rapid and easy preparation process 
consistent with our aim of introducing the TDM of sunitinib in the clinical laboratory 
routine. 
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5.2 Phase Ib clinical trials 
5.2.1 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and bevacizumab in advanced colorectal cancer 
patients 
FOLFIRI is CPT-11 plus infusional 5-fluorouracil/leucovorin (5-FU/LV), and when 
combined with bevacizumab, is one of the standard first-line treatment options for 
patients with metastatic colorectal cancer (mCRC) (Benson et al., 2014). The 
recommended dose of CPT-11 in FOLFIRI is 180 mg/m2 every two weeks based on a 
dose-finding study (Ducreux et al., 1999) that did not take into account the toxicity risk 
conferred by the UGT1A1*28 allele. In fact, the UGT1A1*28 allele confers reduced 
UGT1A1-mediated inactivation of SN-38, the active metabolite of CPT-11, and has been 
associated with severe neutropenia (Innocenti et al., 2004) (Toffoli et al., 2006) (Hoskins 
et al., 2007). The current U.S. prescribing information warns that the UGT1A1 *28/*28 
genotype is a risk factor for neutropenia and states that a dose reduction should be 
considered in these patients. 
Moreover, it has been demonstrated, also in a previous phase I study conducted by our 
group (Toffoli et al., 2010) that patients with the *1/*1 and *1/*28 genotypes are able to 
tolerate more than the standard dose of CPT-11 (Marcuello et al., 2011) (Innocenti et al., 
2014). Anyway, the effect of adding a biologic agent to genotype-guided dosing of 
FOLFIRI was unknown and the safe doses of CPT-11 in *1/*1 and *1/*28 patients 
treated with FOLFIRI plus bevacizumab needed to be identified. 
This phase I trial has been designed in order to clarify these issues. Thus, the safe doses 
of CPT-11 that can be administered in mCRC patients treated with FOLFIRI in 
combination with bevacizumab according to their UGT1A1*28 genotype (excluding 
those with the *28/*28 genotype) has been identified. The results support that CPT-11 
can be safely administered at doses up to 310 mg/m2, compared to the standard dose of 
180 mg/m2. In fact, the genotype-directed MTD of CPT-11 was 260 mg/m2 for *1/*28 
patients, and 310 mg/m2 for *1/*1 patients. As previously reported (Innocenti et al., 
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2004) (Toffoli et al., 2006) (Hoskins et al., 2007), the two genotypes confer different risk 
of toxicity and the *1/*28 patients do not tolerate the same dose of *1/*1 patients.  
It is noteworthy that the MTDs for FOLFIRI plus bevacizumab are lower than those for 
FOLFIRI alone. In fact, in a previous phase I study with a similar design in front-line 
mCRC patients (Toffoli et al., 2010), the MTDs were 370 and 310 mg/m2 for *1/*1 and 
*1/*28 patients, respectively. It is difficult to say whether this downward shift is caused 
by a pharmacodynamic effect of bevacizumab or other factors, as the two studies 
cannot be compared head to head.  
Moreover, the analysis of the CPT-11 PK of in our study seems to rule out that the lower 
MTDs in FOLFIRI plus bevacizumab compared to those of FOLFIRI alone are due to an 
interaction between bevacizumab and CPT-11 increasing systemic exposure to either 
CPT-11 or SN-38. Pharmacokinetic parameters of exposure (Cmax and AUClast) are 
essentially unchanged (Table 37). A limited sampling pharmacokinetic substudy of the 
phase III FOLFIRI study in mCRC (Hurwitz et al., 2004) suggested a 33% increase in the 
AUC0-5h of SN-38 associated with the bevacizumab treatment. This difference has not 
been confirmed in three formal drug-drug interaction studies, including ours (Suenaga 
et al., 2014) (Denlinger et al., 2009). 
This study concludes that, even with the addition of bevacizumab, a genotype-directed 
strategy leads to safe administration of higher doses of CPT-11. For patients treated at 
the MTD, the dose intensity of the regimen was preserved, as CPT-11 was dose-reduced 
only in 35% of patients and both 5-FU and bevacizumab dosing was unchanged. The 
limited number of patients evaluable for efficacy (n = 33) prevents drawing definitive 
conclusions on whether higher doses of CPT-11 lead to increased efficacy of FOLFIRI 
plus bevacizumab. Overall response was more frequently observed at the higher CPT-11 
doses in previous FOLFIRI studies (Toffoli et al., 2010) (Marcuello et al., 2011), but in the 
present study no apparent association was found. The PFS analysis does not show a 
clear trend of improved PFS at the higher doses either (Figure 44). 
Since the efficacy was not the primary endpoint of this study, the hypothesis that 
higher CPT-11 dosing might confer increased efficacy of FOLFIRI plus bevacizumab 
should be tested in a large population prospective study. Thus, based on the MTDs from 
the current study, a phase II clinical trial in front-line mCRC where CPT-11 is dosed at 
310 and 260 mg/m2 in patients with the *1/*1 and *1/*28  genotypes (respectively) is 
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currently ongoing and led by the University of North Carolina Lineberger 
Comprehensive Cancer Centre (NCT02138617 on clinicaltrials.gov). After the initial 
proof-of-concept studies with either FOLFIRI or single-agent irinotecan (Toffoli et al., 
2010) (Marcuello et al., 2011) (Innocenti et al., 2014), this study provides definitive 
evidence for the role of genetic stratification to deliver safe doses of irinotecan in mCRC 
patients treated with a standard of care regimen. Even more importantly, this study 
suggests that the majority of mCRC patients currently treated with FOLFIRI plus 
bevacizumab may be underdosed with respect to irinotecan. The consequences of such 
underdosing on patient survival are unknown.  With the advent of genomic screening in 
cancer patients and pre-emptive genotyping for pharmacogenomics prediction (Gillis et 
al., 2014), available genetic data on the UGT1A1*28 status of patients in medical 
records can be utilized to reach the goal of improving precision in irinotecan-based 
therapies. 
5.2.2 Genotype-guided phase I study of irinotecan 
administered in combination with 5-fluorouracil/leucovorin 
(FOLFIRI) and cetuximab as first-line therapy in metastatic 
colorectal cancer patients 
FOLFIRI is a frequently used chemotherapy regimen for the first-line treatment of 
mCRC. Results of the phase III CRYSTAL trial showed that the addition in this setting of 
the EGFR antibody cetuximab improves the clinical outcome in patients whose tumours 
did not have mutations at K-RAS codons 12 and 13 (Van Cutsem et al., 2009). Some 
other striking results were observed by Heinemann and colleagues (Heinemann et al., 
2014), in an open-label, randomized phase III clinical trial with the first aim of comparing 
the efficacy of cetuximab or bevacizumab in FOLFIRI first-line treatment of mCRC. 
Although the interpretation of the results is quite controversial (Pietrantonio et al., 
2014), it seemed that a statistically significant overall survival advantage was reported 
in favour of cetuximab (median duration 28.7 months [95% CI 24.0–36.6] vs 25.0 
months [22.7–27.6]; HR 0.77 [95% CI 0.62–0.96]; p=0.017) and this was further increased 
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in the subgroup of patients with tumours that were wild-type at all RAS loci (exon 2–4 K-
RAS and N-RAS; 33.1 months vs 25.6 months; HR 0.70 [95% CI 0.53–0.92]; p=0.011).  
Currently, the dose of CPT-11 in FOLFIRI schedule is 180 mg/m2. However, our group 
demonstrated that a higher dose of CPT-11 is tolerated in UGT1A1 *1/*1 and UGT1A1 
*1/*28 patients than UGT1A1 *28/*28 also if the regimen is combined with 
bevacizumab (Eudract 2009-012227-28; Protocol code CRO-2009-25, NCT01183494). 
However, at our knowledge, no data have been generated to demonstrate if these 
higher doses are tolerated when cetuximab is added. 
Having regards to the intriguing results obtained from the previous genotype-guided 
phase Ib studies and the information in the literature that assessed the regimen FOLFIRI 
plus cetuximab as a promising treatment, there was a strong rationale to begin the 
phase Ib study entitled: “A genotype-guided phase I study of irinotecan administered in 
combination with 5-fluorouracil/leucovorin (FOLFIRI) and cetuximab as first-line therapy in 
metastatic colorectal cancer patients”. 
At the moment, due to the relative high frequencies of RAS mutations in CRC patients 
and to the additional step of the UGT1A1*28 screening, just two patients resulted 
eligible and was enrolled in this new clinical study. 
A proper statistical analysis of the PK data obtained during this clinical study will be 
done when the patient’s enrollment will be concluded and the total plasma 
concentrations of CPT-11 and its three main metabolites will be obtained. In fact, only 
at the end of the clinical study, the evaluation of the effect of cetuximab on the CPT-11 
PK could have a statistical significance. 
Anyway, it can be interesting to compare the main PK parameters, such as Cmax and 
AUClast, obtained for the first patient enrolled with the mean values of those 
determined from the patients treated at the same CPT-11 dosage (260 mg/m2) during 
the previous phase I clinical trial of CPT-11 in combination with bevacizumab. In order 
that the comparison is homogeneous, only patients with the same UGT1A1*28 
genotype (UGT1A1*1/*1) were considered in the calculation of the mean values. 
Moreover, as this clinical study is a phase Ib, that is a dose escalation study, only the 
data from the patients treated at the same CPT-11 dosage (260 mg/m2) were taken into 
account for this preliminary analysis. CPT-11 Cmax (2599.96 and 1933.13 ng/mL for the I 
and the II administration, respectively) and AUClast (16968.01 and 14420.32 hr*ng/mL 
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for the I and the II administration, respectively) obtained were in good agreement with 
the mean Cmax and AUClast obtained in the previous study during both the I and the II 
administrations (Cmax: 2354.46±958.98 and 1967.14±479.73 ng/mL for the I and the II 
administration, respectively; AUClast: 15587.97±6996.21 and 13706.79±3824.02 
hr*ng/mL for the I and the II administration, respectively). On the contrary, SN-38 Cmax 
(8.20 and 10.93 ng/mL for the I and the II administration, respectively) and AUClast 
(164.16 and 198.31 hr*ng/mL for the I and the II administration, respectively) were 
overall lower than the mean values previously obtained during both the I and II 
administrations (Cmax: 22.51±14.15 and 15.90±4.92 ng/mL for the I and the II 
administration, respectively; AUClast: 252.01±63.67 and 221.06±60.40 hr*ng/mL for the I 
and the II administration, respectively). The same observation could be done for SN-
38G. In fact, SN-38G Cmax (33.97 and 22.18 ng/mL for the I and the II administration, 
respectively) and AUClast (767.06 and 521.74 hr*ng/mL for the I and the II 
administration, respectively) resulted lower than the mean values previously obtained 
during both the I and the II administrations (Cmax: 94.56±40.78 and 82.95±35.72 ng/mL 
for the I and the II administration, respectively; AUClast: 1326.29±499.24 and 
1182.49±423.10 hr*ng/mL for the I and the II administration, respectively). Finally, also 
APC showed different results respect to the previous data. In fact, APC Cmax (507.14 and 
304.92 ng/mL for the I and the II administration, respectively) and AUClast (6576.38 and 
3644.86 hr*ng/mL for the I and the II administration, respectively) resulted higher than 
the mean values observed during the phase I of CPT-11 in combination with 
bevacizumab (Cmax: 244.44±191.57 and 143.34±49.78 ng/mL for the I and the II 
administration, respectively; AUClast: 2981.55±1859.81 and 1993.59±954.82 hr*ng/mL 
for the I and the II administration, respectively). 
The formation of the two metabolites (SN-38 and APC), follows two different pathways 
(Figure 14). Therefore, the decrease of SN-38 and SN-38G concentrations and the 
parallel increase of APC plasma level, in comparison with the data concerning the 
previous clinical study, could probably be explained by a different activity of the 
enzymes involved in the metabolism. 
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5.2.3 Genotype-guided phase I study for weekly paclitaxel in 
ovarian cancer patients 
PTX is a chemotherapeutic agent with broad antitumor activity. Its dosing and 
scheduling have been optimized during the last two decades, resulting in today’s widely 
applied weekly regimens of 1-h infusions (Takano et al., 2002) (Mielke et al., 2005a). 
The great interindividual differences observed in the PTX PK and the related 
pharmacodynamic profile (toxicity and tumour response) still remain the major concern 
related to this cytotoxic agent. The recent advances in the PGx field, pointed out as this 
high variability among patients could be related to the genetic characteristic of the 
patient. In fact, the recommended dose of weekly paclitaxel as 1-h i.v. infusion is 80 
mg/m2 based on a dose-finding study (Klaassen et al., 1996) that did not take into 
account the advances in the PGx research, which deserves the inclusion of patient 
genetic profiling in the optimization of anticancer drug dosage. 
Several SNPs in genes encoding the well-known metabolizing enzymes (CYP2C8, 
CYP3A4) and transporters ( such as ABCB1) of paclitaxel have been investigated in a 
large number of studies as genetic factors which may be of influence on paclitaxel 
induced adverse events, as recently revised by Frederiks et al. (Frederiks et al., 2015). 
Among them, the 2677G>T/A SNP (responsible for the substitution from alanine to 
serine or threonine) has been shown to correlate with the P-gp expression and 
phenotype. In particular, the 2677G>T/A allele has demonstrated to impact the PTX PK 
and PD in ovarian cancer patients (Hamidovic et al., 2010). Moreover, an association of 
the SNP with higher risk of severe haematological and non-haematological toxicity was 
demonstrated in 118 ovarian cancer patients of Asian ethnicity treated with PTX and 
carboplatin (Kim et al., 2009). Furthermore, a pilot study on 20 carboplatin/PTX treated 
ovarian cancer patients conducted by our group confirmed a lowered PTX Cl for 
patients carrying the variant 2677T/A allele (unpublished data).  
Thus, in order to render the treatment individualization feasible, our group designed a 
genotype-guided phase I clinical trial of weekly PTX in order to define the MTD and 
DLTs according to the ABCB1-2677G>T/A SNP in epithelial ovarian cancer patients. 
More specifically, patients enrolled in this trial have been divided in two different 
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cohorts based on the patients’ genotype: group 1 (ABCB1-2677GG genotype), which is, 
according to the protocol rationale, the one characterized by low risk of toxicity and 
group 2 (ABCB1-2677GT; GA, AA, TT, AT genotypes), the one supposed to be at high risk 
of toxicities. 
Although this dose finding study is still on-going, the safe dose of paclitaxel that can be 
administered in advanced ovarian cancer patients with ABCB1-2677GT; GA, AA, TT, AT 
genotypes  (group 2) has been identified. In this cohort of patients, paclitaxel can be 
safely administered at doses up to 120 mg/m2, compared to the standard dose of 80 
mg/m2. Concerning the patients with ABCB1-2677GG genotype (group 1), the dose 
escalation has not yet been concluded. Anyway, also in this group, doses higher than 
the standard one can be safely administered since the enrollment of patients’ cohort is 
now at the dose level of 100 mg/m2. Two of the three DLTs occurred till now were 
prolonged G3 neutropenia (67%), while the other DLT was a dermatological toxicity. 
A deepened discussion of the clinical results of this phase I study, as reported for the 
previous trial related to FOLFIRI in combination with bevacizumab, should be 
premature, and will be completed when the study will be concluded. For instance, with 
the completion of the clinical data (PFS, ORR, the cumulative haematological and non 
haematological toxicities, number of dose reductions or delays between consecutive 
treatments) collection related to all the patients enrolled in this phase I study, the 
hypothesis of the threshold model, which seems to correlate the toxicity with the 
length of time that PTX concentration exceeds a threshold concentration (Gianni et al., 
1995) (Henningsson et al., 2001) (Mielke et al., 2005b) (Mielke et al., 2005a) (Huizing et 
al., 1997), will be investigated. 
At the moment, preliminary analyses have been done about the pharmacokinetic 
parameters obtained for both PTX and its major metabolite, 6α-OH-PTX. The first 
notable consideration refers to the comparison between the PK obtained during the 
first and the fourth administration, aimed at verifying the hypothesis of the 
autoinduction of PTX metabolism (Gustafson et al., 2005). Our results seemed to 
exclude this effect, since no statistical differences in PTX Cmax, tmax, AUClast, and Cl 
(p>0.05) between the two administrations has been obtained. Moreover, these results 
seems to be reinforced by the significant increased of the PTX t1/2 along with a 
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decreased Vd during the IV administration that have been observed (p>0.0000 in both 
the parameters). 
Noteworthy, up to now, no significant (p>0.05) differences in the main pharmacokinetic 
parameters of both PTX and 6α-OH-PTX between the two genotype groups have been 
obtained from this preliminary test. In particular, no difference in Cl between the two 
patients cohorts have been observed, although it has been reported in literature a 
lowered Cl in patients carrying the 2677T/A genotype (Green, 2008) (Wong et al., 2005). 
Since this comparison has been conducted only at the dose level of 80, 100, and 110 
mg/m2, a further and more complete discussion related to this analysis will be done at 
the study conclusion.  
Given the dose escalation nature of this study, an interesting investigation has been 
conducted on the dose dependent behaviour of PTX PK. In fact, several studies have 
reported a switching from linear to non linear PK when high doses of paclitaxel were 
administered (Henningsson et al., 2001) (Mross et al., 2000) (Gianni et al., 1995). The 
critical threshold for non-linear kinetics has not univocally determined, as it depends 
also from the administration schedule. Our results seemed to be in line with this 
behaviour, indicating the dose level of 110 mg/m2as the turning point: with doses less 
than or equal to 110 mg/m2, paclitaxel showed linear kinetics, which became non-linear 
for doses higher than 110 mg/m2.  
The overall trend of Cl, analysed by the Spearman’s rank correlation test, has shown an 
inverse correlation with the paclitaxel dose (Spearman correlation coefficient = -0.5191 
and 0.4050 during the I and the IV administration, respectively), meaning that the Cl 
decreases with the increasing of the dose (non-linear PK). Moreover, this trend has 
been found statistically significant (p = 0.0012 and 0.0175 during I and the IV 
administration, respectively). More in details, Cl seemed to show the same dual 
behaviour observed for AUClast: for doses less than or equal to 100 mg/m
2 Cl appeared 
to be constant, while a clear decrease has been observed for doses higher than 100 
mg/m2. This consideration seemed to confirm the PTX PK switching from a linear to a 
non-linear behaviour for doses higher than 110 mg/m2. 
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Innovative genotype-guided phase Ib clinical trials are intended to redefine the dose or 
the treatment modalities with conventional cytotoxic drugs taking into account the 
newer pharmacogenetic knowledge. In fact, among all the parameters responsible for 
the high variability, in term of both efficacy and toxicity, observed in patients with the 
same diagnosis and treated with the same drugs, great interest has been reserved to 
the effect of genetic differences among individuals on the response of cancer patients 
to chemotherapy. Thus, the aim of these particular phase I studies is to produce not a 
unique optimal dose for an unselected population (“one dose fits all” model), but 
different dose levels for patients with a different genetic background, as required by the 
personalized medicine approach. 
In this PhD thesis, three genotype-guided phase Ib clinical trials have been described. 
Their principal aim was to define the MTDs and the DLTs of: 
 CPT-11 administered in the FOLFIRI regimen plus bevacizumab or cetuximab in 
mCRC patients according to UGT1A1*28 genotype; 
 weekly PTX according to the ABCB1-2677G>T/A polymorphism in epithelial ovarian 
cancer patients. 
At present, only the phase I related to FOLFIRI in combination with bevacizumab have 
been concluded. The MTD of genotype-directed irinotecan was 260 mg/m2 for *1/*28 
patients, and 310 mg/m2 for *1/*1 patients. The obtained results support that the two 
genotypes confer a different risk of toxicity and *1/*28 patients do not tolerate the 
same dose of *1/*1 patients, although no significant difference in the pharmacokinetic 
parameters between the two genotype cohorts has been observed. Moreover, the 
MTDs for FOLFIRI plus bevacizumab resulted lower than those for FOLFIRI alone (370 
and 310 mg/m2 for *1/*1 and for *1/*28 patients, respectively), as found in a previous 
phase I with a similar design in front-line mCRC patients. In our study, the effect of the 
addition of bevacizumab to the genotype-guided dosing of FOLFIRI has been 
investigated by a pharmacokinetic point of view. The analysis of the PK of CPT-11 and 
its active metabolite seemed to rule out an effect of bevacizumab on CPT-11 and SN-38 
PK.  
Even if the efficacy was not the primary endpoint of this study since the limited number 
of patients evaluable for efficacy (n = 33) prevented drawing definitive conclusions on 
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whether higher doses of irinotecan lead to increased efficacy of FOLFIRI plus 
bevacizumab, no apparent association was found between the overall response and the 
higher CPT-11 doses. Anyway, this hypothesis should be tested in a large population 
prospective study. 
The second phase I study of irinotecan, in FOLFIRI regimen in combination with 
cetuximab, has been recently started. Up to now, just two patients resulted eligible and 
were enrolled in this new clinical study, due to the relative high frequencies of RAS 
mutations in CRC patients. In fact, RAS mutations preclude the use of cetuximab and 
therefore the enrollment in this clinical study. Anyway, the pharmacokinetic profile of 
the first patient treated according to this protocol has already been determined. 
Although it is still on-going, the third phase I study reported in this thesis has already 
demonstrated that a higher than standard dose of PTX could be safely administered in 
patients with ABCB1-2677GT; GA, AA, TT, AT genotypes, the group characterized, 
according to the protocol design, by a high risk of toxicity. In this cohort of patients, 
PTX can be tolerated at doses up to 120 mg/m2, compared to the standard dose of 80 
mg/m2. Concerning the group of patients with ABCB1-2677GG genotype and defined as 
at low risk of toxicity, current data indicated that doses up to 100 mg/m2 can be safely 
administered even if the MTD has not yet been determined. 
Preliminary analyses have been done on the pharmacokinetic parameters determined 
for both PTX and its major metabolite, 6α-OH-PTX. The first notable result refers to the 
comparison between the PK obtained during the first and the fourth administration, 
which seemed to exclude the autoinduction of PTX metabolism (reported in literature), 
since no statistical differences in PTX systemic exposure between the two 
administrations has been observed.  
Moreover, an initial comparison between the two genotype groups has been conducted 
at the dose levels of 80, 100, and 110 mg/m2, and, up to now, no significant differences 
in the main pharmacokinetic parameters of both PTX and 6α-OH-PTX have been 
obtained. In particular, no difference in Cl between the two patients’ cohorts has been 
observed, although it has been reported in literature a lowered Cl in patients carrying 
the 2677T/A genotype. Noteworthy, the investigation on the dose dependent behaviour 
of PTX PK, conducted on the data collected till now, indicated a switching from linear to 
non-linear PK with doses higher than 110 mg/m2 of PTX. 
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In order to support the phase I studies reported above, during this PhD project two LC-
MS/MS methods have been set up for the quantification of the following drugs and their 
relative metabolites in human plasma: 
 CPT-11 and its main metabolites, SN-38, SN-38G, and APC; 
 PTX and its 6α-hydroxy metabolite (6α-OH-PTX). 
Moreover, beyond the phase I projects, a third method has been developed, for the 
quantification of sunitinib and its active metabolite, N-desethyl sunitinib. 
These methods have been conceived in order to be applied to both clinical studies and 
TDM and, for this reason, they were validated. Moreover, the development processes 
have taken in consideration the different and specific requirements that render an 
analytical assay suitable for clinical application.  
First of all, all the three methods developed require a small plasma volume, ranging 
from 30 (sunitinib method) to 100 µL (in the case of CPT-11 and PTX methods). 
Furthermore, in the designed LC-MS/MS methods, the sample processing has been 
based on a simple protein precipitation. Sample preparation, indeed, is one of the most 
time-consuming steps in the bioanalysis aiming to extract the analytes of interest from 
biological matrices.  
These methods have been developed in order to determine the pharmacokinetic 
profiles of the drugs under study. For this reason, the method sensitivity was crucial to 
accurately define the t1/2 of the drugs and a properly low LLOQ was required (the 
designed methods have LLOQ concentrations ranging from 0.1 to 10 ng/mL). At the 
same time, also the ULOQ was important, in particular for those methods developed 
for dose escalation studies, where higher plasma concentrations than those reached 
with the standard dose are expected. The concentration ranges chosen for our new 
methods, in all the cases, generously covered the clinical expected drug concentrations, 
and resulted suitable for both for pharmacokinetic studies and for dose escalation trials 
(high doses). 
A quite interesting result has been achieved in the case of the analytical method for the 
quantification of sunitinib, molecule that undergoes light induced Z-E isomerism. In 
order to prevent the E-isomer formation, most of the already published methods 
proposed to avoid the sample exposure to light in any steps, from the collection to the 
analysis, thus requiring the use of sodium or UV-light  and the setting of suitable dark 
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rooms. Instead, our innovative approach has overtaken the troublesome step of the 
light protection by mean of an additional, but fast, step in sample preparation (a heated 
water bath at 90°C for 5 min) just before the sample analysis. The incubation in the 
water bath allowed the quantitatively reconversion of E to Z-isomer, formed during the 
sample handling. Thus, the method resulted surely more suitable to be used for TDM of 
sunitinib in the clinical laboratory routine.  
Lastly, in order to apply the bioanalytical methods to clinical studies, it was essential to 
demonstrate that the analytical assay was reliable and reproducible for the intended 
use, by means of validating them according to the specific guidelines. In fact, the 
methods described in this thesis were fully validated in accordance to the FDA-EMA 
guidelines on bioanalytical method validation. Noteworthy, taking into account the 
recently revised version of the FDA guidance, we have introduced the incurred samples 
reanalysis assessment during the methods validation, as a further test to verify the 
reliability and reproducibility of the determined sample analyte concentrations.  
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